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Abstract 
Transplantation of genetically engineered neural stem cells (NSCs) into sites of central nervous 
system (CNS) disease/injury is a promising strategy to promote repair of damaged tissue. 
However, translating this strategy into the clinic requires several challenges to be overcome 
including facilitating ‘combinatorial therapy’ (achieving multiple therapeutic goals – essential in 
CNS injury/disease). Nanotechnologies are emerging as multifunctional platforms capable of 
meeting this requirement. For example, magnetic particles (MPs) and implantable hydrogels offer 
several biomedical advantages for transplant populations, including: safe genetic manipulation; 
non-invasive cell tracking, via MRI; and safe and efficient accumulation of cells at sites of injury. 
However, the use of these nanotechnologies remains to be explored in detail for NSC 
transplantation therapies. 
In this thesis, it is shown that MPs can mediate gene delivery to NSCs grown as neurospheres and 
monolayers with the most efficient transfection efficiencies achieved using oscillating 
magnetofection protocols (9.4% and 32.2% respectively). In both culture systems, developed 
protocols had no effect on key regenerative properties of NSCs such as cell viability, proliferation, 
stemness and differentiation. Further, ‘magnetofected’ monolayer NSCs were shown to have 
survived and differentiated in a cerebellum slice model acting as host tissue, indicating safety of 
the procedures. It was also shown that assessing procedural safety and extent of transfection of 
magnetofection protocols may be feasible by employing mass spectrometry and proteomics 
analysis. 
It was also found that tailored enhancement of particle magnetite content offers a means to 
efficiently label NSCs, up to a maximum of 95.8%. Labelling procedures had no effect on cell 
viability, proliferation, stemness or differentiation. In addition, labelled cells could survive and 
differentiate in a slice model of spinal cord injury indicating safety of the labelling procedures. 
iii 
 
Functional labelling was also demonstrated by magnetic capture of labelled cells in an in vitro flow 
system.  
Hydrogels offer major advantages for delivery of transplant populations into injury sites. Here it 
was shown that an intraconstruct genetic engineering approach was feasible for NSCs cultured 
with a clinically translatable, collagen hydrogel system. Magnetofection protocols safely increased 
MP mediated transfection of NSCs grown in ‘2-D’ and ‘3-D’ hydrogel cultures. 
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Chapter 1: General Introduction 
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1.1 Introduction summary 
This thesis covers a broad range of materials and methods for improving neural stem cell (NSC) 
transplantation therapy by utilising various nanotechnology strategies. For clarity, this section 
provides an overview of the areas to be covered by the introduction. Initially, it provides a brief 
description of central nervous system (CNS; brain and spinal cord) disease/injury and why repair is 
difficult to achieve. This is followed by a discussion of the benefits of NSC transplantation for 
repairing the CNS after insult. As CNS disease is highly complex, achieving multiple clinical goals is 
desirable for effective regeneration. In this context, genetically engineering NSCs can enhance 
their therapeutic potential by enabling them to replace lost or damaged cells and deliver 
therapeutic biomolecules, a strategy which will be expanded in Section 1.5. However, there are 
major barriers to the clinical transplantation of genetically engineered NSCs which will be 
expanded in Section 1.6. The key research aims of this thesis are to take steps towards addressing 
these barriers by exploring the potential of combining the rapidly emerging field of 
nanotechnology with NSC transplantation therapy. Therefore, the subsequent sections will outline 
two nanotechnologies, magnetic (nano)particles (MPs) and implantable hydrogels, and discuss 
how these materials can be used as novel tools to benefit NSC transplantation. Within these 
sections, gaps in the literature for applying nanotechnology to NSC transplantation will be 
highlighted and these will serve as the basis for the aims of each of the experimental chapters. 
Finally, the use of primary cells and organotypic slice culture will be introduced as tools for 
assessing the safety and efficacy of nanotechnological interventions. 
 
1.2 Central nervous system injury and disease currently has poor prognosis 
No treatment is currently able to reverse damage caused and restore function of the tissue after 
CNS injury and disease. These conditions can cause severe human disability and frequently 
culminate in premature death (stroke, neurodegenerative disorders and depression are all in the 
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top 20 causes of death worldwide).1 As well as the negative impact on the quality of life of 
patients and their support network, there is also huge cost to healthcare systems as initial 
therapies are expensive and often substantial palliative care is required for the remainder of the 
patient’s life. For example, in the USA, spinal cord injury (SCI) resulting in paraplegia costs about 
$500 000 in the first year then $67 000 for each subsequent year.2 In addition, due to increasing 
life expectancies, the prevalence of neurodegenerative diseases are predicted to increase and 
become one of the leading causes of disability and death by 2030.1 As a result, efforts to find 
therapies which can restore function to the damaged CNS are vital both for human well-being and 
to alleviate the cost-burden for global healthcare services. However, this constitutes a major 
challenge as CNS tissue has a complex cytoarchitecture and a poor regenerative capacity, posing 
considerable obstacles to the development of neuroregenerative strategies.  
In terms of its cytoarchitecture, the CNS consists of two major classes of cells: the neurons and 
their supporting glia. Neurons transmit electrical signals and reside in groups forming multiple 
connections with other neurons to make up neural circuits which perform a common function, for 
example, vision or movement.3 Neurons extend axons which are highly specialised structures 
unique to neuronal cells adapted to relay information within the body.3 Axons are ensheathed by 
layers of an insulating and supporting fatty deposit called myelin. CNS myelin is made and 
maintained by the oligodendrocytes which can myelinate multiple axons.4 Astrocytes are the 
major supporting cell type within the CNS and research is still ongoing into their specific roles 
within this remit. Their currently accepted functions include: maintaining CNS homeostasis; intake 
and potential release of glutamate (a neurotransmitter) to control signal intensity and prevent 
excitotoxicity; providing metabolic support to neurons and roles in synapse formation and 
maintenance.4,5 
Other important CNS glial subtypes include the microglia which are the resident immune cells 
(involved in phagocytosis and cell recruitment to sites of injury)6 and precursor cells – both neural 
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stem cells (NSCs) and oligodendrocyte progenitor cells (OPCs). NSCs will be described in greater 
detail in Section 1.4. OPCs produce their daughter cells the oligodendrocytes throughout 
development but are also present as slowly dividing populations in adulthood and are reported to 
be recruited to sites of injury.5,7 Finally, a mixture of astrocytes and endothelial cells forming tight 
junctions make up the blood brain barrier (BBB) which strictly controls the entry of molecules to 
the CNS. In this manner, it functions to maintain the specific molecular environment (e.g. optimal 
ion concentrations for signal transduction) crucial for the function of the above cell types and 
overall CNS function.3,4 
Unsurprisingly, insult to the CNS affects all these cell types. However, each has their individual 
influence on the poor regenerative capacity of the CNS resulting in a complex, multifactorial 
pathology. Insult generally results in three stages of response: (1) Extensive cell death and 
breakdown of the BBB – involving a wave of neuronal cell death followed by the death of 
oligodendrocytes (which normally receive pro-survival signalling from the neurons). Cell death 
coupled with breakdown of the BBB produces an incredibly hostile environment consisting of 
inflammatory and other cell signalling molecules which act on the surrounding CNS cells. (2) 
‘Reactive gliosis’ – where glia cells are mobilised in response to this environment. This includes 
recruitment of microglia and precursor cells where the former will attempt to clear debris from 
the infarct site. The role of precursor cell migration to sites of injury is yet to be fully understood 
but they may play a part in replacing lost cells. Local astrocytes also respond to the injury and 
display an increase in proliferation. (3) Tissue remodelling – which involves formation of a so 
called ‘astrocyte scar’ – a combination of hypertrophied astrocytes and secreted extracellular 
matrix (ECM) molecules including chondroitin sulphate proteoglycans (CSPGs).5,6,8  
Regeneration of CNS axons in this environment is inhibited in two ways. Firstly, by extrinsic cues 
which include the physical barrier of the astrocyte scar and chemical signals – myelin associated 
proteins released by dying oligodendrocytes and CSPGs have both been shown to be potent axon 
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growth inhibitors.5 Secondly, intrinsic signalling pathways have been shown to sensitise the 
neuron to the extracellular milieu and prevent axon outgrowth. For example, intracellular 
activation of RhoA by myelin fragments causes destabilisation of the neuronal cytoskeleton, 
rendering axon protrusion unfavourable.5 In terms of cell replacement from endogenous sources, 
there is some evidence for neurogenesis in areas of stroke arising from NSCs that have migrated 
from germinal regions within the brain.9 However, there is speculation over the contribution of 
endogenous neurogenesis to functional improvements as only a small percentage of migrating 
NSCs differentiate into mature neurons. In addition, this effect is reported to be lower in older 
animals (an important observation as stroke is most prevalent in the elderly population) and sites 
of severe injury.9 Ultimately, endogenous tissue replacement does not have the capacity to 
restore the original function of the lost tissue. Given the complexity of pathology and the multiple 
parameters that contribute to regenerative processes, there are a number of avenues which 
could be explored for therapeutic interventions, including the use of combinatorial therapies 
which aim to address more than one target. Disrupting the astrocyte scar, removing inhibitory 
signalling molecules, promoting intrinsic neuronal growth and replacing lost neurons are all 
exciting therapeutic avenues which if targeted simultaneously could promote repair in the CNS.  
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Figure 1.1. Schematic highlighting the multiple barriers to regeneration present in sites of 
neurological injury. 
 
Current clinical treatments for neurological injury do not generally promote regeneration and aim 
to reduce symptoms and slow disease progression, for example, by administering drugs to 
modulate inflammation, in SCI,10 or reduce blood clotting in stroke.11 Physiotherapy to improve 
neurological function has shown benefits for patients experiencing stroke, traumatic brain injury 
(TBI) and SCI.12 It is generally used for rehabilitation and to slow disease progression after 
neurological injury. In severe circumstances, surgery may be required to remove blood-clots or 
attempt to reduce bleeding. These treatments offer some relief, and may result in an 
environment which is favourable for regeneration, for example, by reducing inflammation based 
inhibition of axon growth.8,13 However, there is some controversy about the administration of 
anti-inflammatory agents to treat neurological injury as some aspects of neuro-inflammation may 
be beneficial for regenerative processes.10 Ultimately, therapies widely used in the clinic do not 
restore function of the CNS. Some promising alternatives to promote axon regrowth are close to 
clinical use, including drugs which breakdown or antagonise molecules inhibitory to axonal 
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regeneration, for example, Nogo-A inhibitors.14 However, these drugs only address one factor 
within the complex nature of neurological injury. Current research efforts in the field of neuro-
regeneration are therefore focussed on truly regenerative therapies for CNS disease and injury – 
to enhance the repair processes within the CNS and functionally replace lost or damaged cells. 
 
1.3 Cell transplantation shows benefits for neurological injury 
In the context of replacing lost tissue and restoring neurological function, cell transplantation is a 
promising therapeutic strategy. The scientific rationale for cell transplantation involves two main 
objectives: (1) to replace lost or damaged cells and (2) to release molecules to promote repair, 
such as neurotrophic factors. In terms of candidates for cell therapy, many different cell types are 
being investigated for the treatment of neurological injury. Stem cells, owing to their self-renewal 
capacity, offer an attractive source for cell transplantation as they can be expanded to clinically 
required numbers through ex vivo cell culture. Embryonic stem cells (ESCs), generated from 
aborted foetuses, have the capacity to generate any cell in the body. However, in their 
undifferentiated form, they have the potential to generate teratomas after transplantation. 
Consequently, they need to be pre-differentiated prior to transplantation and care is needed to 
ensure no teratoma forming cells remain within the transplant population.15 Mesenchymal stem 
cells (MSCs) have also been used for neurological applications and can be derived autologously, 
from blood or bone-marrow samples, potentially avoiding immune rejection issues surrounding 
cell transplantation. MSCs are not thought to be tumorigenic and demonstrate functional 
recovery in models of neurological injury; believed to be the result of paracrine signalling and 
release of neurotrophic factors which promote the survival of host axons.16 Although MSCs are 
multipotent, doubts remain over the ability of MSCs to effectively replace neural cells.17 A 
relatively new technology has also seen the ability to reprogram terminally differentiated cells 
into stem cells termed induced pluripotent stem cells (iPSCs). These cells have similar properties 
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to ESCs with the advantage of being able to derive them from the patient’s own cells using 
relatively non-invasive procedures. However, engineering cells in this manner is currently 
achieved using viruses which (as expanded later in Section 1.6) are not suitable for clinical 
translation. Further, the efficiency of transformation into stem cells is low (ca. 1%), meaning a 
large number of cells have to be taken from the patient, and doubts remain about iPSC 
tumorigenicity.18,19 Olfactory ensheathing cells (OECs) have also been transplanted into areas of 
spinal cord injury (SCI) and shown to promote functional recovery.20 These cells can be generated 
from autologous mucosal biopsies and propagated in culture. After transplantation into sites of 
SCI they appear to have an innate ability to guide long distance axonal regeneration and recovery 
of locomotion. Although these cells may have considerable promise for SCI therapy their 
application in other neurological deficits is less proven and their inability to produce cells of the 
CNS may hamper their clinical translation for cell replacement therapies. Neural stem cells (NSCs) 
are another cell type widely used in clinical trials for neurological disorders17 and have unique 
properties which may allow them to address the multifactorial nature of CNS injury, as will be 
described in the following section. 
 
1.4 NSCs as promising candidates to promote repair in CNS disease and injury  
NSCs are defined as multipotent precursor cells to the major cell types of the CNS (neurons, 
oligodendrocytes and astrocytes) with the capacity to self-renew.21 They exist in the developing 
nervous system but also reside in specialised niches within the adult CNS. In the brain, these are 
the subventricular zone (SVZ) in the forebrain, which continuously supplies neurons to the 
olfactory bulb, and the subgranular zone which generates new neurons in the granular layer of 
the dentate gyrus.22 NSCs have also been derived from the periventricular tissue region of the 
spinal cord.23,24 NSCs from the different areas have been reported to generate region specific 
neurons or differentiate primarily into oligodendrocytes when taken from the spinal cord,24 which 
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could have an important bearing on choosing a cell source for transplantation as different sources 
could have benefits for different CNS pathologies.25 Primary NSCs can be derived from each of 
these regions using embryonic or adult tissue and are cultured by neuroscience laboratories 
worldwide as monolayers (adherent, 2-dimensional cultures) or neurospheres (3-dimensional, 
floating cell aggregates). NSCs are also routinely derived from ESCs and there are reports of iPSC-
derived NSCs19 involving the reprogramming of post-mitotic cells into stem cells using key 
transcription factors: Oct4, Sox2, c-Myc and Klf4. 
NSCs offer an attractive alternative to commonly used transplant cell populations for several 
reasons. NSCs have been shown to secrete numerous trophic and immunomodulatory factors 
which are thought to be among the main mechanisms by which NSC transplantation slows disease 
progression and imparts functional benefits after transplantation into models of CNS 
disease/injury.26 Molecules such as neutrophin-3 (NT-3), nerve growth factor (NGF) and glial 
derived neurotrophic factor (GDNF) have been shown to be secreted from NSCs with some 
evidence that their release has neuroprotective effects.26 For example, NSCs were transplanted 
into a rat model of Parkinson’s Disease, generated by injecting rats with MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) which renders dopaminergic neurons tyrosine hydroxylase 
(TH) deficient but avoids cell death.27 Transplanted NSCs appeared to migrate to the diseased 
neurons and it was shown that a large proportion of the transplant cells express high-levels of 
GDNF. GDNF has been shown to be neuroprotective of dopaminergic neurons in vitro and in this 
study rescue of TH activity in vivo was observed along with behavioural improvements in rats 
receiving an NSC transplant.  
NSCs also have the ability to cross the BBB28 and display high migration and integration within 
host CNS28,29 exhibiting a phenomenon termed ‘pathotropism’ – the homing of cells towards sites 
of pathology.28,29 Aboody et al. were among the first to demonstrate the pathotropism of NSCs by 
transplantation into rodents with brain tumours, established using highly aggressive glioblastoma 
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cell lines.29 Tumours were always established in the right frontal lobe of the brain. NSCs were 
transplanted into various areas within the brain and in one instance into the vasculature, through 
the tail vein. In all cases, NSC juxtaposition to the tumour was observed, sometimes as rapidly as 
two days after NSC transplantation. In addition, when NSCs were injected directly into the tumour 
bed they could be seen to track single, migratory tumour cells – potentially of considerable 
benefit if attempting to deliver targeted chemotherapy to invasive cancers. This ability to cross 
the BBB and their homing capacity allows NSCs to be administered via systemic routes without 
direct transplantation into the CNS which could mitigate the risk of secondary pathology; 
potentially a critical safety feature of this cell type. Further, extensive NSC migration within the 
CNS could enable treatment of large or multi-focal areas of disease, of particular relevance to 
global disease pathologies such as Alzheimer ’s disease, brain cancer and lysosomal storage 
diseases (LSDs).  
NSCs can differentiate into all three cell types of the CNS lineage21,30 and there is evidence for 
their differentiation into neurons, which form synapses with the host circuitry,31 and myelinating 
oligodendrocytes28,31 after transplantation into CNS models of disease/injury. Pluchino et al. 
demonstrated that tail vein injection of NSCs into a mouse model of multiple sclerosis resulted in 
donor NSCs surrounding areas of myelin loss.28 The majority of donor cells expressed platelet-
derived growth factor-α (PDGF-α, an oligodendrocyte precursor marker) as assessed by 
immunohistochemistry, and were actively involved in remyelination, observed using electron 
microscopy. However, the extent to which functional recovery is due to cell replacement and 
functional integration into the CNS, or trophic support for surrounding neural tissue supplied by 
transplanted NSCs, is currently difficult to confirm.  
NSCs can be isolated from embryonic and adult tissue, allowing the possibility of allogeneic and 
autologous treatment, and can be expanded and genetically manipulated in vitro. The former is of 
clinical relevance as the required quantity of cells for a cell therapy can be generated in culture. 
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To highlight this particular problem, it has been suggested that 8-12 foetuses are required for cell 
transplantation into the brains of Parkinson’s Disease patients.15 In vitro genetic manipulation of 
transplant cell populations can be used to introduce genes which encode therapeutic 
biomolecules. The transplanted cells can then act as ‘vehicular biopumps’ to deliver therapeutic 
factors to sites of injury or disease.32  
NSC transplantation has also overwhelmingly been shown to be safe, with little evidence of 
tumour formation and indeed NSCs are thought to be non-tumorigenic.33 The advantages 
described in this section have led to numerous pre-clinical studies demonstrating promotion of 
neurological recovery after NSC transplantation into sites of injury/disease and their potential as 
therapeutic agents is evidenced by the fact that NSCs are currently utilised in several clinical trials. 
Neuralstem (USA) are currently in phase I clinical trials for transplantation of NSCs into the spinal 
cords of patients suffering from amyotrophic lateral sclerosis (ALS). The NSCs are hypothesised to 
protect surviving motor neurons and prolong the life of ALS patients. Phase I was successfully 
completed with no adverse reactions to the transplantation and phase II trials (NCT01730716) are 
to be initiated.34 Reneuron Group plc (a UK-based stem cell company) have also completed phase 
I clinical trials with their NSC cell line product designed to ameliorate the effects of ischaemic 
stroke. Phase II trials have since been initiated in 10 UK centres (NCT02117635). Phase I clinical 
trials are also ongoing to examine the safety of transplanting NSCs into multiple sites within the 
brain in patients with neuronal ceroid lipofuscinoses (NCL), a form of LSD. Transplanted NSCs are 
thought to migrate within the brain and supply replacement enzyme for cross correction therapy 
of deficient cells. This enzyme acts to reduce build-up of lipofuscin in neurons which is the major 
pathological contributor to NCL.35 
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1.5 Genetically engineering NSCs could provide combinatorial therapy  
Although NSCs possess numerous advantages for transplantation into the CNS, addressing one 
factor by utilising cell replacement (or gene delivery) is unlikely to be sufficient to restore the 
function of the CNS. To promote effective neural repair several factors need to be addressed in 
the context of the complex biological processes in neural disease/injury. 'Combinatorial' 
therapies, which have the ability to achieve concurrent goals such as cell replacement coupled 
with therapeutic gene delivery, are thought to be the most realistic approach to achieve 
functional repair. Several studies have demonstrated enhanced benefits when transplanting 
genetically manipulated NSCs compared to transplantation of NSCs alone. Strategies to improve 
clinical outcomes after transplantation of genetically engineered NSCs vary, but some examples 
are highlighted in the following section and in Table 1.1. 
Some groups introduce genes designed to enhance the survival of NSCs (such as Akt-1 or vascular 
endothelial growth factor, VEGF) to address the well-known problem of abundant cell death post 
transplantation.36,37 Akt-1 is a mediator of the P13K-Akt signalling pathway which is involved in 
pro-survival and anti-apoptotic signalling. Lee et al. introduced this gene into NSCs via retroviral 
transduction and selection by hygromycin resistance. Akt-1 modified NSCs displayed enhanced 
survival when transplanted into areas of stroke induced in mice and improved behavioural 
outcomes in comparison to NSCs alone.36 In this scenario, enhanced neuroprotective effects and 
improved functional outcomes, compared to the non-engineered NSCs, are thought to be the 
result of increased survival of the engineered transplant population allowing more cells to deliver 
a therapeutic effect. Whether introducing genes such as Akt-1 will be applicable in the clinic 
remains to be seen, however, as immortalising cells could lead to potential tumour formation. 
Reneuron have ongoing clinical trials for stroke therapy with their NSC cell line (Phase I: 
NCT01151124 and Phase II: NCT02117635) which has been conditionally immortalised by 
retroviral introduction of c-mycER(TAM). Using this system, expression of the growth promoting 
c-myc can only occur in the presence of a hormone, 4-hydroxy-tamoxifen (4-OHT). With the 
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inclusion of growth factors and 4-OHT in the culture medium, stable clonal expansion of NSCs can 
be achieved for production without chromosomal aberrations (a common risk in late passage cell-
lines),38 up to at least passage 16.39 So far no adverse safety effects have been associated with 
transplantation of NSCs expanded in this manner into areas of stroke, suggesting that introducing 
genes which control cell proliferation could be a viable clinical strategy. Rigorous safety testing 
will have to be performed to ensure the absence of teratoma formation or abnormal cell divisions 
when using this approach. 
A more regenerative strategy involves engineering NSCs to release repair promoting factors such 
as NT-3, GDNF or VEGF.40–43 Transplanted NSCs engineered to release NT-3 and GDNF have shown 
enhanced neurite extension of host axons into lesion sites and greater evidence of neurogenesis 
from the transplanted NSCs when compared to non-engineered controls.40,42,43 For example, in 
one study NSCs were retrovirally modified to secrete NT-3. After transplantation into rat spinal 
cord lesions, both engineered and non-engineered NSCs promoted axon growth into the lesion. 
However, a marked increase in axonal density was observed in the lesion receiving NT-3 
expressing NSCs. Analysis of mRNA levels in the lesion site demonstrated that NT-3 mRNA was 
indeed greatly enhanced after transplantation of engineered NSCs in comparison to non-
engineered NSCs which provides a reasonable explanation for the observations.40 
Along with enhancing axonal outgrowth, a key goal in regenerative medicine is to improve 
vasculature of regenerating tissue in order to supply nutrients to the newly formed tissue. To 
address this, VEGF was introduced into NSCs for transplantation into rat brain in two studies. 
Although increased blood vessel formation was not noted in either study, both studies 
demonstrated enhanced numbers of endothelial cells, which form blood vessels, in the vicinity of 
the NSCs.37,41 In the case of VEGF overexpressing NSC transplantation into a rat stroke model, 
functional improvements occurred at an earlier stage in the study (two weeks post-
transplantation) compared to transplantation of non-engineered NSCs (eight weeks post-
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transplantation) – although by the end of the study functional improvements were broadly similar 
between the two groups.41 The results could suggest that gene expression was not sustained for a 
long enough time period to mediate further functional improvement, highlighting the need to 
consider time-course of gene expression and transfection efficiency when developing an optimal 
clinical strategy for genetically engineering a transplant population.  
NSC mediated delivery of molecules which target underlying disease pathologies have also been 
developed. Two recent studies have demonstrated the neurological benefits of transplanting 
NSCs in models of Alzheimer ’s disease and LSDs. The first showed that NSCs can increase synaptic 
connectivity and neuronal survival and consequently cognitive function in a rat model. 
Subsequent engineering of the NSCs to release neprilysin was shown to further address the 
underlying pathology of Alzheimer’s Disease by breaking down amyloid plaques in diseased 
areas.44 In the model of LSD, NSCs were engineered to release ß- galactocerebrosidase (GALC), the 
enzyme responsible for controlling lysosomal storage which is otherwise deficient in the disease. 
Here, NSCs showed immunomodulatory and neuroprotective effects which slowed down disease 
progression. Overexpression of GALC resulted in widespread delivery through the cerebrospinal 
fluid (CSF) and more cells which were corrected to normal storage phenotypes compared to 
transplantation of non-engineered NSCs.45 Both these studies show the great potential in 
combining neuroprotective efficacy of NSCs with biomolecule delivery to address several 
therapeutic goals in one step. Whilst all the studies described in this section have shown some 
benefits of genetically engineering NSCs prior to transplantation (summarised in Figure 1.2), it is 
overwhelmingly the case that genetic manipulation has been achieved using viral vectors (Table 
1.1). As discussed in Section 1.6 viruses are associated with several disadvantages and currently 
pose a major barrier to the clinical translation of this therapeutic strategy. 
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Figure 1.2. Schematic detailing how genetically engineering NSCs for transplantation offers 
several clinical advantages. 
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Disease model Strategy  Genetic engineering method Outcome Reference 
Alzheimer’s Disease in 
transgenic mice 
NSCs overexpressing neprylsin enzyme (breaks 
down beta-amyloid plaques). NSCs also shown to 
improve synaptic connectivity and neuronal survival 
Nucleofection followed by stable 
transfection selection (6 weeks) and 
lentiviral transduction 
Reductions in beta-amyloid plaques and 
increased synaptic density 
44 
Mouse intracerebral 
haemorrhage stroke 
model 
NSCs modified to survive through introduction of 
Akt1 
Retrovirus Greater NSC survival and improved behavioural 
outcomes 
36 
Intact rat brain  NSCs overexpress VEGF to induce angiogenesis  Adenoviral vector. Transfection efficiency of 
20-30% 
Increased NSC survival and enhanced number of 
endothelial cells after 11 days 
37 
Rat spinal cord lesion NSCs transfected with NT-3 Retroviral system Enhanced axonal growth into lesion compared 
with non-transfected NSCs 
40 
Middle cerebral artery 
occlusion ischemic brain 
model in rat  
NSCs transfected with VEGF to improve 
neuroprotection and angiogenesis 
Lipofection resulting in VEGF expression for 
at least 2 weeks 
Earlier improvement in behavioural scores after 
transplantation of transfected NSCs 
41 
Hypoxic-ischemic model 
in mice 
NSCs transduced with NT-3 to promote 
neurogenesis 
Retroviral transduction and antibiotic 
selection with G418 
Higher numbers of NSC derived neurons in the 
infarct site compared to a previous study of 
non-engineered NSCs 
42 
Middle cerebral artery 
occlusion ischemic brain 
model in rat 
NSCs modified to secrete GDNF which enhances 
progenitor proliferation and exerts neuroprotective 
effects 
Fibre-mutant Arg-Gly-Asp adenovirus vector 
system (50% transfection efficiency with 
reporter plasmid) 
Modified NSC transplantation reduced infarct 
size and resulted in better behavioural 
outcomes than controls 
43 
Compression SCI in mice NSCs modified to produce noggin, a BMP inhibitor – 
BMP signalling is up-regulated in SCI and causes 
NSC differentiation into astrocytes when neurons 
may be more appropriate 
Retroviral system Improved differentiation of NSCs into neurons 
and oligodendrocytes compared to non-
engineered NSCs and enhanced functional 
improvement 
46 
Intracranial brain tumour 
induced by transplanting 
glioma cells 
NSCs genetically engineered to release cytosine 
deaminase. NSCs home towards tumours and 
release therapeutic molecule 
Retrovirus transduction with antibiotic 
selection 
Cytosine deaminase activity metabolises pro-
drug into its active form and caused 80% 
reduction in tumour volume 
29 
Contusive SCI in common 
marmosets 
NSCs engineered to overexpress galectin-1 – shown 
to enhance NSC proliferation and axonal 
regeneration 
Lentiviral system. Over 80% transfection 
efficiency 
Reduced myelination loss and lesion size and 
improved behavioural outcomes compared to 
non-engineered NSCs  
47 
Murine model of globoid 
cell leukodystrophy (LSD) 
NSCs engineered to overexpress GALC to replace 
the deficient enzyme 
Lentivirus (70-90% transfection efficiency) NSC transplantation provided neuroprotective 
effects with GALC overexpression resulting in 
more correction than non-engineered NSCs 
45 
Mouse model of Type-A 
Niemann-Pick disease 
(LSD) 
NSCs engineered to release acid sphingomyelinase 
which corrects disease pathology 
Retrovirus and antibiotic selection Marked reduction to lysosomal pathology in 
genetically manipulated NSC transplanted mice 
compared to non-engineered NSC 
transplantation 
48 
Table 1.1. Examples of genetically engineering NSCs for transplantation into the CNS. NSC – neural stem cell; VEGF – vascular endothelial growth factor; 
NT-3 – neurothrophic factor 3; GDNF – glial derived neurotrophic factor; BMP – bone morphogenetic protein; SCI – spinal cord injury; LSD – lysosomal 
storage disease; GALC – ß- galactocerebrosidase.
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1.6 Barriers to translation of genetically engineered NSC transplantation  
Despite the benefits shown in models of neurological disease/injury of transplanting genetically 
engineered NSCs, many barriers to their translation into the clinic exist (summarised in Figure 
1.3). Overcoming these barriers is therefore a key research goal and one that this thesis aims to 
start to address through the use of nanotechnology. This section will outline four major obstacles 
and the reasons they exist, whilst subsequent sections will highlight the potential of using 
nanotechnologies to address them. 
1) Safe and efficient genetic engineering: For clinical use, the most desirable transfection agent 
to introduce therapeutic genes into NSCs would: combine high transfection efficiency; provide 
minimal toxicity to target cells and host tissue; be amenable to scale-up and have the 
versatility to enable delivery of a range of DNA and RNAi molecules. Currently, the most 
popular method of genetic manipulation of NSCs is achieved using viral vectors (used almost 
exclusively when engineering NSCs for combinatorial therapy [Table 1.1]) which offer high 
transduction efficiencies. However, viruses have several drawbacks including: safety issues, 
associated with toxicity to the target cells and oncogenicity of the transduced population due 
to insertional mutagenesis (especially relevant when using stem cells which have a capacity to 
self-renew); a limit to plasmid size in the most versatile vectors; and a complex, time-
consuming method of application.49,50 Additionally, genes introduced by retroviral 
transduction have been shown to undergo down-regulation over time.51 All of these 
disadvantages pose a considerable barrier to clinical and commercial adoption of stem cells 
transduced with viruses. Although considered safer than viruses, non-viral transfection is 
generally associated with low transfection efficiencies, especially in the case of lipofection and 
electroporation,52,53 or high cell death, in the case of nucleofection.53 In the latter case, 
although nucleofection results in high transfection efficiencies (ca. 50%),53 losing valuable 
cells is costly and transplantation of cellular debris resulting from cell death could lead to 
adverse reactions at the site of transplantation.  
18 
 
 
2) Safe and efficient delivery of cells to injury sites: Accumulation of cells at the desired site is a 
key requirement of successful cell therapy. However, current cell delivery techniques to the 
injured CNS are associated with considerable disadvantages. Direct transplantation of cells 
generally results in a larger accumulation of cells than systemic injection. However, this 
approach is associated with significant risks in the CNS including secondary pathology, 
breakdown of the BBB and embolism.54 Systemic injection, either intra-arterially or 
intravenously, can alleviate these risks so has a higher translational potential, however, cells 
can be cleared by the tissue macrophage system, often ending up in the lung, spleen or liver 
so that few cells are retained at the desired site.55,56 Ramifications of this include the need to 
inject more cells (which will be costly to produce) to compensate for cell loss together with 
the possible need for multiple injections therefore further increasing risk to the patient. A 
further problem, common to both systemic and direct injection, arises from transplanting 
large concentrations of cells within the injected solution (ca. 1 x 105 cells/µL). This leads to 
high viscosity and cell clumping within the injected solution resulting in poor distribution of 
the cellular suspension throughout the lesion site. In addition, direct injection can cause 
damage to the cells and extensive cell death resulting in low numbers of viable cells delivered 
into the lesion (e.g. <5% OECs survived direct transplantation into a SCI site)57 – an issue 
known as ‘low stability’.  
3) Cell tracking post-transplantation 
a) Non-invasive imaging: Cell transplant populations need to be monitored in order to 
correlate cell behaviour with functional outcome and assess integration upon 
transplantation. This applies in vitro, for example, in monitoring cell transplantation in 
slice models of injury, and in vivo, for pre-clinical and clinical work. Real-time, non-
invasive imaging of transplant populations in vivo is essential to monitor correct 
engraftment, both position and viability of the graft, cell migration and ideally cell 
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differentiation. This is commonly achieved by using several techniques such as: magnetic 
resonance imaging (MRI) where the cells are labelled with a contrast agent; 
bioluminescence imaging (BLI) where cells express photon producing enzymes; single 
photon emission computed tomography (SPECT) and positron emission tomography 
(PET), which both detect radioactive labels; or near infrared fluorescence (NIRF) 
microscopy which detects fluorophore labelled cells.58 Each technique has its own 
advantages and disadvantages, for example, MRI has high spatial resolution and tissue 
penetration whereas BLI and PET have a high sensitivity (the ability to detect lower 
numbers of cells) and BLI has the possibility of providing information on differentiation by 
detecting luciferase expression that is under the control of cell specific promoters.59 
b) Histological examination: Ultimately, the tissue has to be analysed post-mortem for 
thorough histopathological examination of integration, migration and differentiation of 
the transplanted cells and also, the effect of the transplant on the host tissue. This means 
that the transplanted population needs to be distinguished from the host cells. This can 
be accomplished by using cells from another species which can be detected with 
antibodies against that species, using cells from mutant animals which express GFP, 
labelling cells with lipophilic fluorescent dyes60, or genetically modifying cells to express a 
detectable marker.42 The first two techniques, although useful in a laboratory setting, are 
not readily translatable. Labelling cells with dyes can result in non-specificity due to 
‘leaky’ dyes61 and virally transducing a cell population to express a detectable gene is 
undesirable from a translational perspective as discussed above. 
4) Functional integration: The therapeutic efficacy of NSCs is often ascribed to their bystander 
effect – the release of neurotrophic and immunomodulatory factors.26 However, a key goal of 
NSC transplantation is to replace lost or damaged cells. Although there are many reports of 
NSCs differentiating into useful cells for the disease pathology,24 NSC differentiation after 
transplantation depends on many factors such as source of NSCs (age of donor, tissue derived 
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from) and injury site environment. Controlling NSC differentiation into required cell types is 
therefore an important area of research to enhance successful function of the transplanted 
cells. In addition, undesirable differentiation of NSCs into astrocytes has been observed in rat 
models of SCI46 and associated with mechanical allodynia24 highlighting the importance of 
careful control over NSC differentiation. 
 
 
Figure 1.3. Schematic highlighting barriers to translation facing genetically engineered NSC 
transplantation therapy. 
 
1.7 Investigating nanotechnologies in order to address translational barriers  
In order to overcome the described obstacles, alternative strategies need to be developed. With 
the field of nanomedicine advancing at a rapid pace, nanotechnology platforms such as nano and 
micro sized particles and engineered hydrogels now offer a wealth of biomedical functions that 
can aid in overcoming the translational barriers identified in Section 1.6. Detailed discussion of 
the properties of MPs and hydrogels and how these relate to their biomedical function will be 
provided in following sections. However, this section briefly summarises how specialised 
nanomaterials may overcome the outlined barriers to translation. Safe genetic manipulation 
(Barrier 1) of neural cells has been demonstrated by using MPs with gene transfer efficiency 
improved by application of oscillating magnetic fields below the culture plate.62,63 Key 
regenerative properties such as cell proliferation, survival and differentiation are unaffected by 
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such protocols – of high importance for clinical application (expanded in Section 1.9 and Chapter 
2). Nanomaterial strategies for safe and efficient delivery of cells to injury sites (Barrier 2) are 
two-fold. Firstly, MP labelled cells have been shown to be amenable to magnetic cell targeting 
where systemically delivered cells can be localised to required sites by external magnets, avoiding 
cell clearance through the tissue macrophage system (expanded in Section 1.11 and Chapter 
3).64,65 Secondly, cells can be evenly distributed in protective, implantable hydrogel matrices. This 
second strategy addresses the issue of low transplant stability and potentially facilitates the 
delivery of a highly viable cell graft (expanded in Section 1.12 and Chapter 4). Post-
transplantation, MP labelled cells have also been tracked (Barrier 3) non-invasively by MRI and in 
fixed tissue using histopathological detection of iron.66 Finally, as will be expanded in Section 1.12 
and Chapter 4 the issue of functional integration (Barrier 4) may be addressed by engineering 
sophisticated hydrogels that can control stem cell differentiation, through tuneable stiffness, and 
potentially provide topographical cues for regenerating tissue.  
Initially, combinatorial therapy was expected to involve cell delivery in conjunction with drug 
delivery. However, through advent of these nanotechnologies combinatorial therapy is being 
redefined as several important biomedical functions could be achieved simultaneously. For 
example, MPs have been separately shown to mediate gene delivery and MP labelled cell 
targeting and tracking through MRI. Engineering a multifunctional MP capable of all these 
features would therefore provide a one-step approach to addressing several barriers to 
translation. In addition, fusion of technology could further broaden the scope of what is 
achievable. In this regard, combinations of MP and hydrogel technology could address all of the 
barriers to cell transplantation outlined in Section 1.6.  
Therefore, given the potential of these technologies for cell transplantation, this thesis aims to 
explore key concepts of utilising nanotechnology for NSC transplantation in more detail. The 
following sections will describe MPs and hydrogels, how they might influence future therapeutic 
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strategies (by addressing the barriers to NSC transplantation therapy and providing platforms for 
the next generation of combinatorial therapies to enhance repair in the CNS) and the gaps in the 
literature which require further research. 
 
1.8 MP composition and properties 
MPs are a class of materials that interact with a magnetic field and can be functionalised to 
perform different tasks. They are used for in vivo imaging as MRI contrast agents,67 drug and gene 
delivery68 and cell or biomolecule separation69 amongst other uses. In general they possess a 
magnetic core surrounded by a biocompatible layer and they can range in size from about 10 nm 
to 1 µm. Functional molecules, such as fluorophores or small targeting molecules, can be added to 
the particle and, recently, due to improvements in the synthesis of these particles, multifunctional 
MPs capable of achieving several goals in one system have been developed (Figure 1.4 and Table 
1.2).68,70,71 MP labelling has been shown not to affect NSC survival and differentiation after 
transplantation in vivo61 indicating these are an attractive technology to explore for clinical 
application. This overview will give a brief discussion of the chemistry of the particles and how 
they can achieve multi-functionality, while subsequent sections will examine the biomedical 
applications of these particles. 
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Figure 1.4. Schematic detailing multiple biomedical applications of MPs. 
 
The core material of an MP dictates how the particle will interact with a magnetic field and total 
core size, crystal size, and iron content all impact on this, reviewed by Laurent et al.72 The most 
popular core material for in vivo use is iron oxide, as magnetite (Fe304) or maghemite (ƴ-Fe2O3), 
which can be metabolised by cells and appears to be non-toxic.73,74 A key property of the core is 
superparamagnetism which occurs when iron-oxide core size reduces to below 30 nm. Iron-oxide 
is normally ferromagnetic which means that it displays strong attraction to a magnetic field and 
remains magnetised after a magnetic field has been removed. Paramagnetic materials display a 
weak attraction to a magnetic field and lose their magnetism once the field has been withdrawn. 
Superparamagnetism is a combination of both characteristics and occurs in the nanoscale 
dimensions of MPs whereby particles display high susceptibility to a magnetic field but do not 
retain magnetism after the magnetic field has been removed.75 Contrast enhancement from MPs, 
in MRI images, is due to the fact that the superparamagnetic particles display high magnetic 
moments which act to shorten proton relaxivity times in the immediate surroundings, leading to 
loss of signal in both T1 and T2 MRI images.
70,76 As the particles do not retain any residual 
magnetism after the field has been removed, aggregation is avoided. This characteristic is 
important for the safety of the particles application in vivo to reduce the risk of aggregate 
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mediated embolization of capillaries. Along with acting as a contrast enhancer, it should also be 
noted that the iron core can be detected histologically using Perls’ stain for identification of 
labelled cells.77 
To coat the particle, natural and synthetic polymers are generally used for their biocompatibility 
(i.e. the ability to interact within a biological system without causing adverse toxicity) and their 
amenability to further functionalisation. Coating materials can be physically associated with the 
core by creating a dense network of cross-linked polymer around the core or can be covalently 
attached through linker molecules.71 The former can degrade over time so any long term 
functionality required of the particles will likely utilise polymers covalently linked to the iron oxide 
core. The functional groups which are available on the coating polymers (e.g. primary amines or 
carboxylic acids) allow for addition of functionalising molecules, such as fluorophores or targeting 
molecules, alone or in combination. Some polymers can also be used to bind drugs or nucleic 
acids68 while leaving their functional groups available for further manipulation. Careful design, 
therefore, could lead to a single nanoparticle with multiple functionalities and therefore multiple 
capabilities. In this respect, 'multimodal' particles have been designed which offer: 
complementary imaging techniques, such as MRI coupled with fluorescence (near infra-red);84 cell 
targeting and imaging capability;85 and the capacity for gene delivery and cellular imaging.83  
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Table 1.2. Examples of MPs and their biomedical applications. 
 
 
Uses Name (if applicable) Core Coating Reference 
MRI Feridex  Superparamagnetic Iron Oxide 
 
Dextran or poly-l-lysine 
67
 
Magnetofection for neuronal 
cells 
Neuromag Iron Oxide +vely charged 
Complexes with DNA or RNA 
 
30,62,63
 
Magnetofection PEI-Mag2 Iron Oxide PEI (+vely charged polymer) 
 
78
 
Magnetofection LS-Mag-PEI Iron Oxide PEI and lauroyl sarcosinate – 
amphiphilic molecule 
 
78
 
Hyperthermia 
Ligands allow uptake by NSCs 
 Cores of Iron oxide Aminosiloxane 
Stealth L1 
Tetra-4-carboxy-phenyl 
porphyrin 
 
79
 
Magnetic cell targeting  Styrene acryl polymers Magnetic ferrite with outer 
layer of peptides 
 
80
 
Examining particle uptake Spherofluor Polystyrene with embedded 
fluorophore 
Iron oxide crystals 
 
81
 
MRI/PET contrast agents Multimodal imaging particle Iron-oxide Poly aspartic acid, 
RGD targeting ligand, 
DOTA – radiolabel for PET 
imaging 
 
82
 
MRI contrast agent 
Histological labelling 
Transfection  
Multimodal 
imaging/transfection particle 
Iron-oxide PEI 
Conjugated to RITC 
83
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The most widely used coating polymer for transfection is PEI,86 a highly positively charged, 
synthetic polymer which has been used as a transfection reagent in its own right.87 PEI is thought 
to display high transfection efficiency for several reasons: firstly, it can condense DNA and act as a 
carrier; secondly, due to its positive charge it can interact with cell membranes and; thirdly, once 
inside endosomes, PEI buffers the internal environment causing proton and concomitant chloride 
ion and water influx resulting in endosome lysis, releasing the DNA which can be transported to 
the nucleus.88 PEI displays dose dependent toxicity probably due to its interaction with cell 
membranes and also lysosome rupturing capabilities. Chitosan, a natural polymer, which displays 
lower toxicity than PEI, has also been studied89,90 but is not as effective a transfection agent as PEI, 
possibly because it has lower buffering capability and therefore less chance of rupturing 
endosomes. However, Kievit et al.90 combined chitosan with low molecular weight PEI to improve 
transfection efficiency of a human umbilical vein endothelial cell line and also make use of 
chitosan’s biocompatibility to reduce toxicity.  
The coating material also has an impact on the capability of the particle to act as a contrast agent 
for MRI. It has been shown that exchanging a hydrophobic coating for a hydrophilic coating 
increases contrast in T2-weighted MRI scans.
91 This is because water molecules can diffuse close 
to the core so the protons experience greater relaxivity. Also, materials closest to the core affect 
the superparamagnetism property of the iron-oxide and ultimately the particles proton 
relaxivity.91 Both these observations are critical to multi-functional nanoparticles as any 
alterations to the particle surface, for example, to enhance drug or DNA binding, will have an 
effect on the in vivo imaging capability of the particle.
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1.9 Application and mechanism of MP mediated gene delivery 
 
Figure 1.5. Schematic of typical magnetofection protocol. 
 
‘Magnetofection’ is the process of delivering genetic material complexed to MPs into cells under 
the influence of magnetic force. The most widely used protocol for magnetofection is the 
application of a static magnetic field, placed beneath the cell culture surface during transfection, 
which draws the particles towards the magnet concentrating them at the cell surface (Figure 1.5). 
It appears that increased cellular interaction with the particles is the mechanism by which 
transfection efficiency is increased by magnetofection rather than the field enhancing uptake or 
forcing the particles inside the cells. Huth et al.92 demonstrated this by applying MPs onto the cell 
surface by centrifugation then performing transfection in the presence or absence of a magnetic 
field. As the concentration of particles is now the same at the cell surface at the start of 
transfection in both protocols, if the magnetic field acts to increase cellular uptake through 
enhanced endocytosis or forcing the particles into the cells, then applying a magnetic field during 
this transfection should see an increase in transfection efficiency. There was no significant 
difference in transfection efficiencies between the two protocols suggesting that the static field 
solely acts to concentrate the particles at the cell surface.  
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The Dobson group has recently been advancing magnetofection technology and have shown the 
addition of an oscillating component (the magnetic plate physically oscillates in an x-y plane 
beneath the culture plate [Figure 1.5]) to the magnetic field can further enhance MP mediated 
gene delivery over and above that of static field transfection.93 The mechanism for the enhanced 
transfection efficiency observed when using oscillating magnetic fields remains to be elucidated 
but there are two theories: (1) the particles are more disperse in solution due to their lateral 
motion and therefore are able to contact more cells; (2) the oscillation of the particles actually 
stimulates membrane uptake of the particles. This stimulation could cause a general increase in 
endocytosis, promote a more specific uptake pathway which leads to nucleic acid transport to the 
nucleus or be a physical shearing effect. The latter seems unlikely as cell viability, proliferation 
and differentiation appear to be unaffected.62,63,93 Despite the advantages of genetically 
manipulating transplant cells using MPs, magnetofection protocols, in particular the application of 
oscillating fields, have not been tested in NSCs. This is an important area of study as these cells 
constitute a population with high clinical impact but data regarding the use of magnetofection 
protocols in other cell types cannot be extrapolated to this cell population.  
 
1.10 MPs for cell tracking  
There is a large body of basic research concerning the use of iron nanoparticles to label transplant 
cells which can be imaged non-invasively by MRI in real time.67,70 Feridex, a dextran coated iron-
oxide nanoparticle, was approved by the FDA to act as a contrast agent in the clinic, highlighting 
these particles' safety.67 Feridex was originally designed as a liver contrast agent as it accumulates 
there, but has since been used to label various stem cell populations.73 NSCs have been labelled 
with MPs and tracked using MRI in various rat and mouse models of disease67 and also in a canine 
model of LSD.94 Using a detailed analysis, Cohen et al. have shown that neurospheres isolated 
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from GFP+ mice and labelled with Feridex can be tracked in vivo using MRI.66 In this study, labelled 
NSCs were transplanted into the cerebral ventricles of mice with an induced form of multiple 
sclerosis (experimental autoimmune encephalomyelitis). Using in vivo MRI, a hypointense region 
where the cells had been injected was observed on day one and was followed by progressive 
migration of the cells into the corpus callosum over 7 days, thought to result from NSC 
pathotropism towards lesion sites. After sacrificing the animal, ex vivo MRI confirmed the 
widespread hypointense signal which correlated well with both GFP fluorescence and Perl’s 
staining, indicating that the signal was derived from the labelled transplant population. One study 
has also examined the feasibility of labelling NSCs with MPs and tracking them using MRI in the 
clinic.95 A hypointense region in the T2-weighted MRI image was observed which was attributed to 
the transplanted and labelled NSCs. However, the study also highlighted some limitations. For 
example, the signal reduces over time (after 7 weeks the signal was no longer detectable) either 
due to migration of stem cells or their proliferation, which dilutes the MP concentration within 
daughter cells. Long term monitoring in vivo has been shown, with MRI signal persisting for 58 
days, although convincing evidence that the signal originates from just the transplant population 
is not available.96 One study has demonstrated that particles released by dead cells are taken up 
by immune cells or microglia leading to a false signal where the labelled NSCs were injected, as 
this is where most transplanted cells die.97 Caution will therefore be required when labelling NSCs 
with MPs for long term tracking purposes as establishing whether MPs have been taken up by 
host cells could be difficult. However, a useful application which does not rely on long term 
retention of the signal, is observing the cells immediately after transplantation using MRI. 
Transplanted cells are often injected using ultrasound observation to guide the surgeon to the 
required site. Ultrasound images do not have the soft-tissue resolution of MRI and it has been 
shown that cell transplants have been injected into the wrong position using ultrasound.98 
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Therefore MRI could be used to check that the correct localisation of the transplanted cells has 
been achieved. 
Although a powerful tool to track transplanted cells non-invasively, MRI does have some 
drawbacks. Signal dilution and particle uptake by host cells has already been mentioned. In 
addition, some conditions that may respond to stem cell therapy, such as traumatic injury, result 
in similar hypointense regions in the MRI signal as those resulting from MP labelled cells. Different 
imaging modalities can provide complementary information to MRI. For example, PET has a high 
sensitivity and the ability to detect low numbers of cells, which could be useful when tracking 
NSCs involved in widespread migration.59 However, PET does not contain anatomical information. 
For real time imaging, fluorescence microscopy can obtain the greatest resolution but does not 
have good tissue penetration.59 MRI contrast enhancing iron-oxide nanoparticles conjugated with 
radiotracers, which can be tracked using PET or fluorophores have been synthesised, which allow 
a combination of imaging modalities to be used. Lee et al.82 have synthesised iron oxide 
nanoparticles for tumour imaging. These are functionalised with a PET radiotracer and an RGD 
targeting peptide which binds integrin αvβ3, expressed on cancer cells. The particles collect at the 
tumour site and allow MRI and PET visualisation of the affected area and the authors speculate 
that these might be used in early cancer detection as the integrin expression is switched on very 
early in tumorigenesis. Similar multifunctional imaging tools may be able to provide complex 
information on stem cell localisation, viability and differentiation.  
 
1.11 Localising MP loaded cells to sites of injury and disease using magnetic force 
To address the need for safe and efficient delivery methods of cells to the CNS, localising 
magnetically labelled cells using magnetic force may be a promising strategy. This approach could 
be especially beneficial for indirect methods of cell transplantation such as systemic injection or 
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lumbar puncture (into the CSF) in the spinal cord. Non-invasive delivery of cells is important in the 
CNS due to the risks of secondary pathology when cells are administered by direct injection, 
however, it is generally associated with low cell retention at the desired site due to cell removal 
through the tissue macrophage system or cell dispersal by the CSF which is produced and cleared 
in humans at rates of about 0.35 mL/min.99 Applying external magnets after transplantation of MP 
labelled cells by both intravenous and lumbar puncture delivery has been shown to enhance cell 
retention post-transplantation in the brain and spinal cord. In one study, GFP+, bone marrow 
stromal cells (BMSCs) were labelled with Feridex complexed to poly-L-lysine (PLL) and 
transplanted into a rat contusion model of SCI via lumbar puncture into the CSF. When 
transplanted in the presence of a magnet over the lesion, the area occupied by the MP labelled 
BMSCs was measured as being 20 times that of non-labelled cells. Localisation of MP labelled cells 
appeared to reduce cavity formation at the site of injury and improved hind-limb function.100 Cells 
transplanted under magnetic field application have also been monitored via MRI, demonstrating 
the potential multifunctionality of MP labelling for clinical applications referred to in Section 1.7 
and 1.8.101,102 
Despite the advantages of using MPs for both non-invasive tracking and targeting of transplanted 
NSCs, clinical use of such protocols is hampered by the lack of available neurocompatible particles 
and the various strategies used to initiate uptake of MPs. As will be expanded in Chapter 3 these 
include use of high iron concentrations in the media, lengthy incubation times, transfection 
agents and cell penetrating peptides (CPPs). All of these strategies are associated with 
considerable drawbacks including toxicity and time-consuming protocols. Novel designs of MPs 
which can display functional efficacy in imaging and magnetic targeting could provide an 
alternative approach to achieving high uptake, however, very few neurocompatible particles are 
described in the literature.  
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1.12 Hydrogels as novel cell delivery devices 
Hydrogels are used for in vitro research and have been used for several applications in 
regenerative medicine including in bone, cartilage and cardiac repair.103,104 They have a jelly like 
appearance but are actually fibrous cross-linked polymers which can mimic ECM. Water 
molecules disperse in-between the pores of the fibres which lends the hydrogel a translucent 
appearance and, as a result of their high water content, biocompatibility. This confers the ability 
to support cell growth including in 3-D structures with cells dispersed through the matrix. They 
can be made up of a variety of materials both natural, for example collagen and hyaluronic acid (a 
spinal cord ECM molecule) which are biocompatible and mimic the native cell environment, and 
synthetic, which can be more readily predefined in terms of binding sites and fibre diameters.105 
In addition to materials, there are numerous features of the hydrogel which can be modified to 
suit the application, such as fibre diameter and spacing which influences porosity, amount of 
crosslinking and availability of cell binding sites. Altering these parameters affects the cells’ 
interaction with and ability to migrate through the construct, the ease at which molecules diffuse 
through the fibres and mechanical properties such as stiffness and biodegradability.105 These 
tuneable features allow for a range of versatile applications for hydrogel technology including for 
neural applications where hydrogels have several attractive features for their use in regenerative 
neurology (Figure 1.6). This section briefly outlines some of the tuneable features of hydrogels 
and how they are useful for cell delivery. 
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Figure 1.6. Schematic depicting advantages of hydrogels for repairing the CNS. 
 
Hydrogel systems provide 3-D support for cells which in terms of cell transplantation provides the 
cells with a pre-formed substrate. This avoids problems such as cell death, dispersal or clumping 
outlined in Section 1.6, which result in a transplant of low stability. Some of the first instances of 
combining cells with hydrogel systems show improved survival of the transplant population 
compared to cells transplanted alone.106 For example, Jin et al. combined NSCs with MatrigelTM 
and cultured the cells for one week before transplanting into an area of ischemic brain in rats.107 
After eight weeks rats were sacrificed to examine the fate of the cells. Compared to a cell only 
group, NSCs transplanted in combination with MatrigelTM displayed higher numbers within the 
cavity site (300 cells/mm2 compared to negligible numbers in the cell only group – judged by 
image of the cavity) and a resultant reduction in cavity size. Some of the surviving cells displayed 
evidence of differentiation into astrocytes and neurons and behaviour outcomes were improved 
in the MatrigelTM compared to the cell only group. However, this study used an NSC cell line 
(which may not be physiologically relevant to primary NSCs, Section 1.13) and as MatrigelTM is 
derived from xenogenic sources it is not suitable for translation. 
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It has also been shown that implanting cells with hydrogels can improve their biodistribution. 
Ballios et al. mixed retinal stem cells (RSCs) with HAMC (a mixture of hyaluronan and 
methycellulose) before injection into the sub-retinal space in mouse eyes.108 Cellular coverage of 
the retinal pigmented epithelial membrane (the tissue targeted for regeneration in therapies for 
age related macular degeneration) was assessed and found to be greater in hydrogel transplanted 
RSCs compared to RSCs transplanted in saline alone. The authors also noted continuous banding 
of RSCs on the membrane when transplanted with HAMC compared to aggregations of cells, in 
non-continuous banding patterns, when cells were transplanted in saline. This study, therefore, 
provides evidence that distribution of a transplant cell population can be improved by using 
hydrogels which could be of benefit when promoting regeneration over large lesion sites. 
Generally hydrogels can be formulated using biocompatible materials that are non-toxic to both 
incorporated cells and host tissue – essential for clinical application – and are biodegradable. 
Using different polymers it is also possible to control the rate of matrix degradation. This is 
important to provide initial support for the growing cell population within the matrix – so as the 
cells grow they can slowly integrate into the lesion site and ensure that further tissue 
regeneration is not inhibited by the construct.105 For additional consideration when delivering 
hydrogels to the CNS, Mahoney et al. showed that neurite extension into hydrogels is dependent 
on matrix degradation rate.109 In that study, NSCs were incorporated into polyethylene glycol 
matrices formulated with different macromers which display different rates of degradation. NSCs 
seeded into the scaffolds formed neurospheres that extended processes on a time-frame which 
correlated with the degradation profile of the hydrogel. This characteristic of an implantable 
hydrogel is an important consideration when they are destined for transplantation into the CNS 
where the aim will be to improve axonal regeneration. 
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In terms of the physical properties of hydrogels, stiffness can be adjusted in a multitude of ways 
such as varying polymers or polymer concentration and increasing the amount of crosslinking 
within the gel. Mechanical properties of the gel can have a profound effect on gel acceptance and 
biocompatibility within host tissue and also on the encapsulated cells.110 For example, Banerjee et 
al. incorporated NSCs into alginate scaffolds of various stiffness (ranging from ca. 180 – 20000 
Pa).111 From initially seeding 4000 cells a much higher number of cells was obtained after one 
week in culture in the softest gel (ca. 65000) compared to the stiffest gel (ca. 10000). In addition, 
higher expression levels of ß-tubulin (a neuronal marker) mRNA were found after the seven days 
in culture in the softest gel. The data suggest hydrogel stiffness could have an effect on cell 
response especially in proliferation and differentiation; two key regenerative properties of 
transplanted cells.  
Various techniques also exist for incorporating guidance cues into the hydrogel formulations. 
These can include imparting a directional mechanical strain on the gel or inclusion of micro or 
nanofibres. For the first approach, East et al. incorporated astrocytes into a collagen scaffold 
which is tethered at two ends.112 As the astrocytes attach to the collagen and contract it the strain 
imparted onto the collagen appears to align the astrocytes (and presumably the collagen fibrils) 
parallel to the direction of force. In this manner, a gel which is tethered at two ends creates areas 
of alignment within it, most notably along the edges of the gel. When dorsal root ganglia cells 
were also incorporated into this construct, their neurites could be seen to extend alongside the 
aligned astrocytes and had a greater length compared to those seeded in areas of unaligned 
astrocytes. For the alternative approach, Weightman et al. seeded astrocytes onto aligned 
nanofibres and then embedded these in a collagen hydrogel.113 By building up layers of PLA fibres 
within collagen the authors demonstrated that spatial control of aligned astrocytes could be 
achieved in three-dimensions. This is particularly important for transplantation into 3-D lesions so 
that repair can be mediated throughout the depth of the injury.  
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Although advances in the field of hydrogel technology for cell transplantation are occurring at a 
rapid pace, several aspects have the potential for improvement which include: (1) The fact that 
most transplanted constructs contain one cell type, which can only address one issue within the 
complex nature of CNS injury. Alternatively, the construct may contain stem cells, which rely on 
correct differentiation to replace a certain cell type. (2) A lack of ability to monitor implants after 
transplantation to assess engraftment and survival and (3) the absence of genetically engineered 
cells within matrices. This is despite the fact that the technology could improve the survival and 
biodistribution of genetically engineered cells to enhance their therapeutic effect. Combinations 
of hydrogel systems with MP technologies could address these issues with the MP platform 
providing the ability to monitor the graft and a means of safe genetic engineering. Enhancing the 
complexity of implantable hydrogels by inclusion of multiple cell types and application of MP 
technology could facilitate the next steps in CNS therapy by promoting repair through 
biomolecule release (from the incorporated cells) and subsequently providing support and 
guidance for regenerating tissue. 
 
1.13 Using cell lines in neuro-nanotechnology research 
Many of the studies investigating the use of MPs for clinical application in NSCs rely on the use of 
cell lines. While these studies can provide useful proof of principle data in the field of 
nanotechnology, especially regarding the transplantation and monitoring of MP labelled cells non-
invasively using MRI, there are questions surrounding the suitability of cell lines as accurate 
predictors of cellular uptake and toxicity of MPs in primary cells. Cell lines are designed to be 
passaged multiple times for ease of study however due to genetic drift and selective pressure 
(fastest growing cells dominate cultures) over time these cells start to lose key functions and traits 
of the cellular source they are supposed to represent.38 Concerns over cell line provenance are 
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widespread with a number of studies potentially reporting erroneous data generated from 
contaminated or misidentified cell line stocks.114 It is estimated that as many as 20% of cell lines in 
use are contaminated and 18% of human cell lines investigated displayed cross-contamination.38 
These findings suggest that data generated with respect to the application of nanotechnologies in 
cell lines might not accurately represent the behaviour of primary cells. An example of this was 
shown recently where PC-12 cells, a cell line widely used as a neuronal model, displayed six-times 
the amount of particle uptake when compared to primary neurons.115  
Further, in terms of clinical application, cell lines are unlikely to be utilised due to high survival 
and proliferation rates and resistance to cell death signals increasing the risk of tumour formation 
post-transplantation. Primary cell sources for NSCs include cells from aborted foetuses, ESC 
derived NSCs and adult NSCs. These populations are generally heterogeneous containing different 
cellular subtypes, cells in different stages of the cell cycle and diverse differentiation states.116 Cell 
lines on the other hand are often homogenous in composition as they have been expanded from 
a relatively small original cell source through multiple passages with the aforementioned selection 
pressures. Therefore, it is preferable to test novel nanomaterials in vitro using primary cells to 
more closely represent clinical application. In the context of nanomedicine, addressing the safety 
of nanomaterials for medical application is critical for the safety of the patient. Concerns 
surrounding cell lines also indicate that these models may not provide accurate data on toxicity of 
nanomaterials to NSCs. This is especially pertinent given the impact the field could have on global 
health which could be stalled with poor safety data.  
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1.14 Testing novel therapies whilst reducing reliance on live animal models 
The gold standard for testing novel regenerative neurology strategies is to use animal models. 
These are no doubt crucial as pre-clinical models and are often the next steps following promising 
in vitro studies. However, animal models have several drawbacks for neural applications, 
including: cost, associated with animal husbandry and the requirement for specialist personnel to 
perform the experiments; significant experimental variability, meaning large numbers of animals 
are required to achieve statistically significant results; and ethical concerns, especially pertinent 
for CNS injury and disease which involve considerable suffering for the animal. Therefore, in 
accordance with the 3R’s principle (to replace, reduce and refine animal usage)117 novel 
techniques are required to test the next generation of regenerative strategies in an efficient, high 
throughput, cost effective and ultimately predictive manner. 
In this context, the use of organotypic slice cultures could be one viable option to precede animal 
studies. Organotypic slice culture involves taking slices of target tissue and culturing at an air-
medium interface and has been demonstrated for neural tissue for many years.118,119 These slices 
can be cultured for several weeks118 allowing long-term analysis of experimental manipulations. In 
terms of their predictive utility, they mimic the cellular composition and cytoarchitecture of the 
tissue they have been derived from and have been shown to follow regenerative events similar to 
those seen in vivo. For example, a slice model of SCI exhibited limited axonal outgrowth, astrocyte 
scarring and microglial infiltration into the lesion site120 – all hallmark traits of SCI in vivo. As 
several slices can be derived from one animal (control and test slices can be derived from the 
same animal) the number of animals for an experiment is reduced but also there is limited 
suffering endured by the animal. 
Slices are easier to monitor post manipulation compared with in vivo models, facilitating detailed 
single cell observation and time-lapse studies for the therapeutic time-course. The utility of 
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organotypic slice cultures for testing nanotechnologies has been demonstrated in several areas 
including investigating the regenerative capacity of aligned nanofibres to promote directed axonal 
outgrowth in a slice model of SCI,120 studying the feasibility of magnetic stem cell targeting using 
MP loaded NSCs,80 MRI tracking of MP labelled NSCs in spinal cord slices121 and also examining the 
survival and differentiation of neural cells post-transplantation after they have been genetically 
manipulated using MPs and magnetofection protocols.30,62,63 However, despite the advantages of 
this system as a useful indicator of the regenerative potential of nanotechnological strategies it is 
often overlooked as a research tool. 
 
1.15 Aims of experimental chapters 
This thesis aims to investigate the potential of using a range of tissue engineering approaches in 
order to address the barriers to translation of genetically manipulated NSCs outlined in Section 
1.6. Given the advantages of MPs for safe and efficient gene delivery and facilitation of non-
invasive cell targeting and tracking this is an especially exciting platform for investigation for use 
with NSCs. Several gaps in the literature have been identified with respect to utilising the MP 
platform in conjunction with NSCs. Firstly, the application of oscillating magnetofection protocols 
has been shown to greatly enhance MP mediated gene delivery in other neural cells, however, 
establishing the optimal transfection protocol by detailed investigation of oscillating field 
magnetofection has not been attempted in NSCs. Further, a comparison of the efficiency of 
magnetofection protocols between NSCs grown as monolayers and neurospheres has never been 
performed. Secondly, although successful non-invasive imaging of labelled NSCs has been 
demonstrated, there is a lack of translatable strategies to achieve high MP labelling in NSCs. As 
most studies in this area use Feridex, there also appears to be a substantial lack of 
neurocompatible particles which can facilitate non-invasive cell tracking and magnetic cell 
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localisation. Lastly, cell delivery strategies using hydrogels have been developed, however, an 
extra level of complexity can be added to these cell-hydrogel composites by developing protocols 
to potentially facilitate multiple cell delivery and genetic manipulation of intraconstruct cells. In 
this regard, developing protocols to culture and differentiate NSCs incorporated in hydrogels and 
combining this with MP mediated genetically manipulation using MPs offers an enticing strategy 
to achieve this. Given the potential for these nanotechnologies to address the described barriers 
to translation and the gaps in the literature present in this area the broad and specific aims of the 
experimental chapters are as follows: 
 
Chapter 2: Safe and efficient gene delivery to NSCs grown as monolayers and neurospheres 
using magnetofection protocols 
The broad aim of this chapter is to address ‘barrier 1 – safe and efficient gene delivery to NSCs’. 
This will be achieved by investigating the feasibility of delivering genes into the NSC population 
using MPs and whether this can be improved by application of oscillating fields. Of significant 
novelty in terms of genetically engineering a transplant cell population a comparison will also be 
performed to examine differences in magnetofection outcomes between NSCs cultured in two 
systems: monolayers and neurospheres. The safety of the developed protocols will be 
investigated using standard techniques for both systems. Owing to the transfection efficiency 
obtained in monolayers this culture format will be taken forward to assess the feasibility of 
revealing subtle changes in cellular biology after magnetofection by mass spectrometry and 
bioinformatics analysis. Further, magnetofected monolayer NSCs will be transplanted onto 
cerebellar slices as an additional safety assessment to investigate their survival and differentiation 
in host tissue. An examination of the utility of using the cerebellar slice as a model to test 
functional capacity of the cells after magnetofection will also be made. 
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Chapter 3: Developing high iron content particles for the efficient labelling of NSC transplant 
populations  
The broad aim of this chapter is to address ‘barrier 2 – safe and efficient delivery of transplant cell 
populations’ and ‘barrier 3 – cell tracking (both non-invasive and post-mortem)’. In an attempt to 
address the lack of neurocompatible particles in the literature, Dr Boris Polyak has kindly 
synthesised PLA based MPs and the tests in NSCs of these are described in this chapter. These 
particles vary in iron content and, as will be expanded in the introduction for this chapter, 
enhancing iron content within MPs in conjunction with magnetic field application may increase 
their uptake in NSCs. Therefore, the aim is to investigate the effects on MP uptake in NSCs of 
systematically modulating iron content of polymeric MPs in conjunction with the applied static 
and oscillating fields used in Chapter 2. The safety and compatibility with NSCs of these 
procedures will also be investigated by utilising standard histological methods and transplantation 
of the labelled NSCs into a slice model of SCI. Further, a preliminary assessment of the functional 
capacity of the particles and labelling protocols will be examined by investigating magnetic 
capture of MP labelled cells in an in vitro flow system. 
 
Chapter 4: Magnetofection of intraconstruct neural cells 
The broad aim of this chapter is to also address ‘barrier 2 – safe and efficient delivery of transplant 
cell populations’ with added complexity in terms of generating a multicellular construct for 
transplantation. In this regard, this chapter aims to take steps towards addressing ‘barrier 4 – 
successful functional integration’ as transplanting cells as part of a hydrogel formulation can 
enhance their survival in the lesion area and potentially provide guidance for directed restoration 
of axonal circuitry. As this is the first time that NSCs have been cultured in the hydrogel format in 
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our laboratory, the first aim of this chapter is to establish successful NSC culture using collagen 
hydrogels. Subsequently, protocols to genetically engineer the intraconstruct NSCs will be 
investigated using MPs in conjunction with magnetic fields. Safety of the culture procedures and 
the protocols developed to engineer the NSCs will also be examined. 
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Chapter 2: Safe and efficient gene 
delivery to NSCs grown as 
monolayers and neurospheres using 
magnetofection protocols 
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2.1 Introduction 
In the General Introduction the multifactorial nature of CNS disorders was discussed along with 
the general opinion that, to address these multiple challenges, combinatorial therapy (for 
example replacement of lost or damaged cells and concomitant therapeutic biomolecule delivery) 
is necessary to achieve successful repair (Sections 1.2 and 1.5). Genetically engineering transplant 
cell populations so that they produce and release therapeutic biomolecules into transplant sites 
may be one strategy to achieve this.32 NSCs are an especially attractive target for such genetic 
manipulation as they integrate into endogenous tissue and display considerable migratory 
behaviour post-transplantation into the CNS, potentially allowing biomolecule delivery to a wide 
variety of pathologies (including lesions of different sizes and shapes and diseases with multiple 
lesion sites).28,29,32 Further, they differentiate into the three major cell types of the CNS, 
generating cells useful for repair e.g. oligodendrocytes for supporting and protecting axons.28 
Although the potential clinical utility of this approach has been shown in several animal studies, 
researchers have overwhelmingly relied on viral vectors to introduce genetic material into the 
NSC transplant population36,42,44 and, as discussed in Section 1.6, this strategy cannot yet be 
translated into the clinic, primarily for safety reasons.50 Therefore, there has been a major drive to 
find non-viral alternatives; however, the most widely used techniques for non-viral gene delivery 
to NSCs also have significant drawbacks for their potential use in the clinic including low 
transfection efficiency and low post-transfection cell viability.52,53 A promising alternative in this 
regard is to use MPs – a novel class of transfection agent with multiple clinical applications 
(expanded in the General Introduction, Section 1.8) – to bind and condense DNA for cellular 
delivery. There are many instances of neural cell transfection achieved using MPs in vitro.86 This 
technique is increasingly being adopted due to its simplicity, well-established and good safety 
profile and the potential for gene delivery to ‘hard to transfect’ cell types, such as mature neurons 
and primary cells.86,122 All these features are also applicable to a potential clinical grade 
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transfection protocol, although as far as I am aware, no study has utilised magnetofection as a 
procedure to introduce genetic material into a transplant cell population for therapeutic 
application (in humans or animal models). 
Our laboratory has shown that transfection of several neural transplant cell populations is 
achievable using MPs.30,62,63 In both astrocytes62 and OPCs63 transfection efficiency could be 
enhanced to a similar order to viral transfection by utilising oscillating magnetofection protocols 
(e.g. in the astrocyte population, transfection efficiencies using magnetofection were 54% 
compared to wide-ranging viral transfection efficiencies of 14-100%). The developed protocols did 
not demonstrate adverse effects on cell viability or morphology, and did not diminish key 
regenerative properties of the cells such as proliferation or stemness (in vitro). Further, 
magnetofection did not adversely impact transplant cell survival or differentiation post-
transplantation onto an organotypic slice model acting as host tissue. The data from these studies 
suggest magnetofection is a technique with significant translational potential. Therefore, this 
chapter aims to investigate the use of oscillating magnetic fields to enhance MP-mediated 
transfection efficiency of NSCs when grown in two distinct culture systems, both commonly used 
worldwide to propagate NSCs – neurospheres and monolayers (described in the General 
Introduction, Section 1.4).  
Magnetofection using a static magnetic field has been attempted with NSCs expanded as both 
neurospheres30 and monolayers.123 In neurospheres, no benefit was derived from applying a static 
field during transfection procedures; although a repeat transfection step (the following day) was 
utilised to achieve a final transfection efficiency of 22%.30 In monolayers, a transfection efficiency 
of 15% was achieved under static field magnetofection,123 however, no comparison was made to 
the absence of a magnetic field during transfection, necessitating further study to determine 
whether magnetofection provides enhanced transfection efficiency in NSCs grown as monolayers. 
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In both studies, the novel step of performing transfection in the presence of an oscillating 
magnetic field was not tested, yet reports from other cell types suggest that this could confer a 
substantial increase in transfection efficiency.62,63 Further, in previous studies, protocols to obtain 
enhanced transfection differed between cell types. The most effective transfection levels in 
astrocytes62 and OPCs63 were achieved in fields oscillating at 1 Hz and 4 Hz respectively, 
suggesting the most effective magnetofection frequency needs to be established for each unique 
cell type. Additionally, significant differences have been observed in particle handling and uptake 
between various neural cell types in both monocultures and co-cultures.124 These observations 
mean it is imperative that novel particles and magnetofection protocols are investigated and 
optimised for each neural transplant cell population.  
 
2.1.1 Why does magnetofection need to be studied in NSCs cultured as neurospheres and 
monolayers? 
NSCs are routinely cultured in neuroscience laboratories worldwide using two culture systems: as 
3-D cell aggregates in suspension, termed neurospheres, and as 2-D adherent cells termed 
monolayers. Both culture systems are also used when expanding NSCs (including human NSCs) for 
pre-clinical and clinical cell transplantation25,125–128 and have associated advantages and 
disadvantages for this purpose (Table 2.1).  
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Clinical consideration Neurospheres Monolayers 
Neurogenic potential   
Survival after transplantation  
enhanced by 
maintenance of cell-
cell contacts 
 
Scalable expansion  
via suspension 
bioreactor 
 
Automation of culture   
Online monitoring of cell characteristics 
 
 
allows observation of 
individual cells 
Table 2.1. Clinical advantages of expanding NSCs as neurospheres vs monolayers 
 
 For example, NSCs maintained as monolayers are thought to develop as a relatively homogenous 
population of cells which largely retain their ability to generate neurons.116 In contrast, 
neurospheres are a relatively mixed population of cells, with some differentiation occurring within 
the sphere, and reports showing reduced ability of NSCs to generate neurons post-
transplantation, following prolonged expansion as spheres.125 This may impact the choice of 
culture system when expanding NSCs to be transplanted in order to replace lost or damaged 
neurons, particularly in diseases such as Parkinson’s or Alzheimer’s, where efficient generation of 
neurons from the NSC grafts would be highly desirable. However, transplantation of NSCs as 
neurospheres is thought to result in higher levels of cell survival post-transplantation when 
compared with dissociated cells, although direct comparisons are rare in the literature.129 The 
reasons for these post-transplantation differences could be two-fold. Firstly, transplanting NSCs 
as neurospheres avoids cell death and toxicity associated with enzymatic and mechanical 
dissociation into single cells. Secondly, neurospheres have complex ECM and physical cell-cell 
interactions which are thought to promote NSC survival and, at least in vitro, enhance the 
response of the NSCs to growth factors (namely EGF and FGF-2) which stimulate proliferation and 
cell survival.130 
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One major issue in the cell therapy field is the production of large numbers of cells to satisfy the 
requirements of treating multiple patients (for example 8-12 foetuses are required per patient for 
a cell graft to treat Parkinson’s).15 Growing NSCs as neurospheres has the advantage of 
propagation in suspension which allows more cells to be produced using a smaller surface area 
than 2-D culture. The scalability of suspension culture makes this possible with estimates 
suggesting that, using bioreactors with similar footprints, cells propagated in suspension can 
generate 100-fold more cells when compared to adherent culture.131  
In terms of generating the large cell numbers required for the global regenerative medicine 
market it is widely accepted that automation of culturing procedures will be essential for 
manufacturing cell therapies.132 In this regard, both suspension and adherent automated cell 
culture systems are available, although adherent cultures provide a more technically simple 
platform, as routine media changes are much simpler (without the need to collect cells in 
suspension). In addition, novel imaging systems coupled with state of the art image analysis 
software can provide online information on adherent cell proliferation and differentiation.133 
These systems rely on the propagation of cells in 2-D so as to distinguish individual cells and also 
to determine cellular morphology, which would not be feasible in 3-D cell aggregates. This will be 
important for quality control purposes, including demonstrating cellular identity and health to 
regulators. 
The differences described here between monolayers and neurospheres, in terms of constituent 
cell-types and cytoarchitecture, offer distinct advantages and disadvantages to their clinical use 
but could also lead to significant differences between the two culture systems in terms of particle 
handling and response to magnetofection protocols. Given the potential for both culture systems 
to be used for clinical cell transplantation, it is crucial to investigate protocols designed to 
manipulate NSCs in both monolayer and neurosphere cultures. 
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2.1.2 The need for rigorous, high throughput safety testing of nanotechnology protocols to 
genetically engineer NSCs 
Nanomaterials for translational applications are made from a variety of materials and have wide-
ranging physicochemical properties including size, shape and surface charge. How each of these 
parameters relates to nanomaterial cellular toxicity is poorly understood, with further levels of 
complexity arising from synergistic effects between the parameters, meaning the toxicity of novel 
nanomaterials is difficult to predict.134 As the field rapidly expands, protocols for quick and 
accurate assessment of the effects of novel materials on cell health will need to be developed to 
facilitate testing of large numbers of different materials.  
Currently, cellular toxicity of nanoparticles is assessed in vitro with numerous tests, for example, 
the MTT (Methylthiazolyldiphenyl-tetrazolium bromide) assay, LIVE/DEAD staining, viability 
testing and cell marker expression (Table 2.2). Although these tests are useful for determining the 
overall acute toxicity of a nanomaterial, it has been reported that MTT assays and other 
fluorimetric readouts can experience interference from adsorption of the dye to the 
nanomaterial, resulting in inaccurate absorbance readings.135 In addition, these tests may mask 
more subtle molecular changes within the cells which could lead to aberrant cell behaviour – of 
particular concern to manipulated cell transplant populations. For example, some studies utilise 
assays to measure reactive oxygen species (ROS) generation which is thought to be one of the 
main mechanisms behind nanomaterial toxicity.136 ROS generation has been observed in one 
study without obvious effects on cell health as measured by the MTT assay101 indicating that 
underlying molecular changes in cells exposed to nanomaterials may be missed by commonly 
used safety assays.  
A further point to note is that not all cellular effects of nanomaterials result in membrane rupture 
or mitochondrial malfunction (for example effects on cell migration or proliferation) and may 
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have other underlying molecular features not exposed by routine toxicity tests. In addition, 
knowledge of the mechanism of toxicity is becoming increasingly important in the nanotoxicology 
field to provide a systematic evaluation of specific biological effects of particular materials and 
formulations at the nanoscale. Such detailed information on molecular changes would require 
more thorough examination of cellular biology which could be provided by either genomic or 
proteomic approaches. There are many examples of the wealth of data which can be generated 
from both genomic and proteomic analyses of cells labelled with nanoparticles,137–139 however, 
most studies of this nature have been performed using non-neural cells – commonly macrophage 
cell lines as these are the cell types expected to encounter nanoparticles after human exposure. 
One study has used global gene expression profiling to identify differentially expressed genes in 
NSCs after labelling with a clinically approved MP, Feridex – proposed as a possible cell tracking 
agent for non-invasive imaging by MRI.140 The authors found that the overwhelming majority of 
genes were expressed at similar levels in labelled and control cells and these included genes 
involved in programmed cell death, regulation of cell metabolism and neural differentiation, 
suggesting the labelling procedures are largely safe. Changes in gene expression were noted at 
early time-points (1-2 days post-labelling) for proteins involved in iron metabolism (an 
observation also reported by others in mesenchymal stem cells141 and not shown to affect cell 
viability) and later time-points (4-7 days) for proteins involved in controlling cell stress (such as 
ceruloplasmin, a protein responsible for converting Fe2+ to the less oxidative form, Fe3+). The 
findings highlight the power of this technique for examining specific molecular pathways but also 
reveal some potential stress responses in MP-treated cells. Although a useful study in terms of a 
detailed investigation into the effect on cell biology of labelling with MPs, the results were 
generated using an NSC cell line and no protein expression analysis was performed. Cell lines 
might not be representative of primary cells in terms of their response to nanoparticles (Section 
1.13) and it is known that increases in gene expression may not correlate to increases in protein 
51 
 
 
expression,142 therefore detailed analysis of protein expression in NSCs after labelling with MPs is 
desirable. In addition, with the benefits of magnetofection protocols to enhance labelling of 
neural cell populations becoming apparent, detailed proteomic analysis is required to test the 
safety of these procedures prior to clinical translation. The feasibility of this approach for 
examining molecular changes in primary NSCs after manipulation with MPs in conjunction with 
magnetic fields has never been demonstrated. 
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 Test Description 
Cell viability Morphological 
assessment 
Microscopic evaluation of nanomaterial effect on normal cell 
morphology and adherence. 
 
 MTT, MTS and 
WST-1 assay 
 
Tetrazolium based solution added to cells. Active mitochondria 
break down tetrazolium leading to an absorbance change 
proportional to mitochondrial activity. 
 
 LIVE/DEAD 
assay 
Consists of calcein AM which can diffuse across intact cell 
membranes but will only fluoresce in live cells and ethidium 
homodimer-1 which can only cross disrupted membranes. 
 
 Trypan blue 
exclusion 
Trypan blue only crosses damaged membranes therefore only 
labels compromised cells. 
 
Molecular 
changes 
Cell marker 
expression 
 
Evaluation of characteristic cell marker expression  
 ROS 
production 
The level of GSH is determined colorimetrically which is 
proportional to the levels of ROS. 
 
 Genomics or 
proteomics 
Either assesses mRNA transcription or protein expression to 
determine pathways which have been up or down regulated in 
response to nanomaterials. 
 
Functional 
assays 
Stem cell 
differentiation 
 
Following cell differentiation after cell labelling/manipulation with 
nanomaterials. 
 Organotypic 
slices 
Effects of nanomaterials on cellular survival, integration and some 
function can be determined by transplanting into host tissue and 
monitoring microscopically, live and post-fixation. 
 
 Animal 
models 
Large numbers of live animals are required for statistically 
relevant data, and large quantities of tissue will need to be 
processed. This process is expensive and low-throughput. 
Table 2.2. Safety and functional assays for nanotechnology platforms. MTT - 
Methylthiazolyldiphenyl-tetrazolium bromide; MTS – 3-(4,5-Dimethylthiazol-2-yl)-5- (3-
carboxymethoxyphenyl)-2-(4-sulfophenyl) 2H-tetrazolium; WST-1 – Water soluble tetrazolium 
salts; ROS – Reactive oxygen species; GSH – Glutathionine. 
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The next step in nanomaterial testing is to evaluate safety and function in vivo and is often 
performed in animal models. Although testing novel nanomaterials in animals is vital to precede 
their use in humans, these are low-throughput and costly experiments with associated ethical 
concerns as described in the General Introduction (Section 1.14). Therefore, there is a 
requirement for rapid screening techniques to reliably predict in vivo function without heavy 
reliance on animal experimentation. Our laboratory has been developing and characterising 
organotypic slice models for use as host tissue for transplantation studies and potentially to 
assess the functionality of novel nanotechnologies. Specifically, we have recently developed and 
characterised cerebellar slice models which might be useful to test the transplantation of 
magnetofected NSCs. We have shown that cerebellar slices after 8-10 days in vitro display 
retention of cytoarchitecture, with defined white matter tracts apparent, and astrocytes, OPCs 
and Purkinje cells all present in the slices.143 Therefore these slices provide a good representation 
of the cerebellum in vivo; however, their utility for testing genetically engineered NSCs has not 
been investigated. 
 
2.1.3 Objectives 
Given the lack of knowledge of how NSCs will respond to oscillating magnetic field 
magnetofection protocols especially grown in the two widely different culture systems the 
objectives of this chapter are: 
(i) To determine optimal magnetofection protocols in NSCs grown as monolayers and 
neurospheres and compare transfection efficiencies in each culture system. 
(ii) To assess the safety of magnetofection procedures using standard microscopic 
analyses in both monolayers and neurospheres. 
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(iii) To perform several routinely used safety assays and examine the feasibility of using a 
mass spectrometry approach to assess molecular changes in monolayer NSCs after 
magnetofection. 
(iv) To investigate the utility of using the cerebellar slice model to assess post-
transplantation survival and differentiation of NSCs magnetofected as monolayers. 
 
2.2 Methods 
Although the methods described in the individual chapters have similarities, they are sufficiently 
different that a separate methods section has been provided within each chapter for clarity. 
However, an expanded methods section appears in this chapter which will be referred to when 
necessary in the subsequent chapters. Some of the methods have been adapted from publications 
in which the work features and these have been indicated as footnotes in the text. 
 
2.2.1 Reagents 
Cell and slice culture: Cell culture reagents were from Invitrogen (Paisley, Scotland, UK) and Sigma 
(Poole, Dorset, UK). Basic fibroblast growth factor (FGF-2) was from Peprotech (Rocky Hill, NJ, 
USA) and epidermal growth factor (EGF) was from R&D systems Ltd (Abingdon, UK). Penicillin and 
streptomycin were from Fisher (Loughborough, UK). Accutase was from Sigma and DNase I was 
from Roche (Welwyn, UK). Nunc T25 cell culture flasks, Nunc 24 well plates, 24 well suspension 
culture plates and other cell culture grade plastics were purchased from Fisher Scientific, UK. 
Millicell culture inserts, Omnipore membrane and the Immobilon-P membrane were from 
Millipore (Watford, UK).  
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Viability analysis: 3-(4,5-Dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS) assay reagent (CellTiter 96 AQueous One Solution Reagent) was from 
Promega UK (Southampton, UK). The LIVE/DEAD Viability/Cytotoxicity Assay Kit was from 
Invitrogen (Paisley, UK). 
Antibodies: Primary antibodies were rabbit anti-β-tubulin (Tuj-1) from Covance (Princeton, NJ), rat 
anti-myelin basic protein (MBP) from Serotec (Kidlington, UK), rabbit anti-glial fibrillary acidic 
protein (GFAP) from DakoCytomation (Ely, UK), mouse anti-nestin from BD Biosciences (Oxford, 
UK) and rabbit anti-SOX-2 from Millipore (Watford, UK). A summary of antibody targets is given in 
Table 2.3. Cy-3 and Fluorescein isothiocyanate (FITC) conjugated secondary antibodies were from 
Jackson Immunoresearch Laboratories Ltd (Westgrove, PA, USA). Vectashield mounting medium 
with 4,6-diamidino-2-phenylindole (DAPI) was from Vector Laboratories (Peterborough, UK).  
 
Antigen Description 
Nestin NSC cytoskeletal protein 
SOX-2 Transcription factor expressed in NSCs 
GFAP Cytoskeletal protein in astrocytes 
Tuj-1 Major constituent of microtubules in neurons 
MBP Main component of myelin produced by oligodendrocytes 
Table 2.3. Targets for the antibodies routinely used for immunocytochemistry 
 
Animals: The care and use of all animals used for cell culture were in accordance with the Animals 
(Scientific Procedures) Act of 1986 (UK) with approval by the local ethics committee. 
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Plasmids: Plasmid maps are shown in Figure 2.1. The pmaxGFP plasmid (size 3.5 kb; encodes 
green fluorescent protein [GFP]) was from Amaxa Biosciences (Cologne, Germany) chosen for 
brightness to ensure transfection efficiency levels could be accurately determined. Clontech 
(Saint-Germain-en-Laye, France) supplied the pCMV-DsRed-Express2 plasmid (herein termed 
pDRE2; size 4.6 kb; encodes red fluorescent protein [RFP]) used for transfection of NSCs before 
transplantation into cerebellar slices – pDRE2 has low phototoxicity so is suited for in vivo tracking 
applications but is a different size to pmaxGFP so results in slightly lower transfection 
efficiencies.143 
 
 
Figure 2.1. Schematics of plasmids used in experiments. Plasmid maps of (A) pmaxGFP and (B) 
pDRE2. CMV – cytomegalovirus promoter for constitutive expression in most mammalian cells. 
 
2.2.2 Primary NSC derivation and maintenance 
Primary NSCs were used for all experimental studies performed. These were derived by 
mechanically dissociating the subventricular zone of CD1 mice using previously established 
procedures30 and seeding cells in a 5 mL suspension at 1 x 105 cells/mL in T25 flasks. By using 
appropriate seeding densities and growth factor stimulation, selective propagation of NSCs from 
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an initial mixed population of cells can be achieved. NSCs were maintained in suspension at 
37oC/5% CO2 in complete medium (referred to herein as NS-M, Table 2.4) and as the NSCs 
proliferate they remain attached to each other to form so called ‘neurospheres’ – a well-
established culture system for NSCs (Figure 2.2). For routine maintenance, neurospheres were fed 
every 2-3 days and passaged weekly by dissociation using a 0.1X solution of DNase I in Accutase 
and re-seeded at 0.2-1 x 105 cells/mL in T25 flasks. For experiments, dissociated cells were 
plated/seeded as required. Cells from passages one to three were used for experiments. 
 
 
Figure 2.2. NSC derivation from the SVZ and propagation as neurospheres. (A) Diagram depicting 
the localisation of the SVZ from which all NSCs described in this thesis were derived. (B) After 1 
week in defined culture conditions, dissociated cells from the SVZ form neurospheres. 
 
2.2.3 Coverslip washing and coating 
It has been observed in our laboratory that NSCs more reliably adhere to nitric acid washed 
coverslips than non-washed glass. Therefore coverslips for all adherent NSC culture were washed 
in 1% nitric acid overnight. The nitric acid was removed by six washes in deionised H2O (dH2O) and 
sonication in 70% ethanol. The washed coverslips were stored in 70% ethanol. To coat coverslips 
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(or any culture surface) for adherent NSC culture, sequential incubation with poly-ornithine (MW 
30-70 000 Da, 0.002%, 1 h, 37oC) and laminin (5 μg/mL, 1 h, 37oC) was performed followed by 
three sterile water washes. Coated coverslips were used immediately. 
 
2.2.4 Neurosphere and monolayer culture for transfection experiments 
 To investigate and compare magnetofection protocols in NSCs grown as monolayers and 
neurospheres, single cell suspensions of NSCs were generated from NSC maintenance cultures as 
above (Section 2.2.2). To generate experimental neurosphere cultures, these were resuspended 
in NS-M at 1 x 105 cells/mL and 500 µL was added to each well of a suspension 24 well plate. To 
generate monolayer cultures, single cells were resuspended in monolayer medium (herein 
referred to as ML-M, Table 2.4) at 3 x 105 cells/mL then 400 µL was added to wells containing 
coated coverslips in 24 well plates. Cells were cultured for 24 hours (37oC/5% CO2) before particle 
addition. 
Media Composition 
 
Complete medium (NS-
M) 
DMEM:F12 (3:1), 2% B27 supplement, 50 U/mL penicillin, 50 µg/mL 
streptomycin, 4 ng/mL heparin, 20 ng/mL of EGF and FGF-2 
 
Monolayer medium 
(ML-M) 
DMEM:F12, in a 1:1 mix, 1% N2 supplement, 50 U/mL penicillin, 50 
μg/mL streptomycin, 4 ng/mL heparin, 20 ng/mL FGF-2 and EGF 
 
Differentiation medium Complete medium minus growth factors, supplemented with 1% FBS 
 
Slicing medium Earle’s balanced salt solution (EBSS) buffered with 25mM HEPES 
 
Slice culture medium 
(cerebellum slices) 
50% minimum essential medium, 25% EBSS and 25% horse serum; 
supplemented with 1mM glutaMAX-I, 36mMD-glucose, 50 U/mL 
penicillin and 50 mg/mL streptomycin 
 
Slice culture medium 
(spinal cord slices) 
As for cerebellum slice culture medium but with addition of 250 ng/mL 
amphotericin B 
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Table 2.4. Composition of media used in experiments throughout thesis 
 
2.2.5 Magnetic array details 
The desired magnetic fields were applied using the magnefect-nano oscillating magnetic array 
system, with a 24-magnet array (NdFeB, grade N42; field strength of 421 ± 20 mT)63 supplied by 
nanoTherics Ltd (Stoke-On-Trent, UK). The array is adapted to fit a 24 well culture plate and either 
remains static (also referred to as F = 0), or can be programmed to move in the (horizontal) x-axis 
with oscillation frequency (F) and amplitude controlled via a computerised motor (Figure 2.3). 
Amplitude in all experiments was set to 0.2 mm as this has been previously observed to be more 
effective than other amplitudes for transfection in various neural cell types.144 
 
 
Figure 2.3. Image depicting the magnefect-nano system and important features. 
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2.2.6 MP mediated transfection 
To assess the efficiency of transfection protocols, a reporter plasmid was used: pmaxGFP (Figure 
2.1). All transfections were carried out with a commercial transfection-grade magnetic particle: 
Neuromag. These particles are designed to transfect primary neurons but have been shown to 
transfect a range of neural cells in our lab including astrocytes,62 OPCs,63 oligodendrocytes143 and 
NSCs.30 They have an average diameter of 160 nm (range: 140-200 nm),123 ca. 0.5% iron content 
and a positive surface charge (actual value undisclosed by manufacturer). It has been previously 
established that the optimal Neuromag:DNA binding is 3.5 µL/µg62 which was used for all 
experiments. Field application was restricted to 30 min as heating effects were observed in pilot 
experiments using oscillating fields for longer time periods, and static fields applied for 24 h 
resulted in significant particle aggregation (especially using MP-5X particle formulation, Chapter 
4).  
 
2.2.7 Monolayer transfection 
At 24 h post-plating, medium was replaced with fresh ML-M (0.225 mL) before addition of 
transfection complexes. To prepare complexes, 176 ng pmaxGFP plasmid was diluted with 75 µL 
base medium (DMEM:F12 mixed in 1:1 ratio) and added to 0.62 µL Neuromag before mixing by 
trituration and subsequent incubation for 20 min (RT). The complexes were added drop-wise to 
cells whilst gently swirling the plate to ensure even particle distribution. Controls were treated 
with an identical concentration of plasmid without particles in base medium. Plates were 
returned to the incubator, and exposed to the desired magnetic field for 30 min. Magnetic field 
conditions were: no-field, F = 0 Hz and a range of oscillating fields from F = 0.5 Hz to F = 4 Hz. 
Monolayer transfection efficiency and NSC marker expression were assessed using fixed cells at 
48 h post-transfection. Some cultures were enzymatically detached for estimation of cell number 
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and viability (Section 2.2.20), then re-plated in 8 well chamber slides (4.8 x 104 cells per well; 
differentiation medium) for assessment of differentiation potential, or lysed for protein extraction 
in order to assess the effect of magnetofection on protein expression of the samples (Section 
2.2.15). 
2.2.8 Neurosphere transfection 
After NSCs had been allowed to form neurospheres for 24 hours, 0.44 µL Neuromag and 125 ng 
pmaxGFP were mixed in 50 µL base medium (DMEM:F12 mixed in a 3:1 ratio). Plasmid-MP 
complexes were allowed to form for 20 minutes (RT) then added to the neurospheres while gently 
swirling the culture plate. It is worth noting that movement was kept to a minimum as this 
appeared to cause sphere aggregation which could result in reduced transfection due to fewer 
cells being exposed to transfecting complexes. Controls consisted of plasmid addition alone, 
without Neuromag. In pilot experiments, a trend for increased transfection was observed up to a 
frequency of 4 Hz. A frequency of 5 Hz displayed a reduction in transfection efficiency compared 
to 4 Hz so this was not studied further. The plates were returned to the incubator and exposed to 
the desired magnetic field for 30 min with post-transfection incubation for either 10 or 48 h. Four 
field conditions were tested: no-field, F = 0 Hz, F = 1 Hz and F = 4 Hz oscillating fields. At 10 or 48 h 
post-transfection, spheres were dissociated and estimates of transfection efficiency (Section 
2.2.19), cell number (48 h time-points only) and viability were made (Section 2.2.20). From 
spheres dissociated at 48 h, cells were plated in 8 well chamber slides (4.8 x 104 cells per well) in 
either ML-M for 24 h (for assessments of NSC marker expression and pyknotic nuclei) or 
differentiation medium for 7 days (for assessing differentiation potential, Section 2.2.9). 
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2.2.9 NSC differentiation 
In order to assess the influence of magnetofection protocols on the differentiation profile of NSCs, 
both neurosphere and monolayer cultures were dissociated 48 h post-transfection and 
resuspended in differentiation medium (Table 2.4) at 3 x 105 cells/mL. 160 µL of each solution was 
added to coated wells of an 8 well chamber slide then cultured for seven days (37oC/5% CO2), 
which produces a mixed cell population typically containing ca. 85% astrocytes, 10% neurons and 
5% oligodendrocytes. Cultures were fed every 2-3 days with a 50% medium change. 
 
2.2.10 Organotypic cerebellar slice derivation and culture 
For an assessment of the transplantation potential of transfected NSCs, organotypic cerebellar 
slice cultures were used as an in vitro ‘host tissue’ system. The cerebellum was dissected from the 
brains of CD1 mice at postnatal day 10 and transferred to slicing medium (Table 2.4). Meninges 
were removed by rolling on paper tissue then 350 µm parasagittal slices were cut using a 
McIlwain tissue chopper and collected in ice cold slice medium. Slices were incubated on ice for 
30 min before transfer to pieces of Omnipore membrane (which allows manipulation of individual 
slices) sitting on the membrane of Millicell culture inserts in six well plates. Slices were cultured at 
an air-medium interface with cerebellum slice culture medium (Table 2.4). 
 
2.2.11 Transplantation of magnetofected NSCs onto slices 
To examine the functional capacity of NSCs transfected as monolayers, these were transfected 
with pDRE2 which encodes RFP using the same protocol as used for pmaxGFP. RFP was used as 
the reporter plasmid as GFP has been observed to form rod-like crystals several days post-
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transfection. Cell viability does not appear to be affected by rod formation (as judged by 
examining cellular and nuclear morphology); however, their presence confounds analysis of 
transfected cells. RFP was not observed to display this crystallisation so was chosen as the 
reporter plasmid for transplantation studies. After 24 h, half of all transfected cultures were 
detached and transferred to 24 well suspension plates (500 µL, 1 x105 cells/mL) for 24 h to 
produce neurospheres. This method was chosen due to the higher survival of NSCs transplanted 
as neurospheres in vivo.129 48 h post-transfection, monolayers were detached or neurospheres 
were collected and 0.5 µL was focally transplanted onto cerebellar slices at a concentration of 50 
x 106 cells/mL. Success and localisation of transplantation was judged 30 min post-
transplantation. Survival and differentiation of transplanted NSCs were judged in fixed slices 72 h 
post-transplantation as this time-point coincides with robust RFP expression (occurs across 24-
120 h).145 Where applicable, immunostaining was performed on fixed samples against the neural 
markers outlined in Section 2.2.1. 
 
2.2.12 LIVE/DEAD staining 
To assess slice and NSC (48 h post-transfection) viability, cells or slices were washed with PBS, 
incubated for 15 min with 4 µM calcein AM (produces green fluorescence in live cells) and 6 µM 
ethidium homodimer-1 (produces red fluorescence in dead cells), washed again with PBS, then 
mounted for fluorescence microscopy. 
 
2.2.13 MTS assay 
For an additional safety measure of magnetofection protocols on monolayer NSCs, an MTS assay 
was performed. Cells were plated and transfected by the described protocols in triplicate wells. 
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Blanks consisted of medium alone. MTS reagent was added to each well 48 h post-
magnetofection and incubated for 3 hours at 37°C/5% CO2. 200 µL medium was then taken from 
each well and added to a 96 well plate for absorbance measurements at 490 nm. Absorbance 
measurements were adjusted by subtracting blank readings from the test readings. The adjusted 
absorbance was then expressed as a percentage of the control readings. 
2.2.14 Fixation 
Cells and slices were washed once in PBS before fixation using 4% paraformaldehyde (PFA; 15 
min, RT) for immunocytochemistry. Samples fixed in PFA were washed three times in PBS before 
further processing.  
 
2.2.15 Preparation of peptides from magnetofected monolayer NSCs for mass spectrometry 
analysis  
In parallel with the histological safety assessments, a proteomics based analysis was performed 
on one set of samples (n = 1). This was to assess the feasibility of using mass spectrometry for 
detailed examination as to whether there are any alterations in protein expression or specific 
signalling pathways when NSCs are exposed to MPs and magnetic fields. Four conditions were 
tested utilising the developed protocols for monolayer transfection: no-field without particles 
(control), plus no-field, F = 0 Hz and the 4 Hz oscillating field conditions (all with particles). Protein 
was extracted from cells at 48 h as this correlates with peak GFP expression as observed 
previously30,63 and with the time-points used for the other safety analyses (cell number, cell 
viability and stem cell marker expression) to allow for a comparison between histological and 
molecular readouts.  
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Protein extraction from NSCs: Initial experiments, using either Triton-X or RIPA buffer to lyse the 
cells, failed to yield sufficient protein content from the collected cells. Therefore, a protocol was 
developed which used the following extraction buffer: 50 mM Tris (to buffer the solution), 150 
mM NaCl, 200 µM Ethylenediaminetetraacetic acid (EDTA, prevents cell adherence), 10% glycerol, 
0.5% NP40 (detergent/cell lysing agent), 0.2% protease inhibitors and 1% DNAse (prevents 
aggregates of DNA and cell fragments which hamper gel separation step). One million cells were 
lysed with extraction buffer (100 µL, 60 min, 4°C) with periodic vortexing to break cell membranes 
and aggregates in order to release proteins. The protein content of each sample was then 
normalised before gel electrophoresis using Bradford assay.  
Polyacrylamide gel electrophoresis: To initially separate the proteins within the sample 
polyacrylamide gel electrophoresis was performed. Here, 100 µg of protein from each 
experimental sample were denatured using 5x Laemmli buffer [0.3 M Tris, 50% glycerol, 10% 
(w/v) sodium dodecyl sulphate (SDS), 8% (w/v) dithiothreitol (DTT), 0.1% bromophenol blue; 5 
min, 95°C]. The denatured samples were added to pre-cast gels and run using approx. 200 V, 
whilst maintaining current between 35 and 50 mA. Upon run completion, gels were stained with 
InstantBlue (Expedion, Cambridge, UK), then destained in high performance liquid 
chromatography (HPLC)-grade water and imaged using a FluorChemTM M (ProteinSimple, San Jose, 
California). This image was used to annotate and dissect the gel into suitable pieces for digestion – 
assessed semi-quantitatively by observing the protein staining density in different regions of the 
gel. 
In-gel protein digestion and extraction: In order to identify proteins from gel pieces by tandem 
mass spectrometry, proteins typically need to be digested into peptides, which are then extracted 
from the gel. This is achieved following removal of Coomasie (from the InstantBlue staining) from 
stained gel bands (25 mM ammonium bicarbonate, 50 % acetonitrile), then preparing the proteins 
66 
 
 
for trypsin digest by reduction (10 mM DTT, 45 min, 56°C) and alkylation (55 mM Iodoacetamide, 
RT, 1 h in the dark). In gel trypsin digestion was performed with 200 ng of trypsin per excised gel 
piece (25 mM ammonium bicarbonate 37 °C, 16 h). Residual trypsin activity was stopped and 
peptides extracted using extraction buffer (50% acetonitrile, 0.1% trifluoroacetic acid). Extracts 
were dried and dissolved in HPLC-grade water with 0.1% formic acid. Depending on analytical 
technique, these could be desalted using Zip-Tip® (Millipore) pipette tips according to the 
manufacturer’s instructions. 
 
2.2.16 LC-MS/MS peptide identification 
Peptides were identified using a Liquid chromatography tandem mass spectrometry (LC-MS/MS), 
which sequentially eluted samples through a 5-95% acetonitrile gradient using a Quadrupole 
time-of-flight mass spectrometer premier (Waters Corporation, Manchester, UK). An initial MS 
survey mode identified abundant peptides with ≥ 2+ charge. These are then selected for MS/MS to 
produce a product ion spectrum (averaged from multiple scans, depending upon product ion 
intensity). The gathered spectra (from individual peptides) are processed through Distiller 2.5.1.0 
(Matrix Scientific, Colombia, SC) to enable Mascot 2.5.0 (Matrix Scientific) searching against a 
custom, GFP-Mus musculus concatenated database (GFP from Pontellina plumata and Uniprot 
mouse database, downloaded 01/02/2013). Search settings were as follow: mass tolerances 200 
ppm (precursor), 0.6 Da (products), 1 missed tryptic cleavage per peptide, with fixed modification 
by Cys-CAM (carbamidomethylation of cysteine residues by iodoacetamide in the alkylation step) 
and variable methionine oxidation states. Identified peptides were then analysed by Scaffold Q+ 
4.3.3 (Proteome Software, Toronto, ON) software, using 95% confidence interval and ≥ 2 peptides 
per protein filtering parameters, for output to Ingenuity Pathway Analysis (IPA, Qiagen, Limburg, 
Netherlands). IPA generates files for clustering analysis which was performed using R (Foundation 
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for Statistical Computing, Vienna, Austria). Relative protein abundances are then displayed within 
a heatmap. 
 
2.2.17 Immunocytochemistry 
Fixed cells and slices were immunostained to detect markers of neural cells. Samples were 
blocked (5% normal donkey serum in PBS supplemented with 0.3% Triton X 100; RT; 30 min), then 
incubated with primary antibody (4°C; overnight); antibody dilutions (in blocking buffer) were: 
1:200 for nestin and MBP, 1:500 for GFAP and 1:1000 for SOX2 and β-tubulin. After washing, 
samples were incubated with blocking solution (RT; 30 min), then with Cy3- or FITC-labelled 
secondary antibody (1:200 in blocking solution; RT; 2 h). Samples were washed and mounted 
using Vectashield mounting medium with or without DAPI. 
 
2.2.18 Imaging 
Fluorescence and light microscopy: Fluorescence microscopy of monolayers and tissue slices was 
performed using an AxioScope A1 microscope equipped with an Axio Cam ICc1 digital camera and 
AxioVision software (release 4.7.1, Carl Zeiss MicroImaging GmbH, Goettingen, Germany). Phase-
contrast and fluorescence microscopy of live cells was performed using a Leica DM IL LED inverted 
microscope equipped with a FC420C digital camera and Leica Applications Suite software version 
3.4.0 (Leica Microsystems, Wetzlar, Germany). Images were merged using Adobe Photoshop CS3 
(version 10.0.1) prior to quantification. 
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2.2.19 Assessment of transfection efficiency 
Microscopic analysis was used to analyse transfection in monolayer NSCs. This approach was 
chosen as simultaneous assessment of GFP expression can be conducted in parallel with features 
of cell health, such as adherence and morphology. Although a useful and robust methodology for 
quantifying transfection efficiency or particle uptake and several parameters of cell health (e.g. 
apoptosis and cell cycle analysis), flow cytometry was not used here as the number of cells 
required for flow cytometric analysis were not routinely produced.  
Maximum GFP expression occurs in NSCs at 48 h after MNP mediated transfection therefore this 
was chosen as the time-point at which GFP expression was analysed.30 Transfection efficiency of 
fixed monolayer samples was determined from double merges of DAPI and GFP images; a 
minimum of 200 cells at X200 magnification were scored. Transfection efficiency in neurospheres 
was assessed after dissociation into single cells, adding a small sample to a haemocytometer and 
counting numbers of the live cells which expressed GFP (>150 cells scored at X200 magnification). 
In both cases, care was taken to assess the GFP exposure level using controls (no transfection) to 
rule out background fluorescence, with exposure levels kept constant for each individual 
experiment. 
 
2.2.20 Assessment of cell number and viability  
To examine procedural effects on NSCs grown as neurospheres and monolayers, they were 
dissociated and a small proportion of cells were mixed with trypan blue which stains non-viable 
cells. Using a haemocytometer, an estimate of cell number per well and cell viability were made 
for each condition. 
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Counts were also made of pyknotic nuclei (an indicator of cell death evidenced by nuclear 
shrinkage, fragmentation or DNA condensation) in cells dissociated from both culture systems and 
plated as monolayers for 24 h, to evaluate effects of the developed protocols on cell viability. 
Three fields were assessed, with at least 100 nuclei assessed for each condition.  
Cellular viability as measured by the LIVE/DEAD assay was quantified by counting green (LIVE) and 
red (DEAD) cells and expressing the number of LIVE cells as a percentage of total cells (green + 
red) from a total of three images taken at X400 magnification. 
 
2.2.21 NSC stemness and differentiation potential 
Stem cell marker expression was assessed in monolayers from double merged images of DAPI and 
nestin/SOX2 stained cells; a minimum of 100 cells at X400 magnification were scored. The 
expression of neural cell markers after differentiation was also determined from double-merged 
images; a minimum of 200 cells at X400 magnification were scored. 
 
2.2.22 Statistical analysis 
All comparable groups were analysed by one-way ANOVA and Bonferroni’s multiple comparison 
test (MCT) using Prism software (version 4.03; Graphpad, USA). Data are expressed as mean ± 
SEM with ‘n’ referring to the number of cultures, each derived from a separate mouse litter. 
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2.3 Results 
2.3.1 Culture purity 
Monolayer cultures displayed elongated and bipolar morphologies typical of NSCs and were of 
high purity as judged by immunostaining for the NSC markers nestin and SOX2 (96.0 ± 2.0% and 
95.0 ± 2.0% positive respectively; Figure 2.4A-C). NSCs seeded in suspension formed small clusters 
of cells over 24 h consistent with normal formation of neurospheres (Figure 2.4D). When these 
spheres were dissociated they yielded high purity populations of NSCs with 94.5 ± 2.0% and 97.3 ± 
0.7% cells positive for nestin and SOX2 respectively.  
 
Figure 2.4. NSC culture characterisation. (A) Phase contrast micrograph depicting typical bipolar 
morphology of NSCs with (B) fluorescence counterpart indicating high proportions of NSCs are 
nestin positive (94.5 ± 2.0%). (C) Merged phase and fluorescence micrographs of monolayer 
cultures showing bipolar NSCs positive for NSC specific marker SOX2, also present in a high 
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proportion of cells (97.3± 0.7%).  (D) Small clusters of cells forming in suspension after 24 h, 
indicative of neurosphere formation. 
2.3.2 Influence of magnetic fields on transfection efficiency in monolayer and neurosphere 
cultures 
Monolayers: GFP expression was observed in all transfection conditions (and was absent in 
plasmid only controls) in healthy, morphologically normal (adherent and bipolar) NSCs. Basal 
transfection efficiency (no magnetic field) was 9.4%, with efficiency approximately doubled when 
transfection was performed in the presence of a static magnetic field (18.4%). Several oscillating 
magnetic field conditions were tested, all of which resulted in enhanced transfection efficiency 
over basal levels. There was a frequency-dependent trend of increasing transfection efficiency up 
to a maximum of 32.2% when using an oscillating magnetic field of 4 Hz (Figure 2.5A-B and 6A). 
Notably, the most effective oscillating field condition significantly outperformed the static field 
condition. 
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Figure 2.5. Magnetofection enhances transfection efficiency in NSCs cultured as monolayers and 
neurospheres. Representative micrographs of monolayers 48 h post-transfection under (A) no-
field and (B) F = 4 Hz conditions. Representative images of neurospheres 48 h after transfection 
performed under (C) no-field or (D) an oscillating field of 4 Hz. (D – inset) Control culture with 
plasmid addition only. Scale bar in the inset is also 200 µm. Note that in both culture systems GFP 
expression appears to be increased in the F = 4 Hz conditions. These effects have been quantified 
in Figure 2.6. 
 
Neurospheres: An optimal Neuromag dose (previously established in our laboratory) was used to 
investigate the effect of applying oscillating magnetic fields on transfection in neurosphere 
cultures. Similar to that observed in monolayers, NSCs appeared healthy post-transfection with 
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phase bright cells forming neurospheres similar in size and number to controls (Figure 2.5C-D). 
Transfected spheres were intact and GFP expressing cells appeared throughout the sphere. In this 
instance, basal transfection efficiency (no-field) was 4.2 ± 0.4% (Figure 2.6B). A similar frequency-
dependent trend in transfection efficiency was observed to that in monolayers, however only F = 
4 Hz produced a statistically significant enhancement of transfection above basal levels (Figure 
2.5D and 2.6B). Here, transfection efficiency was doubled to 9.9 ± 1.7%. No transfected cells were 
observed in the plasmid only control samples. GFP expression was also observed to occur at 
earlier time-points when transfection was performed using the oscillating magnetic fields. The 
proportion of GFP expressing cells 10 h post-transfection was 3.3 ± 1.0% in the F = 4 Hz condition 
compared to almost no transfection observed in the no-field condition (0.2 ± 0.2%), although this 
difference was not found to be significant (p = 0.07, one-way ANOVA, Bonferroni’s MCT). Cells 
from both groups also displayed high viability (>90%), as judged by trypan blue staining, 
suggesting there is no short term toxicity associated with these procedures. 
Comparing transfection levels between culture systems: A clear difference in transfection 
efficiency between culture systems is evident (Figure 2.6A-B). The greatest transfection efficiency 
achieved in monolayers is over three times that in neurospheres. Further, applying the oscillating 
field during transfection yields a three-fold increase in transfection efficiency over basal levels in 
monolayers; compared to double the basal level in neurospheres. As both systems are important 
for clinical application, it was decided to perform basic safety analyses using both culture systems. 
However, only monolayers were taken forward for more rigorous safety analysis in the form of a 
proteomics-based assessment of the potential molecular changes incurred by magnetofection as 
well as functional assessments following transplantation onto cerebellar slices. 
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Figure 2.6. Quantification and comparison of transfection efficiency in monolayers and 
neurospheres. (A) Bar chart displaying quantification of the percentage of GFP expressing cells in 
monolayers for each transfection condition. Significant differences are: *p<0.05, ***p<0.001 vs 
no-field transfection and +++p<0.001 vs static (F =0 Hz) field transfection (one-way ANOVA and 
Bonferroni’s MCT, n = 4). (B) Bar chart displaying quantification of the number of GFP positive cells 
following dissociation of neurospheres transfected under different conditions. The 4 Hz oscillating 
field condition significantly improved transfection efficiency over the no-field condition (*p<0.05, 
one-way ANOVA and Bonferroni’s MCT, n = 6).  
 
2.3.3 Magnetofection has no effect on NSC proliferation and viability 
Assessment of the safety of magnetofection protocols in monolayers was conducted in three 
conditions: no-field, static field and F = 4 Hz and all experimental conditions were assessed in 
neurospheres. Across all conditions, no effect was seen on total cell number or cell viability 
(Figure 2.7). Numbers of pyknotic nuclei were also assessed in re-plated, transfected 
neurospheres and counts were low (ca. 2%) and similar across all conditions (Figure 2.7).  
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Figure 2.7. Magnetofection has no effect on NSC numbers or viability in either neurosphere or 
monolayer cultures. Bar charts displaying quantification of cell number and viability as indicated 
in the figure across the selected magnetic field conditions. Numbers reported for the different 
assays in this panel are similar (and not statistically different) across conditions suggesting the 
protocols are not having an effect on these measures of cell health. 
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2.3.4 Magnetofection has no effect on ‘stemness’ of NSCs 
Highly pure populations of NSCs were generated from both transfected monolayer and 
neurosphere cultures with the majority of cells displaying the NSC specific markers nestin and 
SOX2. Importantly, cells expressing GFP also displayed normal patterns of NSC marker staining 
and regular circular nuclei as judged by DAPI staining (Figure 2.8A and B). GFP expression was 
found throughout the cytoplasm of these transfected NSCs (Figure 2.8A and B). There was also no 
difference between the proportions of cells expressing these markers in any condition (Figure 
2.8C-F). 
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Figure 2.8. Stemness of magnetofected NSCs is unaffected. Representative images of cells 
positive for stem cell markers nestin (main images) and SOX2 (insets) from NSCs transfected as (A) 
monolayers or (B) neurospheres with each individual channel shown from the nestin images. Note 
that GFP expressing cells also express the NSC specific markers. Bar charts displaying 
quantification of the proportions of cells positive for NSC marker nestin after transfection as (C) 
monolayers or (D) neurospheres across selected magnetic field conditions. Bar charts displaying 
quantification of the proportions of cells positive for NSC marker SOX2 after transfection as (E) 
monolayers or (F) neurospheres across the selected magnetic field conditions. Proportions of NSCs 
expressing both the quantified markers are similar across all conditions suggesting the 
magnetofection protocols are not having an effect on the stemness of the NSC population. 
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2.3.5 LIVE/DEAD staining and MTS assays reveal no effects on cellular viability of selected 
magnetofection conditions on NSCs grown as monolayers 
Some additional safety tests, routinely used in nanoparticle toxicity studies, were performed 
following monolayer transfection. After LIVE/DEAD staining, the majority of cells had normal 
bipolar NSC morphologies and were seen to stain green (LIVE) with small numbers of rounded 
cells appearing red (DEAD) in all conditions (Figure 2.9A). Using this assay, cell viability in 
magnetofected samples was observed to be high (>90%) and similar to controls (Figure 2.9A-B). 
The results of an MTS assay also showed no cytotoxicity following magnetofection procedures, 
with absorbance readings indicating comparable levels of mitochondrial function similar across all 
conditions (Table 2.5). 
 
 
 
Figure 2.9. LIVE/DEAD staining of magnetofected NSCs grown as monolayers. (A) Representative 
fluorescence micrographs showing LIVE cells appearing green and DEAD cells appearing red 
(arrows) 48 h after 4 Hz oscillating field magnetofection and (inset) no manipulation. (B) Table 
showing quantification of LIVE cells as a percentage of total cells. No significant differences were 
noted between groups (n = 3). 
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Experimental condition Viability (% of control) 
No field Control 100.0 ± 0.6 
  Complex 95.4 ± 3.7 
F = 0 Control 99.5 ± 1.4 
  Complex 98.9 ± 1.5 
F = 4 Control 99.4 ± 1.7 
  Complex 97.2 ± 2.8 
Table 2.5. MTS assay results from magnetofected monolayer NSCs. Absorbance readings are 
given as percentage of control. No significant differences were observed between any conditions 
(n = 3). 
 
2.3.6 Differentiation profile of NSCs is unaffected by magnetofection 
Astrocytes, neurons and oligodendrocytes were all produced from transfected NSC cultures in 
similar proportions across all conditions similar to the proportions generated in control cultures 
(Figure 2.10). Further, these cells displayed normal morphologies with broad, multipolar star-like 
astrocytes, immature neurons with generally one or two short processes and highly processed 
oligodendrocytes (Figure 2.11A-C). GFP expression in these mixed cultures was predominately 
confined to the astrocytic progeny (of normal morphology) with no GFP expressing neurons or 
oligodendrocytes observed in cultures derived from transfected neurospheres, and GFP 
expressing neurons were rarely observed (< 1% Tuj-1 positive cells) in cultures derived from 
transfected monolayer cultures (Figure 2.11D). 
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Figure 2.10. The relative proportions of NSC-derived daughter cell types are unaffected by 
magnetofection. Bar charts depicting the proportions of each cell type (indicated in table) in 
mixed cultures generated from NSCs treated under different conditions.  
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Figure 2.11. Magnetofected NSC cultures can generate the three major cell types of the CNS. 
Representative images of cells positive for the neural cell markers (A) GFAP for astrocytes – 
fluorophore channels split to highlight overlap of GFP expression and GFAP staining –  (B) MBP for 
oligodendrocytes and (C) Tuj-1 for neurons derived from magnetofected NSC monolayers. White 
arrows point to the named cell type in each image. Note that in (A) GFP expressing cells positive 
for GFAP staining are present (white arrows) and in (B) and (C) GFP expressing cells have the 
morphological appearance of astrocytes. (D) Rare example of a GFP expressing neuron, with the 
inset clearly showing the GFP expression throughout the neuronal processes. 
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2.3.7 Proteomic analysis of magnetofected monolayer NSCs 
To assess the feasibility of characterising the effect of magnetofection on protein expression and 
specific signalling pathways, a proteomics based analysis was performed. Cultures that were 
detached for the analysis had similar numbers of cells (ca. 3 x 105 cells per well) and high cell 
viability (> 95%). The subsequent banding pattern after gel electrophoresis of the extracted 
proteins was similar between each group, suggesting similar protein expression (Figure 2.12). LC-
MS/MS of the excised protein bands and subsequent database searching identified >450 proteins 
in each group. The samples were similar in terms of the proteins that were identified and relative 
expression of these can be semi-quantified, represented in this case by a heatmap (Figure 2.13 – 
judged by colour coding of individual bands). Clustering analysis revealed that, although the 
relationships between samples were close, similarity decreased so that relation to control 
followed the pattern: no-field > F = 0 Hz > F = 4 Hz. Specific cellular pathways could also be 
interrogated by this method. The example shown here is the Mitogen-activated protein kinase 
(MAPK) pathway which is involved in NSC proliferation and maintenance of phenotype.146 As 
shown, the expression levels of the proteins within this pathway can be evaluated, however, 
some differences are apparent in the banding between samples (Figure 2.14). As expected, GFP 
could be identified within the transfected samples but was absent from the control. Two GFP 
peptides were detected (Figure 2.15A) and the mass spectrum produced was matched to the GFP 
peptide as shown in Figure 2.15B and C. Lowering the threshold of confidence of identity also 
revealed that more peptides were identified for GFP in the 4 Hz oscillating group than the other 
transfection groups, which is suggestive of more protein being present although this method of 
analysis cannot be considered conclusive.  
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Figure 2.12. Gel electrophoresis of proteins extracted from magnetofected NSCs. Densitometer 
image of the gel resulting from gel electrophoresis of control and magnetofected NSCs from 
selected conditions. Overall banding intensity and pattern appears similar between samples. MW 
– molecular weight; M – molecular weight markers; NFC – no-field, no particles; NFT – no-field, 
particles; F0 – static field, particles; F4 – 4 Hz oscillating magnetic field, particles.  
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Figure 2.13. Overall comparison of expression levels for identified proteins. Clustering analysis 
indicates that similar proteins were identified in each sample. Clustering of proteins by similarity of 
expression level is displayed in the family tree on the left of the heatmap. The number of peptides 
identified for each separate protein provides a semi-quantitative assessment of the amount of 
each protein in each sample which is represented by colour (green indicates greater protein levels). 
The clustering of the samples indicates that all conditions are similar, but F = 4 Hz exhibits more 
differences compared to control than either F = 0 Hz or the no-field conditions. 
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Figure 2.14. Heatmap of identified proteins from the MAPK pathway. Individual cellular 
signalling pathways can be interrogated as in Figure 2.13. Here the MAPK pathway (involved in 
proliferation of NSCs) has been highlighted and displays no major difference in proteins identified.  
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Figure 2.15. GFP can be identified in magnetofected samples. (A) Survey spectrum from the 
MS/MS analysis indicating two peaks which were attributed to GFP. (B) Product ion spectrum of 
one of the tryptic fragments showing the b- and y-ions identified by MASCOT and matched to a 
peptide from GFP. (C) Peptide sequence displaying the various b- and y-ion fragments. 
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2.3.8 Transplantation of monolayer magnetofected NSCs into organotypic slice models 
To investigate the transplantation of magnetofected NSCs, transfected cells were transplanted 
onto organotypic cerebellar slices. These slices have been previously characterised in our 
laboratory143 and contain multiple neural cell types with similar cytoarchitecture to that observed 
in vivo, therefore representing a pre-animal, test-bed for cell transplantation studies. Here, these 
were successfully derived and could be maintained for at least 30 days with high viability as 
judged by LIVE/DEAD staining (Figure 2.16A). Focal transplantation of transfected NSCs was 
achieved, using both re-formed neurospheres (Figure 2.16B – inset depicts re-formed 
neurosphere with RFP expressing cells within the structure) and dissociated monolayers (Figure 
2.16C). Cell aggregates expressing RFP (20-50 µm in diameter) were observed on the slice 
following neurosphere transplantation, in contrast to the disparate (red) cells apparent after 
transplantation of detached monolayers (Figure 2.16B and C). At 72 h post-transplantation, RFP 
positive cells in both groups were seen displaying multiple processes indicating cell survival 
(Figure 2.16D and E). RFP positive cells predominately expressed GFAP signifying their 
differentiation into astrocytes, which is similar to NSC differentiation profiles on glass where the 
astrocytes are also the dominant daughter cell type generated (Section 2.3.6). Some RFP positive 
cells also retained expression of the NSC transcription factor SOX2 (Figure 2.16F). 
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Figure 2.16. Transplantation of transfected NSCs onto cerebellar slices. (A) LIVE/DEAD staining of 
cerebellar slice after 30 days in culture. Live cells take up calcein so appear green and dead cells 
take up ethidium homodimer-1 so have a red appearance. Dead cells mostly appear towards the 
slice margins. (B) Focal transplantation of transfected neurospheres (magnetofected NSC 
monolayers were re-formed into neurospheres), with transfected cells retaining cell-cell 
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associations typical of neurospheres (B - inset). (C) Focal transplantation of single cells after 
monolayer dissociation with an absence of sphere morphology. Following transplantation of both 
(D) neurospheres and (E) dissociated monolayers, there is evidence of transfected cells integrating 
into the ‘host’ tissue, extending processes and differentiating into astrocytes, as indicated by 
expression of GFAP. (F) Some transfected cells were also found to retain the NSC specific marker 
SOX2. Where applicable, channels have been shown separately so that co-localisation of 
fluorophores can be observed. 
 
 
2.4 Discussion 
As far as I am aware this is the first report of utilising oscillating magnetic fields to enhance MP 
mediated transfection in primary NSCs, a highly clinically relevant cell population. Crucially, 
oscillating fields were shown to safely enhance transfection in NSCs propagated as both 
monolayers and neurospheres. The finding in neurospheres is of particular interest as it is the first 
time oscillating magnetofection protocols have been successfully demonstrated in a suspension 
culture. A number of safety analyses have also been performed including histological, molecular 
and functional tests encompassing a broad spectrum of cell behaviour. This is novel in the field of 
testing nanotechnologies and the assays described here could provide a benchmark for future 
testing of novel multifunctional MPs. 
 
2.4.1 The utility of magnetofection protocols for NSC transplantation therapy  
In terms of genetic manipulation strategies of transplant cell populations, viral transduction 
generally results in the highest levels of transduced cells; however, use of viruses may be 
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undesirable for clinical application for a number of reasons. Viral delivery is a complex procedure 
– involving transfecting a carrier cell type with up to three plasmids, collecting viral particles, and 
determining the amount of virus in the supernatant before transduction, which is often repeated 
several times to ensure high levels of target cell infection.147 In combination with the necessity to 
house all viral preparation in biosafety level II containment facilities, viral transduction is not 
readily scaled up to clinical levels of production. Use of viruses to transduce transplant cells is also 
associated with significant safety risks, including insertional mutagenesis and oncogenicity,49,50 of 
particular concern when transducing stem cell populations which already have the capacity to 
self-renew and proliferate. This drawback was exposed in a recent clinical trial where autologous 
CD34+ cells (haematopoietic stem cells) were retrovirally transduced to produce a replacement 
enzyme to treat a form of human severe combined immunodeficiency.148 After transplantation, 
although the enzyme was successfully produced, with resultant correction of disease pathology, 4 
out of 20 patients treated developed leukemia which was traced to the genetically engineered 
stem cells.148 
Nucleofection performs well as a non-viral transfection process (80% transfection efficiency in 
NSCs),149 but results in substantial loss of cell viability post-transfection. From a translational 
viewpoint, this would increase production costs associated with generating more cells, to replace 
those lost during the nucleofection protocol, and could also lead to transplantation of a large 
number of dead cells – unfavourable for transplant survival and potentially detrimental to the 
host. Other non-viral strategies generally result in low levels of transfection and some systems 
have been shown to be toxic (through membrane rupture) to NSCs.52 Table 2.6 summarises some 
of the key properties of gene delivery strategies and their advantages or disadvantages for clinical 
application.  
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The data presented in this chapter suggests that using oscillating magnetic fields in combination 
with MP mediated transfection could provide an alternative strategy to genetically modify 
transplant NSC populations and address the problems encountered with other techniques, as 
outlined above. The MPs used in this study were shown to be non-toxic to NSCs and 
magnetofection protocols to enhance MP mediated transfection efficiency were also shown to be 
safe with regards to key regenerative properties of NSCs including proliferation, stem cell marker 
expression, differentiation and survival after transplantation into host cerebellar slices. In addition 
to the good safety profile of magnetofection, the highest transfection levels in NSCs achieved in 
this study (ca. 32% in monolayer NSCs with application of a 4 Hz oscillating magnetic field) are 
comparable to some viral systems and compare favourably to other non-viral gene delivery 
techniques (Table 2.6). Studies on transplanting genetically engineered NSCs which have seen 
benefits in pre-clinical models of neurological injury report transfection efficiencies of 20-80% 
(General Introduction, Section 1.5). This suggests magnetofection protocols could be utilised for 
this application whilst avoiding the safety issues associated with viral gene delivery. Finally, MPs 
can be routinely produced in large quantities, and are already used in the clinic,70 and plasmid 
DNA production can also be scaled up to meet clinical requirements.150 Combined with the 
simplicity of the technique, scale-up of magnetofection protocols seems feasible for both manual 
and automated operation. As discussed in Section 2.1.1, automation is thought to be a key 
requirement of scaling up cell therapies to clinical levels. The simplicity of the technique could 
allow for the adaption of existing automated cell culture systems, such as the CompacT SelecT, to 
magnetofection protocols – a strategy already being investigated for scale-up of non-viral 
transfection of HEK 293T cells using PEI.151  
In terms of therapeutic delivery, plasmid transfection generally results in transient gene 
expression in the target cells. In our laboratory we have seen GFP expression persist for ca. 21 
days in NSCs propagated as neurospheres; although a low proportion of spheres are GFP positive 
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by this point (<1%). Neurological injury and regeneration, as stated in the General Introduction 
(Section 1.2), is a highly complex process with temporally controlled gene expression precisely 
controlling cell recruitment and tissue remodelling. Therefore, in terms of therapeutic delivery, 
transient gene expression could be considerably advantageous when delivering therapeutic 
factors to promote repair in sites of CNS injury and disease. For example, factors could be 
released to recruit and drive proliferation of local progenitor cells for combined neuroprotection 
and cell replacement over a short period of time during an identified window of opportunity, then 
cease, avoiding transgene interference with subsequent stages of repair. Indeed, long term 
expression of factors involved in this process is likely to be detrimental to progenitor cell 
maturation and therefore functional cell replacement. Overexpression of FGF-2, which can 
promote NSC survival and angiogenesis has also been shown to stimulate astrogliosis (a process 
which can contribute to the astrocyte scar) and can disrupt myelin production in mature 
oligodendrocytes.152  
Even greater levels of magnetofection efficiency may be required for clinical applications, and 
there are several strategies through which this may be achieved. Increasing particle size (from 187 
nm to 375 nm) has been shown to enhance MP mediated gene delivery into smooth muscle cells 
and bovine aortic endothelial cells.153 This could be the result of an enhanced capacity for binding 
DNA allowing the particle to deliver more plasmid copies to the cell. However, the authors also 
noted that the large particles avoided lysosomes and delivered DNA to the cytosol (although the 
comparison with smaller particles was absent) potentially resulting in low rates of DNA 
degradation. Several reports show that modifying particle chemistries through use of different 
polymers or combinations of polymers and use of CPPs can enhance uptake in various cell 
types,154 however, few neurocompatible particles have been described. Optimising particle design 
to either enhance particle uptake or promote endocytosis routes more favourable for transfection 
could therefore represent a novel, if complex, route to improving MP mediated transfection in 
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NSCs. A simpler approach to enhance transfection levels could be to employ a repeat transfection 
procedure. Multifection has been shown to safely enhance gene delivery into NSCs grown as 
neurospheres30 and findings from our laboratory suggest that the same is true for astrocytes 
grown as adherent monolayers (unpublished data, Jacqueline Tickle, Keele University). As the 
transfection efficiency was almost doubled in the neurosphere model, this suggests that 
combining magnetofection with multifection could be a potent strategy to enhance gene delivery 
to NSCs grown either as neurospheres or monolayers. Although promising strategies, optimising 
particle design and delivery will most probably need to be undertaken for each individual cell 
type, as results from one cell type cannot reliably be extrapolated to another. This further 
highlights the requirement for high-throughput analyses of novel particle function and safety in 
order to assess numerous particle formulations potentially in multiple cell populations and culture 
systems.  
The findings are also of clinical relevance with respect to the potential for MPs to provide a multi-
functional platform for regenerative medicine applications, including cell tracking through MRI, 
gene or drug delivery and magnetic stem cell targeting. In this regard, a recent study proved a 
high iron content particle coated with fluorescent PEI could act as a contrast agent for MRI and be 
used to label primary astrocytes.83 From a clinical perspective this particle could potentially be 
used to detect transplant cells by MRI (for non-invasive imaging), and fluorescence microscopy 
(for post-mortem evaluation of cell fate). The particle was also shown to be able to bind DNA and 
deliver this to astrocytes, albeit with relatively low levels of transfection (<1%).83 An oscillating 
magnetic field was not used in this study; therefore it may be of value to test whether the 
protocols developed in this chapter could be useful for enhancing uptake and transfection when 
using this and other novel multimodal particles. 
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Table 2.6. Comparison of transfection efficiencies and clinical considerations for different strategies to genetically engineer NSCs. 
Transfection 
method 
Transfection 
efficiency 
Capacity Scalable production? Safety Comments 
Retrovirus49,155 High (>80%) 8 kb Large scale production 
of moderately pure 
vector 
Initial exposure 
toxic 
 
Risk of 
insertional 
mutagenesis 
Some viral genes left in 
construct which could result 
in immune system clearance 
or homologous replication 
with WT replication 
competent virus 
Lentivirus156 High (>80%) 4.7 kb – possibly 
extendable to 10 
kb 
Scalable production 
available 
Risk of 
insertional 
mutagenesis 
Similar to retrovirus. 
AAV49,157 Low – utilising 
different coat 
proteins may 
increase this 
4.7 kb – stringent Scalable production in 
use 
Low 
pathogenesis 
 
Low 
immunogenicity 
Preferred method of in vivo 
transduction due to safety 
profile 
 
Common vectors inefficient at 
transducing NSCs 
Amplicon158 No data available  Theoretically – 
150 kb 
No method to 
produce large, 
contamination free 
stocks 
Non-pathogenic 
 
Non-toxic 
Not investigated in neural 
stem cells 
Nucleofection53,149 Up to 80% Large capacity Potentially scalable No effect on cell 
behaviour 
Low cell viability post-
transfection (40%) 
Lipofection52 Low (11-16%) Large capacity Potentially scalable Can be toxic Diffusion limited transfection 
rate 
Magnetofection Medium (ca. 32%) 3.5 kb plasmid 
delivered here  
Large scale production 
of MPs and plasmid 
DNA available 
Non-toxic 
 
No effect on cell 
behaviour 
Comparable transfection 
efficiency to viruses 
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2.4.2 The advantages of a proteomics analysis of magnetofected NSCs 
In the preliminary analysis of the ability of a mass spectrometry approach to compare the 
proteome of treated and untreated NSCs, a large number of proteins were identified (>450) and 
compared across conditions. Replicates will need to be performed in order to indicate any 
significant differences that might be present in protein expression between the magnetofected 
samples. As several proteins from a specific pathway could also be identified, alterations in global 
NSC function could be interrogated in more detail in the future. Quantification of all the proteins 
in the pathway could provide information on whether multiple proteins from the pathway are 
differentially expressed between samples which would be a strong indicator of the loss or gain of 
the function of that pathway. 
One previous report has used genomic analysis to assess the effect of labelling NSCs with a clinical 
grade MP (Feridex), finding little evidence of an up-regulation of genes associated with cell death 
and stress.140 However, no magnetic field was applied in these studies, which could be a key 
clinical uptake enhancing strategy. In addition, although the preliminary data presented here is 
semi-quantitative, it demonstrates the ability to map the proteome of magnetofected cells, which 
could facilitate the detection of functional changes within a cell, which examination of mRNA 
expression cannot stringently provide (i.e. mRNA presence does not automatically infer protein 
presence).  
Future work will concentrate on developing proteomics analyses with greater quantitative power; 
however the approach described here does already provide several advantages over commonly 
used safety assays. As the field of nanoparticle design is rapidly advancing, novel particle designs 
will potentially have widely varying molecular effects on cells. Therefore it might be necessary to 
test for a number of pathways known to be associated with toxicity, for example, production of 
ROS or mitochondrial dysfunction. Using a proteomics approach could therefore allow a range of 
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different pathways to be interrogated for evidence of cellular toxicity. In addition, this approach 
could provide an unbiased and standardised protocol for the assessment of toxicity of novel 
nanomaterials in stem cell populations. Of particular interest to nanotechnology approaches to 
genetically engineering transplant populations, GFP was reliably detected in the magnetofected 
samples. Therefore, using a relatively simple and rapid one-step technique, pathways involved in 
cellular toxicity and gene delivery success could be assessed simultaneously. Further, by using 
advanced quantitative mass spectrometry analysis, transfection efficiency could be compared 
between different delivery strategies, such as the use of different oscillation frequency 
parameters in magnetofection protocols. 
 
2.4.3 Advantages of assessing the safety of magnetofection protocols using cerebellar slices 
Transplantation of genetically engineered NSCs onto cerebellar slices demonstrated survival of 
magnetofected cells, with some maintaining SOX-2 expression and some differentiating; only 
astrocytes exhibited transgene expression in this study. Survival, stemness and differentiation are 
key regenerative properties of the NSCs suggesting that the developed magnetofection 
procedures are safe for genetically engineering cell transplant populations. The data also highlight 
the utility of the slice model to act as a further safety assessment of genetic manipulation 
approaches by transplantation of the engineered cells into host tissue representing an in vivo 
environment. To further enhance the clinical relevance of the model, neurological injury can be 
simulated in cerebellar slices using, for example, demyelinating agents. NSCs have been 
previously shown to generate oligodendrocytes which subsequently myelinate axons in a model 
of multiple sclerosis.28 Therefore, the slice could also be used to test the functional outcome of 
genetically engineering cells and transplanting them into sites of disease. In combination with the 
proteomics analysis of magnetofected cells detailed data could be readily obtained on the safety 
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and functional nature of genetically engineering transplant cell populations with nanoparticles. A 
hierarchical analysis such as this could dramatically reduce the reliance on animal models to 
provide such data and circumvent cost and animal suffering associated with these studies. In 
addition, results generated from proteomics analysis and slice work could inform animal studies 
allowing for more focussed data acquisition and reduced animal usage, all in accordance with the 
3Rs principle to reduce, refine and replace animals used in experiments. 
 
2.4.4 There are differences in magnetofection efficiency between NSCs cultured as 
monolayers and neurospheres 
The data presented in this chapter reveal distinct differences between monolayer and 
neurosphere cultures in terms of their responses to magnetofection protocols. Primarily, it was 
observed that MP mediated transfection is higher in monolayers under all field conditions. In 
addition, application of a static magnetic field enhanced MP mediated transfection efficiency in 
monolayers above that of a no field condition, but this was not found with neurospheres – in 
agreement with previously published reports.30 Oscillating magnetic fields significantly increased 
transfection efficiency over basal levels in both culture systems, with the greatest transfection 
efficiency being observed at the same frequency of oscillation (F = 4 Hz). However, the ability of 
the oscillating field to enhance transfection, above the no field condition, was not as great in the 
neurosphere culture system, producing a doubling of transfection efficiency (from ca 5 to 10%) 
compared to a tripling of transfection efficiency (from ca 10 to 30%) observed in monolayers. The 
physical characteristics of neurospheres and monolayers are very different which could account 
for the striking differences in transfection efficiency when utilising magnetofection protocols. The 
3-D nature of neurospheres means that cells are both ‘hidden’ from the transfecting particles and 
also, cells at the top of the neurosphere are further from the magnet, which could have an effect 
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on how much influence the field has at that point. In contrast, monolayer cells are all exposed to 
particles in the media, are the same distance from the magnet and therefore uniformly 
experience the benefit of the field. In addition, cells within a neurosphere generally have a 
rounded appearance compared to monolayer NSCs which generally have two long processes. It 
has also been suggested that rounded cells are in more of a ‘resting state’ potentially therefore 
being less endocytotically active than adherent cells which can be highly processed. Differences in 
membrane activity could therefore be a mechanism for the lower transfection efficiencies 
observed in neurospheres compared to monolayers. It may be possible to assess membrane 
activity of NSCs grown in the two culture systems by stimulation with MPs then visualisation using 
electron microscopy – in particular in conjunction with OTOTO staining which allows for high 
resolution membrane imaging. OTOTO involves staining cell membranes with osmium (O) and 
then increasing the staining density, and therefore electron conductivity, through sequential 
staining with a high affinity osmium binding agent, thiocarbohydrazide (T) and osmium. This 
technique removes the need for gold coating of samples which can obscure membrane features 
and particles on the membrane surface; therefore is ideally suited to observing particle-
membrane interactions in high resolution. In addition the stained samples are visualised by field 
emission scanning electron microscopy (together termed OTOTO-FESEM) facilitating observation 
of numerous cells at once. Therefore it also represents a higher throughput microscopy technique 
compared to transmission electron microscopy (TEM) where only thin (ca 250 nm) sections of a 
few cells can be visualised at one time.  
Although the mechanism by which the oscillating magnetic field enhances transfection efficiency 
is not yet known, the proposed mechanisms for the enhanced uptake when using oscillating 
magnetic fields are: (i) increased dispersion of the particles, (ii) a physical stimulation of the cell 
membrane or (iii) a combination of both. In neurospheres there may be an additional element 
whereby magnetically labelled spheres are pulled down by the field, and then experience 
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subsequent membrane stimulation by the oscillating field (Figure 2.17). For both culture systems, 
elucidating the mechanisms behind the enhanced transfection efficiency observed when using 
oscillating magnetic fields needs to be determined to inform future particle design and delivery 
strategies to NSCs. This may be investigated by the OTOTO-FESEM method for examining 
membrane activity as described above. Potentially, time-lapse microscopy could also be utilised to 
visualise fluorescent particles and examine their interaction with the membrane in real time 
during exposure to an oscillating magnetic field to determine differences in particle dispersion or 
activity on the membrane. 
 
 
Figure 2.17. Schematic depicting possible mechanisms for enhanced MP mediated transfection 
efficiency in neurospheres when oscillating magnetic fields are applied during transfection. 
 
 
101 
 
 
2.4.5 GFP expression was largely confined to astrocytes  
As has been described, no differences in NSC differentiation profiles were noted under any 
culture or magnetofection conditions, in terms of ratios of astrocytes, neurons and 
oligodendrocytes. However, following differentiation of transfected monolayer and neurosphere 
cultures, GFP+ progeny were largely identified as astrocytes (%GFP+ cells expressing GFAP;  ca 
100%), in proportions greater than would be expected given the differentiation profile of NSCs (% 
astrocytes derived from NSCs is 80-85%). This phenomenon has been reported previously by our 
laboratory when investigating MP mediated transfection of neurospheres.30 In the present study, 
differentiation of NSCs transfected as neurosphere cultures produced no transfected neurons, 
and transfected neurons were rarely observed following differentiation of transfected NSC 
monolayer cultures. This observation could partly be explained by the fact that there appear to be 
fewer neurosphere derived neurons in this study (Section 2.3.6), a finding shown in other 
studies,116 therefore leading to a lower percentage chance observing  transfected neurons. 
Generation of transfected oligodendrocytes was never observed from either culture system. It 
remains to be seen whether this will be an issue for clinical application. Post-transplantation, NSC 
in vivo differentiation appears to depend on local environment and therefore it could be that 
transfected NSCs do differentiate into transfected neurons in a certain environment or injury 
pathology. In addition, there are reports that populations of transplanted NSCs can remain in a 
stem cell state and in that way mediate their neuroprotective effects. If this is the case, 
therapeutic proteins will be delivered by the engineered NSC population and not their daughter 
cells. Finally, even if NSCs mostly differentiate into astrocytes the data presented here indicate 
that these cells will still be able to express the transgene and deliver the desired therapeutic 
factor to sites of transplantation. However, in some disease states it may be beneficial to produce 
transfected neurons in particular, for example to promote neuronal survival. Cell specific peptides 
and antibodies have been conjugated to nanoparticles for cell targeting in human dendritic159 and 
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macrophage cells.160 Investigating peptides for targeting neuronal or oligodendroglial pre-cursors 
may provide a strategy to increase particle uptake, and therefore transfection, in these sub-
populations, however, neural specific targeting peptides are currently rare in the literature. 
Alternatively, transfecting NSCs from different sources or developmental stages may provide a 
greater yield of transfected neurons. Preliminary results from our laboratory indicate that a 
greater proportion of transfected neurons could be generated when NSCs were taken from 
embryonic rats and magnetofected, compared with the post-natal NSC derivation protocol used 
here. However, these results have yet to be quantified and are from a different rodent model so 
will need to be validated.  
 
2.4.6 Conclusions and future work 
The data presented in this chapter demonstrate that oscillating field magnetofection can be used 
to enhance MP mediated gene delivery to NSCs without affecting key regenerative properties of 
the cells. The current work was performed with a commercially available transfection grade MP 
which may not be clinically translatable (the formulation is undisclosed by the manufacturer). In 
addition, the particle used is single function, being designed exclusively for gene delivery and, 
although comparable levels of transfection to those of viruses were observed, it may be required 
to increase transfection levels for clinical application. Further work in improving transfection 
levels, through particle and plasmid design, and investigating the application of magnetofection 
protocols to novel neurocompatible multifunctional  particles (e.g. capable of gene delivery and 
MRI tracking) will broaden the applicability of magnetofection as a clinically relevant technique to 
enhance particle uptake. 
103 
 
 
Safety of the developed protocols was evaluated with a hierarchical microscopical, molecular and 
functional assessment of cellular toxicity. Further refinement to the proteomics analysis used here 
will need to be investigated to develop quantitative protocols for measuring protein expression 
which will aid in defining mechanisms of cellular toxicity and potentially provide information on 
gene delivery success. Combined with developing the clinical utility of the slice model (by 
introducing disease pathologies) the steps outlined in this chapter could be used by nanoparticle 
researchers as a key battery of tests to assess the safety and function of gene delivery mediated 
by MPs.a 
 
 
 
 
 
 
 
 
 
 
                                                          
a
 Most of the data relating to transfection of neurospheres has been published in Nanomedicine:NBM. The 
paper is attached as Appendix 1 and has been licensed for use in this Thesis by Elsevier. 
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Chapter 3: Developing high iron 
content particles for the efficient 
labelling of NSC transplant 
populations 
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3.1 Introduction 
As discussed in the General Introduction (Section 1.6), safe delivery of transplant cells to sites of 
injury and disease is a major barrier to the clinical translation of NSC transplant populations. In 
recent years, a novel and minimally invasive approach to accumulate transplant cells at the 
desired site is to localise magnetically labelled cells using external magnetic fields. A description of 
this strategy and the physical principles underlying the technique is provided in the General 
Introduction (Section 1.11). The feasibility of this approach has been shown in vitro80,161,162 and 
also in vivo for cardiac stem cell localisation to sites of myocardial infarction,163 endothelial cell 
localisation to the surface of magnetised stents65,164 and for some neurological applications, 
including sites within the spinal cord100,102 and brain,101 albeit with non-neural cell populations. 
Both studies combining magnetic capture with cell transplantation into the spinal cord utilised 
lumbar puncture to deliver the cells into the CSF, a less invasive procedure than direct injection. 
Both demonstrated that more cells accumulated at the lesion site when transplanted under 
external magnetic field application.100,102 This demonstrates the spinal cord is an especially 
attractive neurological target for magnetic localisation strategies given the potential proximity to 
external magnets, due to its limited depth, facilitating efficient magnetic capture of labelled cells.  
Two studies have been performed utilising magnetic localisation of MP labelled NSCs and are, as 
far as I am aware, the only studies of magnetic targeting of neural cell populations. In the first 
study, NSCs were associated with modified MPs designed to attach to the cell membrane (and not 
be internalised) by addition of an RGDS peptide to the surface of the particle. In this study 
labelled NSCs were transplanted, with and without magnetic targeting, into an organotypic slice 
model of axonal regeneration. Here, spinal cord slices are placed adjacent to cortex slices and 
axons projecting from the cortex to the spinal cord are counted to provide an assessment of the 
regenerative capacity of NSCs transplanted onto the spinal cord slice. A greater extent of axonal 
outgrowth was observed when labelled NSCs were transplanted in the presence of a magnet 
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compared to the non-magnet group. The authors attributed this effect to localisation of NSCs and 
therefore a more concentrated effect on stimulation of axon growth by the magnetically targeted 
NSCs compared with more ‘scattered’ NSCs in the no magnet group; although accumulation of 
NSCs was not quantified.80  
In the second study, Song et al. labelled an NSC cell line with Feridex, using poly-L-lysine (PLL) as a 
transfection agent. Cerebral focal ischaemia was induced in rats who then received tail vein 
injection of the magnetically labelled NSCs with or without a magnet applied to the skull above 
the infarct site. Greater numbers of labelled NSCs were observed, in the infarct, in the magnet 
group compared to the no magnet group as judged by an examination of the area of Prussian blue 
staining (detects iron) and quantification of the amount of iron in the tissue surrounding the 
infarct by spectrometry. Further, transplantation of labelled NSCs in the presence of a magnet 
significantly reduced the infarct volume compared to controls and non-magnet treated groups, 
demonstrating a functional improvement when utilising this strategy.64 This latter study is 
particularly exciting in terms of translating magnetic stem cell targeting to the clinic as the 
labelled cells were injected intravenously, a considerably safer means of cell administration than 
direct transplantation into the CNS, and still observed to accumulate at the desired site and exert 
a functional effect. 
Although these two studies are promising from a mechanistic point of view, the first utilised MPs 
which labelled the exterior cell membrane of NSCs. This strategy may show utility in an 
organotypic slice model, but the MPs may have an increased likelihood of removal in vivo (e.g. 
through enzymatic cleavage of the linkers attaching the particles to the cell) – which would result 
in loss of their functional capacity and the potential for toxicity to surrounding tissue. The second 
study utilised a transfection agent to enhance uptake in NSCs. Transfection agents have been 
shown to demonstrate toxicity165 and therefore, may not be a clinically translatable strategy for 
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cell labelling (expanded in Section 3.1.1). This study was also performed with an immortalised cell 
line, which as discussed in the General Introduction (Section 1.13) may not be a reliable indicator 
of particle uptake and toxicity in primary NSCs – a more physiologically relevant cell population. 
Therefore, there is a current requirement to develop neuro-compatible particles, with the 
capacity to mediate magnetic targeting, and protocols to efficiently label primary NSCs without 
affecting key regenerative properties. 
 
3.1.1 The need for a clinically applicable approach to improve MP labelling in NSCs 
In studies where magnetic localisation strategies have worked previously, cells have been highly 
loaded with MPs resulting in high intracellular iron concentrations (24.7 pg/cell in endothelial 
cells101 and 225 pg/cell in MSCs161). This improves the responsiveness of the cells to a magnetic 
field and therefore enables their manipulation by magnetic force. Some cells appear to inherently 
take particles up to a large extent, including endothelial cells101 and MSCs161 (both demonstrated 
to be amenable to magnetic localisation approaches) without the use of particle uptake 
enhancing strategies. However, non-phagocytic cells, including stem cells, are generally thought 
to be difficult to label with MPs alone.166 For example, Neri et al. studied labelling of NSCs with 
two clinical contrast agents: Sinerem and Endorem. Sinerem (incubated for 48 h) labelled ca. 50% 
of NSCs and Endorem (incubated for 24 h) ca. 60%. For both particles, only small accumulations of 
MPs (<50% of the nuclear area estimated from images in this paper) were observed in the NSCs as 
judged by Perl’s staining.167 Confirming this finding, we have observed in our laboratory that 
primary NSCs display low accumulation of several MPs, including, two commercially available 
fluorescent MPs, SpherofluorTM and nano-screenMAG/P-CMX (both formulations labelling ca. 40% 
cells), and a clinical MP used as a contrast agent for MRI, Lumirem® (ca. 40% cells labelled). 
Reasons for the low levels of labelling achieved in NSCs are not yet clear, however, a barrier to 
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particle uptake in NSCs could be their limited endocytotic activity. We recently showed using a 
high resolution membrane imaging technique (termed OTOTO-FESEM, described in Section 2.4.4) 
that cellular membrane activity can be correlated to MP uptake in cells of the CNS.168 When the 
technique was used to visualise NSC membranes, these were found to be relatively quiescent, 
indicating low endocytotic activity. Low NSC membrane activity is most apparent when compared 
with microglia and astrocytes – two cell types with phagocytic and endocytotic functions in the 
CNS (Figure 3.1). Manipulating cells using magnets requires high intracellular iron content, in a 
large proportion of the transplant population. Therefore, it is critical to overcome low labelling of 
NSCs in order to achieve functional levels of intracellular MPs for therapeutic applications in MRI 
tracking or magnetic cell targeting. 
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Figure 3.1. Comparison of relative membrane activity of neural cells. Representative images of 
(A) a microglial cell (B) an astrocyte and (C) an NSC fixed by OTOTO and imaged using FESEM. 
Note that the membranes of the microglia and astrocyte cell seem more active displaying a 
greater extent of ruffling (especially apparent on the microglial cell) and cellular protrusions 
(arrows) than the NSC. 
 
In this context, several strategies have been used in an attempt to achieve highly loaded NSCs in 
order that they can be visualised by MRI; a technique widely studied for non-invasive tracking of 
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cells after transplantation. These include high iron concentrations in the media, long incubation 
times (>48 h), use of transfection agents and novel particle design (summarised in Table 3.1) 
which may all be disadvantageous in terms of a clinical labelling strategy. High iron concentrations 
could lead to cellular toxicity and also particle aggregation; undesirable from a clinical point of 
view as transplanting iron aggregates can lead to false identification of cell localisation. Long 
incubation times are inefficient for use in the clinic and increase chances of infection associated 
with longer culture periods. Transfection agents such as PLL and protamine sulphate are widely 
used in this field and can dramatically improve labelling, both percentage of labelled cells and 
extent of MP accumulation within labelled cells. For example, for a 48 h incubation period, 
proportions of NSCs labelled with Sinerem (clinical grade MP designed for lymph node imaging) 
increased from 50 to 100%, with large deposits of iron in each cell, when labelling was performed 
in the presence of PLL.167 Although protamine sulphate is approved for clinical application, use of 
transfection agents to enhance MP uptake may not be a clinically viable strategy. A range of 
transfection agents have been shown to display dose dependent toxicity, including PLL, through 
mechanisms such as pore formation in the cellular membrane leading to an imbalance of the 
intracellular ionic environment.165 Further, there is a risk of complexes precipitating when using 
MPs in conjunction with transfection agents. This can affect uptake dynamics or potentially lead 
to adverse immune reactions if the cells are to be transplanted.169 
The capacity of a few novel particles to act as MRI contrast agents in NSCs has also been tested. A 
chitosan coated particle has been shown to provide in vitro contrast enhancement for MRI of 
labelled cells.170 Chitosan is a natural cationic polymer capable of acting as a transfection agent 
and is therefore proposed to interact with the cell membrane to enhance particle uptake. In this 
study, chitosan coated MPs appeared to be more readily taken up than naked MPs and displayed 
large intracellular accumulations as judged by TEM. It was reported that no naked MPs were 
observed intracellularly resulting in greatly reduced MRI contrast enhancement compared to 
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chitosan coated MP labelled cells. However, some dissociation of chitosan from the MPs was 
observed which could lead to toxicity in a similar manner to other polycationic transfection agents 
i.e. pore formation in the cellular membrane and an intracellular ionic imbalance. Further, no 
information was provided on the extent of NSC labelling. Therefore, it is not clear whether the 
whole population of cells is labelled and ultimately trackable. Fluorescent silica MPs have also 
been synthesised and shown to internalise in NSCs.171 These particles are designed to display high 
relaxivity values to increase the sensitivity of MP labelled cell tracking by MRI. In this study, NSCs 
were labelled with the silica MPs and injected intravenously into the tails of mice which had been 
experimentally treated to model stroke. NSCs were shown to localise to areas of ischemic brain by 
MRI which was confirmed with histological analysis. Although an interesting study, labelling was 
performed in the C17.2 NSC cell line (which may not be clinically relevant as explained in the 
General Introduction, Section 1.13) and no data was provided on the effect of labelling on 
differentiation of the stem cells; an important property given their potential to replace lost cell 
populations in lesion sites. 
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Cell type Particle and labelling 
strategy 
Proof of uptake Labelling efficiencies Functional readout? Reference 
Mouse NSCs Feridex 
PLL 
- 95% Ex vivo, In vivo MRI 66 
Human NSCs from Stem 
Cells Inc. 
 
Feridex 
24 h incubation + 
protamine sulphate 
Prussian blue 98% In vivo MRI 172 
C17.2 NSC cell line Feridex 
24 h incubation 
Prussian blue 85% In vivo MRI 96 
PC-12 cell line Feridex complexed with 
viral vectors 
6 h incubation 
Prussian blue, MRI in 
vitro, AAS 
Fe: 5.6 pg/cell In vitro MRI though no 
values of relaxivity  
173 
Transduced cell lines to 
express transferrin 
receptor 
MP conjugated to 
transferrin 
Prussian blue, AAS Fe: 0.25 pg/cell In vitro MRI 174 
Mouse NSCs Endorem, Resovist and 
Sinerem 
72 h incubation 
Prussian blue Endorem: 97% 
Resovist: 100% 
Sinerem: 15% 
In vitro + In vivo MRI 175 
Human NSC cell lines Endorem 
24 h incubation + PLL 
Sinerem  
48 h incubation 
Prussian blue >80% 
ca. 70 and 50% for non-
toxic doses of endorem 
and sinerem w/o TA 
In vivo MRI 167 
Rat NSCs Feridex 
48 h incubation 
Prussian blue 100% 
Fe: 5.3 pg/cell 
In vivo MRI 176 
Rat NSCs not reported 
whether primary 
Chitosan coated particle 
2 h incubation 
TEM, confocal Not reported NMR and MRI 
measurements on cells 
in gels 
170 
C17.2 NSC cell line Silica MPs Confocal, Prussian blue Fe: 10 pg/cell In vivo MRI 171 
HB1.F3 human NSC cell 
line 
Feridex 
1 h incubation + PLL 
Prussian blue Fe: 260 pg/cell In vivo magnetic 
targeting 
64 
Table 3.1. Labelling strategies and efficiencies achieved in NSCs. AAS – atomic absorption spectroscopy; TA – transfection agent; NMR – nuclear 
magnetic resonance imaging.
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Novel particle engineering strategies are also being investigated to improve cell uptake. CPPs have 
been widely shown to be useful in increasing uptake of quantum dots, liposomes and 
nanoparticles.177 CPPs are peptides which can cross cellular membranes and the most commonly 
used is the HIV-1 TAT peptide. One study has engineered MPs with TAT to improve gene delivery 
using MPs into the NT-2 human NSC cell line.178 However, in this study the main target was U251 
cells, an astrocytoma cell line, and no toxicity data was reported when delivering the MPs into 
NSCs. Although this may be a promising strategy, CPPs are associated with several concerns for 
potential therapeutic use. For example, it has been shown that gold nanoparticles modified with 
TAT can translocate into the nucleus,179 especially undesirable for iron oxide based nanoparticles 
as free iron can cause oxidative damage to DNA.166 In the same study, it was also observed that 
particles tended to be cleared from the cell over 24 h, possibly through exocytosis although this 
was not confirmed.179 This last point results in the particles being ejected from the cells 
potentially before they have been useful for cell tracking or magnetic cell targeting. Currently, the 
use of CPPs to enhance uptake in neural cells is poorly researched both in terms of functional 
outcome and safety therefore their translation into the clinic is not expected to be imminent. 
To avoid the use of transfection agents and modification of MPs, an alternative ‘physical’ particle 
delivery strategy could be to use magnetic fields to pull particles onto the surface of the cells. This 
strategy was explored in Chapter 2 and is widely used for magnetofection procedures (and most 
commonly for gene delivery grade particles but not MPs acting as labelling agents for MRI or 
magnetic targeting).86 This approach utilises cells’ natural endocytotic machinery92 ensuring cells 
retain their membrane integrity (as opposed to transfection agent use) resulting in high safety. In 
addition, particle association with cells can be in the order of minutes and cells can be incubated 
with lower doses of particles whilst still achieving efficient labelling. Despite these advantages, 
detailed examination of this physical delivery strategy to enhance NSC labelling using functional 
MPs (e.g. capable of mediating magnetic cell targeting) has not been performed. It should be 
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noted that, although this strategy has proven efficacious in neural cells for transfection grade 
particles, these particles generally have a low iron content so are not suited for cell tracking 
through MRI or magnetic cell targeting. Further, the uptake of these particles in neural cells is 
predominately driven by the transfecting component; therefore, findings using these particles 
may not extrapolate to studies using particles proven efficacious for MRI or cell targeting (e.g. 
Feridex). In light of these observations, this chapter aims to investigate the use of 
magnetolabelling strategies (the application of static/oscillating magnetic fields during MP 
incubation) to overcome low intracellular particle accumulation in NSCs.  
 
3.1.2 The need to investigate tailoring of MP magnetite content 
In terms of a magnetolabelling approach, MP response to a magnetic field is proportional to its 
magnetic moment. Therefore, it may be predicted that a promising strategy to improve 
magnetolabelling efficiency would be to increase magnetite entrapment within MPs so that, in 
the presence of a magnetic field, MP sedimentation and subsequent cellular contact would be 
enhanced. Increasing particle magnetite content will also increase particle density which may 
have a further effect on the particles sedimentary properties additionally facilitating enhanced 
cellular uptake through increased contact. Application of magnetic fields and modulating 
magnetite content of MPs has shown benefits for labelling BAECs.162 Here, three PLA-based 
particles of different iron content were added to the culture medium either in the absence or 
presence of a magnet beneath the culture plate for the duration of the labelling procedure (24 h). 
Greatest labelling efficiency (Fe: 26 pg/cell) was achieved using the highest magnetite content 
particle in conjunction with an applied magnetic field. Although interesting in terms of labelling 
endothelial cells, these cell types show relatively high levels of particle internalisation in the 
absence of uptake promoting strategies.101 In addition, oscillating magnetic fields have been 
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shown to enhance uptake of transfection grade MPs in neural cells but were not studied here. 
Therefore, an additional goal of this chapter is to investigate how application of static and 
oscillating magnetic fields effects labelling of ‘hard to transfect’ NSCs when using particles 
containing different magnetite contents. 
 
3.1.3 Assessment of the translational potential of the developed protocols using in vitro 
models 
The safety and utility of the developed protocols will also be tested by transplanting labelled NSCs 
into a slice model of SCI, to investigate cell survival and differentiation post-transplantation. Use 
of organotypic slices could reduce, refine and replace animal usage in accordance with the 3R’s 
principle. As outlined in the General Introduction (Section 1.14) and Chapter 2 (Section 2.1.3) 
organotypic slice culture may be used for a rapid and cost effective assessment of transplantation 
into host tissue representative of in vivo environments. In Chapter 2 a slice model of the 
cerebellum was used as host tissue to test the transplantation of genetically engineered NSCs into 
a ‘healthy’ representation of CNS tissue (i.e. no injuries or disease states were induced in the 
model). The slice model of SCI, also developed in our laboratory, potentially has more clinical 
utility in representing a pathological condition for testing various nanotechnological interventions. 
To generate the model, spinal cords are dissected from mice, sliced longitudinally and these slices 
are cultured at an air-medium interface. A transecting lesion can then be introduced to mimic SCI. 
This model has been extensively characterised and shown to display signs of astrocyte scar 
formation, axonal regeneration and microglial infiltration into the lesion site; all characteristic 
features of in vivo SCI.120 Therefore, the model provides a pathological system to test novel 
nanomaterials and cell transplantation but the utility of the model for investigating 
transplantation of labelled NSCs in the model has not been tested.  
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In addition to the slice model, an in vitro flow system will be used to examine whether 
magnetically labelled cells can be captured by magnetic force. In a similar manner to the in vitro 
slice model, this test could provide a rapid readout as to whether the developed protocols can 
sufficiently label cells for magnetic localisation strategies, reducing the reliance on animal models 
for these experiments. Use of these in vitro models may therefore provide two functional 
readouts important for assessing the ultimate translational potential of the developed protocols, 
namely, survival of the cells in host tissue mimicking injury pathology and capacity of the 
protocols to produce cells which can be trapped by magnetic force.  
 
3.1.4 Chapter objectives 
Given the lack of clinically applicable protocols for efficiently labelling NSCs, this chapter will 
explore whether modulation of the magnetite content of MPs in conjunction with application of 
magnetic fields can offer a safe, alternative strategy to enhance NSC labelling. This will be 
achieved using PLA-based particles, without a transfection component, whose magnetite content 
can be tuned to endow the particles with different magnetic properties. Importantly, this can be 
achieved without varying other key physicochemical properties of the particles including size and 
surface charge. This is critical for exclusively relating particle magnetite content to uptake as size 
and surface charge can both affect cellular internalisation. These particles have been kindly 
formulated by Dr Boris Polyak. For clarity and in order to be able to observe the differences 
between the particles, the formulation and characterisation (performed by Dr Boris Polyak and Dr 
Humphrey Yiu [Heriot Watt University, Edinburgh]) of these particles are outlined in the Methods 
and Results sections respectively. The specific objectives of this chapter are to: 
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(i) To investigate the effect of systematically modulating magnetite content on MP 
uptake in primary NSCs in the absence or presence of magnetic fields (static and 
oscillating). 
(ii) To examine effects of the developed protocols on key regenerative features of the 
NSC population. 
(iii) To investigate the utility of the slice model of SCI to assess survival and differentiation 
of labelled NSCs after transplantation. 
(iv) To test the translational potential of the developed protocols by investigating 
magnetic cell targeting of labelled NSCs in an in vitro flow system. 
 
 
3.2 Methods  
All materials and methods are the same as for Chapter 2 including NSC derivation, media 
composition, fixation and immunostaining unless otherwise stated. 
 
3.2.1 Reagents 
Magnetic particles (BP): Poly(D,L-lactic acid) (PLA, average Mw: 75–120 kD), ferric chloride 
hexahydrate, ferrous chloride tetrahydrate, sodium hydroxide, oleic acid, and poly(vinyl alcohol) 
(PVA, 87-90% hydrolyzed, average Mw: 30-70 kD), were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). PLA covalently labelled with BODIPY® 564/570 (Life TechnologiesTM) was a generous 
gift of Dr. Robert Levy from the Children’s Hospital of Philadelphia. All solvents were of HPLC 
grade and supplied by Fisher Scientific (Pittsburgh, PA, USA). Deionised water used in particle 
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synthesis procedures was obtained using a Milli-Q water purification system. Glass fiber 1.0 µm 
and 5.0 µm syringe driven filters were purchased from Millipore (Millipore, Bedford MA, USA). 
Cell and slice culture: TrypLE was from Fisher. Amphotericin and DAPI were from Sigma.  
 
3.2.2 Magnetic particle synthesis (BP) 
To examine whether changing the physicochemical properties of magnetic particles affects their 
uptake by NSCs four particles were synthesised with different magnetite contents. A schematic of 
the synthesis is provided as Figure 3.2. A mass ratio of 1:3:7 of magnetite was used to prepare 
three MPs which resulted in a weight percent ratio of incorporated magnetite within their 
polymeric matrix of 1:3:5; originating the names for the MP formulations as MP-1X, MP-3X and 
MP-5X. A non-magnetic particle with no magnetite was also synthesised and termed Non-mag. 
Magnetite was prepared from ferric and ferrous chloride by alkaline precipitation (Massart 
method)180 as previously described.162,181 In brief, for MP-1X, 65 and 24 mg of ferric and ferrous 
chloride were dissolved in 9.04 mL of water and precipitated with 0.96 mL of 1N NaOH; for MP-
3X, 195 and 72 mg of ferric and ferrous chloride were dissolved in 7.12 mL of water and 
precipitated with 2.88 mL of 1N NaOH; for MP-5X, 455 and 168 mg of ferric and ferrous chloride 
were dissolved in 3.28 mL of water and precipitated with 6.72 mL of 1N NaOH. After magnetic 
separation precipitated magnetite in each formulation was washed twice with degassed deionised 
water, re-suspended in 2 mL of ethanol and coated with 100 mg (for MP-1X), 150 mg (for MP-3X) 
or 200 mg (for MP-5X) oleic acid by heating under argon to 90°C for 10 min in a water bath. 
Phase-separation of excess oleic acid was achieved by drop-wise addition of 4 mL of water 
followed by two washes of the lipophilic magnetite with ethanol. The different amounts of 
lipophilic magnetite for the different formulations (28, 84 and 196 mg, based on the input of iron 
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salts) were dispersed in 6 mL of chloroform, forming stable magnetic fluids which were used for 
the rest of the particle formulations. PLA-based magnetite-loaded particles were prepared by the 
modified emulsification-solvent evaporation method as described elsewhere.162,181 To formulate 
fluorescent PLA-based MPs, 180 mg of non-labelled PLA and 20 mg of fluorescently labelled 
BODIPY® (564/570) PLA were added to 6 mL of the appropriate magnetic fluid to form an organic 
phase. The organic phase was emulsified in 15 mL of pre-chilled 1.5% (w/v) PVA by sonication, 
and the organic solvents were removed by evaporation under reduced pressure at 30°C. The 
particles were passed through a 1.0 µm glass fibre before being lyophilised with 10% (w/v) 
trehalose as a cryoprotectant. Lyophilised MPs were kept at 4°C in 100 µL aliquots and re-
suspended in deionised water before use. 
 
Figure 3.2. Schematic diagram for synthesis of PLA based MPs. (BP + HY) 
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3.2.3 MP characterisations (BP + HY) 
Particle size and zeta-potential measurements were determined by DLS using a DelsaNano C 
particle size analyzer equipped with two laser diodes (658 nm, 30 mW, Beckman-Coulter, CA). The 
magnetic properties of MPs were obtained from the hysteresis curves of dry samples measured 
by an alternating gradient magnetometer (Princeton Instruments Corporation, Princeton, NJ, 
USA). The magnetite content of MPs was determined after MP degradation with 1N NaOH (90°C, 
30 min), and dissolution of the iron precipitate in HCl, by spectroscopy (using Synergy 4TM 
multimode plate reader, BioTek Instruments, Inc. Winooski, VT, USA and UV compatible 96-well 
plates, BD Biosciences, Franklin Lakes, NJ, USA) and comparison to a standard curve.162,181  
Fourier transform infrared (FTIR) spectroscopic analysis, to examine molecular composition of the 
particles, was carried out using a Perkin Elmer (Coventry, UK) Spectrum 100 spectrometer fitted 
with an attenuated total reflection sampling unit. For the sample measurement, 32 scans in the 
region from 650 to 4000 cm-1 were accumulated with a resolution of 4 cm-1.  
To examine the crystal structure of the particles, a Bruker D8 Advance diffractometer was used 
for powder XRD (x-ray diffraction) analysis on the particles with Cu Kα1 radiation (λ = 1.542 Å). 
The diffraction pattern was collected from 2θ = 5° to 80°, at a step size of 0.009° and a step time 
of 120 s.  
CHN (carbon, hydrogen, nitrogen) elemental analysis was carried out using an Exeter CE-440 
Elemental Analyser. The inorganic content of the particle samples was calculated based on the C% 
(with an accuracy of ± 0.2%) from the CHN analysis results. 
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3.2.4 Labelling NSC monolayers with MPs 
In this chapter labelling of NSCs with the different particle formulations was assessed in 
monolayer cultures. As described in Chapter 2, this culture system has specific clinical advantages 
for transplantation but also for particle labelling (all cells are exposed to the particles and 
experience a uniform magnetic field application). NSCs were plated out at slightly lower 
concentrations than Chapter 2 (1.2 x 105 cells in 600 µL ML-M per well) as this achieved more 
spatial separation of cells adhered to the coverslip. This reduces cell clustering which can 
confound particle internalisation analysis. NSCs were plated in 24 well plates on coated glass (or 
aclar for TEM analysis) coverslips. 
NSCs were cultured as monolayers for 24 h before changing to fresh ML-M with or without 
particles. To prepare particle suspensions, 100 µL lyophilised aliquots (containing the same 
number of particles for each particle type) were re-suspended in 100 µL water and added to ML-
M to achieve the desired concentration. An optimal particle dose was established by incubating 
NSCs with increasing ratios of particle suspensions to ML-M (0.01, 0.1, 1, 2, 5 and 10 µL/mL) and 
observing cell adherence and morphology, to determine effect on cell health, and extent of 
uptake. 
For subsequent experiments a concentration of 1 µL/mL was chosen (which correlated to 
approximately 13 µg/mL of dry weight for Non-mag particles, 15 µg/mL for MP-1X, 19 µg/mL for 
MP-3X and 26.5 µg/mL for MP-5X). Cells were incubated for 24 h under no-field or with exposure 
to static or oscillating (F = 4 Hz) magnetic fields for the first 30 min. Only one oscillating field of 4 
Hz was chosen as it had been previously shown to be optimal for NSC transfection (Chapter 2, 
Section 2.3.2). Field application was also restricted to 30 min as significant particle aggregation on 
the surface of the cells was observed when incubating with the MP-5X formulation in combination 
with 24 h field application. After incubation, cells were washed 3-5 times with PBS to remove 
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particles not internalised. Cultures were then either: fixed for immunocytochemistry or TEM 
(Section 3.2.8 and 3.2.9), to assess particle uptake, numbers of nuclei and pyknotic nuclei per 
field and stem cell marker expression; dissociated for magnetic cell capture experiments (Section 
3.2.13); or switched to differentiation medium and cultured for a further 7 days with media 
changes every 2-3 days, to assess NSC differentiation profiles post-labelling. 
 
3.2.5 MTS assay 
To investigate the effects of the labelling protocols on mitochondrial function, an MTS assay was 
performed. Here, NSCs were labelled as per the protocols described in Section 3.2.4 in duplicate 
wells. After 24 h labelling, MTS reagent was added into the wells and incubated for 3 h. Blanks 
consisted of media containing the appropriate particles and controls were untreated cells. After 3 
h incubation 200 µL aliquots from each well were added to a 96 well plate and the absorbance 
measured at 490 nm. Adjusted absorbance readings were calculated by averaging the results from 
the two duplicate wells and subtracting blank readings. These were then displayed as a 
percentage of the control readings. 
 
3.2.6 Organotypic spinal cord slice derivation and culture 
To generate organotypic SCI models to investigate labelled NSC transplantation, spinal cords from 
mice pups (post natal days 1–3) were dissected out into slicing medium and sliced longitudinally 
using a McIlwain tissue chopper (set to 350 µm). Slices were incubated on ice for 60 min before 
transfer to pre-cut Omnipore membranes sat on Millicell slice culture inserts. They were cultured 
in spinal cord slice culture medium (Chapter 2, Table 2.4) at 37oC/5% CO2 for a maximum of 14 
days, with feeding every 2-3 days (80% medium change). To create a model of SCI, slices were 
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lesioned after 2-4 days in culture using a tool developed in the laboratory, constructed from two 
parallel scalpel blades, which allowed a section of tissue ca. 400 µm to be excised. Any remaining 
tissue in the lesion site was removed by careful aspiration which ensured complete transection 
between the two halves of the spinal cord allowing visualisation of regenerative events. 
 
3.2.7 Labelled NSC transplantation into organotypic slice cultures of SCI 
For transplantation of labelled NSCs into lesions of the organotypic SCI model, NSCs were labeled 
with DAPI at 20 µg/mL for 20 minutes and washed twice in PBS before 1.2 x104 NSCs were 
resuspended in 0.25 µL of ML-M. These were focally transplanted into lesion sites 24 h after 
lesioning. Slices were subsequently fixed 2 h, 48 h and 1 week post-transplantation. 
 
3.2.8 Fixation 
Cells and slices were fixed for immunocytochemistry as in Chapter 2 (Section 2.2.14). For 
examination of particle internalisation by TEM cells on aclar coverslips were fixed in 2.5% 
glutaraldehyde in SCB (0.1M sodium cacodylate buffer containing 2mM calcium chloride) for 2 h 
at RT. Glutaraldehyde fixed samples were washed three times in SCB before further processing. 
 
3.2.9 TEM processing of NSCs  
Glutaraldehyde fixed, NSC samples were post-fixed in 1% osmium tetroxide in SCB. Samples were 
washed three times in SCB then dehydrated through an ethanol series. Dehydrated samples were 
embedded in Spurr resin which was subsequently polymerized (60°C, 16 h). Samples were 
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sectioned perpendicular to the aclar sheet using a Reichert (Buffalo, NY, USA) Ultracut E 
microtome. As there was some difficulty in viewing sections which were mounted on grids due to 
bars obscuring the sample, formvar grids were utilised. These consist of a TEM grid with an empty 
middle section. Coating the grid with a thin layer of formvar (ca. 300 nm), which spans the middle 
section, allows sections to be mounted on an electron permeable membrane and for the whole 
section to be examined. Mounted sections were stained with 2% uranyl acetate in 70% ethanol 
(RT, 20 min) and 2% Reynolds lead citrate (RT, 5 min) before being examined. 
 
3.2.10 Imaging 
Fluorescence and light microscopy: Imaging was performed as in Chapter 2 (Section 2.2.18).  
Z-stack microscopy: Z-stacks of NSCs labelled with PLA based MPs were obtained using a Nikon 
Eclipse 80i microscope fitted with a CA742-95 camera (Hamamatsu Photonics, Hamamatsu, 
Japan), with 1.0 μm incremental manual focus stepping. The resulting stacks were processed 
using Nikon NIS Elements (version 3.00).  
TEM: Sections mounted on grids were examined using a JEOL (Tokyo, Japan) 100-CX transmission 
electron microscope operated at 100 kV. Images were captured using a SIS systems Megaview III 
digital camera (Olympus, Tokyo, Japan). 
TEM of MP samples (BP) was performed by using JEM-1230 electron microscope (JEOL ltd, Japan) 
operated at 80kV. MP samples were diluted 1:10 with deionised water and deposited on carbon 
coated grids (Electron Microscopy Sciences, USA) with no use of contrast staining. 
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3.2.11 Assessment of PLA particle labelling efficiency 
Particle internalization was quantified microscopically in fixed, nestin positive NSCs. Microscopic 
analysis of particle uptake was chosen as this permits analysis of particle internalisation and 
parameters of cell health to be conducted in parallel. In particular for particle uptake analysis, 
particle localisation within the cells can be discriminated from adherence to the cell membrane 
and the extent of particle uptake can also be assessed - important in primary NSCs which display 
heterogeneous particle uptake. Also, techniques such as flow cytometry do not allow evaluation 
of cellular morphology and therefore particle localisation within cells (e.g. peri-nuclear). Other 
techniques for assessing MP uptake into cells include colorimetric absorbance assays of lysed cells 
to measure ‘intracellular’ iron content, however, these values can be confounded by membrane 
bound MPs indicating that this may not be a robust measure for particle uptake in neural cells. 
Quadruple merged microscopic images (including phase images), taken at X400, were used to 
confirm whether particles were intracellular. Proportions of labelled cells and the extent of 
cellular labelling (unlabelled, low, medium or high labelling) were then determined from three 
fields with ca. 250 nuclei counted for each labelling condition. The extent of labelling was 
estimated by subjective assessment of the area occupied by particles within each cell: <10%, 10-
50%, >50% of the average nuclear area being scored as ‘low’, ‘medium’ and ‘high’ labelling 
respectively, as previously described.81,124 Iron quantification (related to the number of 
intracellular MPs) within cells was also determined spectrophotometrically after lysing cells with 
radioimmunoprecipitation assay buffer and dissolving the particles in 1N HCl (λ = 335 nm) which 
was performed by BP as described elsewhere.162,181 
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3.2.12 Examining the safety of labelling protocols  
Using samples fixed at 24 h post-labelling, assessment was made of nuclei per field, pyknotic 
nuclei and the expression of NSC specific markers, nestin and SOX2 as in Chapter 2 (Section 2.2.20 
and 2.2.21). Generation of daughter cells from labelled NSCs was assessed using samples fixed 
after 7 days differentiation (8 days post-labelling) by counting specific neural cell markers as in 
Chapter 2 (Section 2.2.21). 
 
3.2.13 Assessment of magnetic localisation capability of MPs 
To examine magnetic localisation of the labelled NSCs, cells were labelled for 48 h with 
application of the F = 4 Hz magnetic field for the first 30 min. Labelled cells were washed three 
times with PBS to remove free particles, then trypsinised (using TrypLE) and triturated to produce 
a single cell suspension. Cells were collected by centrifugation followed by two more washes with 
PBS before finally re-suspending in PBS at a concentration of 1 x 105 cells/mL. Labelled cells were 
subjected to a single pass through a 1.6 mm diameter tubular flow system (Figure 3.3). 
Preliminary experiments indicated that flow rates ≤1 mL/min resulted in high cell loss, presumably 
due to cellular adherence and aggregation within the flow system, whilst flow rates ≥4 mL/min 
resulted in minimal magnetic capture. Therefore, an optimal experimental flow rate of 2 mL/min 
was chosen with an approximate flow velocity of 1.7 cm/s broadly similar to blood flow rates in 
arterioles and venules.182 To generate the magnetic field for cell capture, the tubing was placed 
on top of a magnetic plate (field strength: 316 ± 8 mT) and surrounded by two bar magnets (field 
strength: 410 ± 10 mT). Magnetic field strengths were measured by an F.W. Bell 5080 Gaussmeter 
(Pacific Scientific-OECO, Milwaukie, OR). Cell density was estimated before and after passage 
through the flow system using a haemocytometer and the percentage value for cell retention 
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within the system was calculated as (cell count after magnet application)/(cell count before 
magnet application) x 100. 
 
Figure 3.3. Schematic of the in vitro flow system used to assess the capability of magnetically 
capturing labelled NSCs. 
 
3.2.14 Statistical analysis 
Data was split into comparable groups (i.e. with only one variable change per group, for example: 
Non-mag, MP-1X, MP-3X and MP-5X uptake compared under the no-field condition only, 
represented a single dataset) for analysis by one-way ANOVA and Bonferroni’s MCT using Prism 
software (version 4.03, Graphpad). Data are expressed as mean ± SEM with ‘n’ referring to the 
number of different cultures, each derived from a different mouse litter, except for the magnetic 
localisation experiments where ‘n’ refers to number of experiments. A two-way ANOVA was not 
performed in this chapter as comparisons were not made between groups of data sets. 
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Comparisons in this chapter are between field conditions for the same particle or between the 
different particles in each field.   
 
3.3 Results 
3.3.1 Culture purity 
Monolayer NSC cultures were routinely produced displaying normal adherence, bipolar 
morphology and circular and intact DAPI nuclei staining as judged by light and fluorescence 
microscopy respectively. Cultures were also of high purity with 98.3 ± 0.7% (n = 5) and 96.4 ± 1.4% 
(n = 5) cells expressing nestin and SOX2 respectively. 
 
3.3.2 Particle synthesis and characterisation (BP + HY) 
Observation of the particles with TEM revealed they were of similar size with a spherical shape. 
However, each particle displayed a distinct pattern of magnetite distribution where packing 
density of magnetite appeared to increase from MP-1X to MP-5X (Figure 3.4).  
 
Figure 3.4. TEM analysis of MP formulations. Images show particles were of a similar size and 
that iron appears to be more densely packed from MP-1X to MP-5X. 
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The magnetic responsiveness of the particles matched this pattern of magnetite packing with no 
response shown from the Non-mag particles (as expected) and increasing response with increased 
magnetite content (Figure 3.5A). It is important to note here as well that the particles display 
superparamagnetic response curves with no significant hysteresis (Figure 3.5A). DLS confirmed 
particle size measurements from TEM (Figure 3.5B – values in Table 3.2) although the particle 
suspensions had a relatively high poly-dispersity index (0.15-0.23) indicating a heterogeneous size 
population. However, this was consistent among the formulations so was not a product of 
increased magnetite content. Zeta-potentials by DLS were all slightly negative with a small 
increase as magnetite content increased (Table 3.2). Size, zeta-potential and magnetisation data 
are summarised in Table 3.2. 
 
Figure 3.5. Magnetic responsiveness and size of the different particle formulations. (A) 
Magnetisation curves of MP formulations measured by alternating gradient magnetometer. Note 
response increases with increasing magnetite content and curves are absent of hysteresis which is 
indicative of superparamagnetism. (B) Size distributions of the MP formulations by DLS indicating 
similar sizes. 
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Table 3.2. Physicochemical properties of the formulated PLA- magnetite MPs. 
 
Similar organic composition of the particles was confirmed using FTIR spectroscopy with expected 
peaks observed for PLA, oleic acid and PVA (Figure 3.6A - example peak identities are in the 
legend). XRD spectrum of all particles was dominated by PLA suggesting the magnetite is buried 
within a PLA matrix, however, XRD of the oleic acid coated iron oxide used to formulate the 
particles confirmed its magnetite nature (Figure 3.6B). 
 
 
 
 
 
Formulation 
description 
Weight of formulation 
corresponding to 
magnetite (%) 
MP average 
size (nm) 
Poly-dispersity 
index 
-potential 
(mV) 
Magnetization at 5 
kOe (emu/g 
composite) 
 MP-5X 
 MP-3X 
 MP-1X 
 Non-mag NP 
35.4 
19.2 
6.7 
- 
 278 ± 1.6 
 254 ± 2.8 
 262 ± 9.6 
 267 ± 0.7 
 0.17 
 0.23 
 0.15 
 0.14 
 -14.4 ± 0.3 
 -11.5 ± 0.1 
 -9.5 ± 0.1 
 -9.0 ± 0.2 
 24.6 ± 1.2 
 15.2 ± 1.0 
 2.1 ± 0.1 
 - 
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Figure 3.6. FTIR and XRD analysis of MP formulations. (A) FTIR spectrum of the different MP 
formulations. Characteristic bands for oleic acids (CH stretching at 2950 and 2850 cm-1, C=O 
stretching at 1710 cm-1 and CH2 bending at 1430 cm
-1) were identified. The adsorption band at 
1530 cm-1 is assigned as the COO stretching coordinated to iron atoms.183 In all samples 
vibrational bands indicative of PLA were also observed (OH stretching at 3495 cm-1, CH stretching 
at 2945 cm-1, C=O stretching at 1758 cm-1, CH3 bending at 1450 cm
-1, CH2 wagging at 1360-1380 
cm-1 and C-O stretching at 1050-1270 cm-1.184 The broad peak at 3500 cm-1 is attributed to the OH 
stretching mode of PVA and moisture. (B) Powder XRD diffractions for the different MP 
formulations. The patterns in (i) are indicative of magnetite. 
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3.3.3 Establishing optimal particle dose for labelling NSCs 
Preliminary experiments indicated that MP-5X particles were taken up more readily than the 
other particle formulations. To achieve the experimental aim (investigating the modulation of 
magnetite content of particles independent of other factors such as surface chemistry or particle 
concentration) it is vital that the concentration of particles remains the same, therefore, as 
toxicity is related to levels of uptake, it was decided that an optimal concentration of MP-5X was 
established which would then be compared to equal amounts of the other particle formulations. 
For this, a series of MP-5X concentrations were tested from 0.01 µL/mL – 10 µL/mL. Particle 
uptake was found to be concentration dependant (Figure 3.7) with the highest levels of labelling 
achieved at 1 µL/mL. Concentrations of MP-5X tested above 1 µL/mL (2, 5 and 10 µL/mL) incurred 
substantial cell loss with the appearance of multiple rounded cells, indicative of cell death, which 
was attributed to excessive particle uptake by the NSCs. Given these findings it was decided that 
the concentration used for the rest of the experimental work would be 1 µL/mL. 
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Figure 3.7. Optimising particle concentration for labelling NSCs. (A) Bar chart depicting 
percentage of cells labelled when using different concentration of the MP-5X particle formulation. 
Statistical difference are *p<0.05 and ***p<0.001 vs 0.01 µL/mL; +++p<0.001 vs 0.1 µL/mL one-way 
ANOVA with Bonferroni’s MCT, n = 3). 
 
3.3.4 Confirmation of particle uptake in NSCs 
After establishing a safe dose of particles it was assessed whether NSCs internalised the particles. 
Z-stack microscopy revealed both MP-1X and MP-5X particles accumulated within the cytoplasm, 
often localising in the peri-nuclear region, but rarely in the cellular processes (Figure 3.8A). TEM 
confirmed this pattern of internalisation although striking differences were seen between MP-5X 
and MP-1X particles (Figure 3.8B): MP-5X particles displayed a strongly electron dense ring-like 
structure and often appeared as clusters. This was in contrast to MP-1X which were always 
observed as single particles and had a similar ring-like structure but of apparently much less 
electron density. No particles were ever observed in the nucleus by z-stack microscopy or TEM 
and no particles were observed in control NSCs (not exposed to the particles). 
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Figure 3.8. Confirmation of particle uptake in NSCs. (A) Z-stack microscopy revealing clusters of 
peri-nuclear particles (MP-5X) which the z-stack indicates are in the same plane as the nucleus. (B) 
TEM section through a labelled cell shows a cluster of MP-5X particles, with a ring like structure of 
electron dense material, adjacent to the nucleus (Nu). The inset shows a MP-1X particle, always 
observed as single particles within the cytoplasm. Also, note the less electron dense ring-like 
structure corresponding to lower magnetite content than the MP-5X formulation. 
 
3.3.5 Effects of magnetite modulation and magnetic field application on MP uptake in cells 
NSC labelling was observed in all conditions with intracellular patterns of labelling as described in 
Section 3.3.4. Basal levels of labelling were observed when using the Non-mag particles of 
approximately 35% with no effects on levels of labelling achieved when fields were applied. MP-
1X labelling without field addition (39.6 ± 2.7%) was similar to that of the Non-mag particle 
labelling (Figure 3.9A and 3.10). However, field application systematically enhanced MP-1X 
labelling (Figure 3.9A-B and 3.10) from static field (53.4 ± 2.4%) to a maximum using the 4 Hz 
oscillating magnetic field (63.7 ± 3.5%). The percentage of labelled cells then increased with 
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increasing iron content (within each magnetic field condition) so that the following paradigm 
existed: MP-1X < MP-3X < MP-5X with optimal labelling achieved in this study using the MP-5X 
particles with the 4 Hz oscillating field (95.8 ± 1.0%, Figure 3.9C and 3.10). It should be noted that 
although there was a trend towards enhanced labelling when the oscillating field was applied for 
both MP-3X and MP-5X the increases were not statistically significant in terms of percentage of 
cells labelled. 
 
Figure 3.9. Differences in NSC labelling when using particles of different formulations under 
various magnetic field conditions. NSCs labelled using MP-1X (A) without a field and (B) with 
application of an oscillating magnetic field (F = 4 Hz). (C) Optimal NSC labelling; achieved using 
MP-5X in conjunction with an oscillating magnetic field (F = 4 Hz). Numbers of NSCs labelled and 
the extent of particle uptake are quantified in Figures 3.10 and 3.11 respectively. 
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Figure 3.10. Quantification of NSC uptake of the different MPs. Bar chart displaying percentage 
of NSCs labelled when using each particle formulation in conjunction with the indicated magnetic 
field. Statistical differences are: **p<0.01 and ***p<0.001 versus no-field condition labeling at the 
same particle iron concentration; +++p<0.001 versus MP-1X labeling under the same field condition; 
##p<0.01 and ###p<0.001 versus MP-3X labeling under the same field condition (one-way ANOVA 
with Bonferroni’s MCT, n = 5). 
 
A semi-quantitative assessment was also made of the extent of uptake of each particle type which 
generally increased as particle magnetite content increased with more cells displaying ‘medium’ 
and ‘high’ levels of labelling when using MP-5X compared to MP-1X. Although there was a trend 
towards enhanced particle uptake when using applied magnetic fields, for a given particle 
formulation these were not statistically significant (Figure 3.11). At the optimal labelling condition 
the average iron content of NSCs was found to be 5.7 pg/cell as measured by spectrophotometry.  
137 
 
 
 
Figure 3.11. Semi-quantitative assessment of the extent of particle uptake. Bar chart displaying 
the breakdown of labelled NSCs into cells displaying ‘low’, ‘medium’ and ‘high’ levels of labelling 
as judged by a semi-quantitative estimate of the area of internalised particles. Statistical 
differences were analysed between comparable low, medium and high groups and are: *p<0.05, 
**p<0.01 and ***p<0.001 versus MP-1X labeling under the same field condition; +p<0.05, ++p<0.01 
and +++p<0.001 versus MP-3X labeling under the same field condition (one-way ANOVA with 
Bonferroni’s MCT, n = 5). 
 
3.3.6 Labelling protocols do not affect cell health, proliferation or ‘stemness’ of NSCs 
As described in Chapter 2 safety of novel nanotechnologies is essential and of paramount 
importance to their eventual adoption into clinical use. Therefore, a number of assessments of 
the safety of labelling NSCs with these novel particle formulations have been performed. Under 
phase microscopy, labelled cells were adhered to the substrate and displayed typical bipolar 
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morphology. Assessing the numbers of cells per field revealed no significant differences in the 
proliferation of the NSCs (Figure 3.12A). Cell viability, as judged by counting the percentage of 
abnormal (pyknotic) nuclei, was also low and similar across all conditions (Figure 3.12B). As a 
further measure of cell health a MTS assay was performed which showed there were no 
significant differences between the ability of cells from each condition to reduce the tetrazolium 
dye (Table 3.3). Taken with the microscopic analysis, which showed the cell numbers are equal 
between conditions, this result suggests that labelling did not affect cell metabolism.  
Normal expression of NSC specific markers, nestin and SOX2, was maintained in cells that had 
taken up the particles under all conditions. The proportions of cells expressing the markers were 
also unaltered in all labelling conditions and similar to those in control cultures (Figure 3.13A and 
B). 
 
 
Figure 3.12. Effect of labelling on cell proliferation and viability. Bar charts displaying 
quantification of (A) numbers of nuclei per field, a measure of the proliferative capacity of the 
cells, and (B) percentage of pyknotic nuclei, an indicator of cell death. Numbers are similar across 
all conditions suggesting the protocols are not having an effect on these measures of cell health. 
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Field 
Condition 
Particle Formulation 
 Non-mag MP-1X MP-3X MP-5X Control 
No field 101.1 ± 10.8 97.3 ± 10.8 97.8 ± 10.5 97.8 ± 11.9 100.0 ± 9.3 
Static field 100.8 ± 11.2 96.1 ± 13.1 92.4 ± 13.0 92.6 ± 12.9  
F=4Hz 
oscillating field 
98.3 ± 10.9 92.5 ± 10.8 90.8 ± 11.4 93.8 ± 11.0  
Table 3.3. MTS assay absorbance readings from the different labelling conditions. Absorbance 
readings are expressed as a percentage of the control. No significant differences were observed 
between the groups. 
 
 
Figure 3.13. Labelling with the various particle formulations does not affect NSC marker 
expression. Bar charts displaying the percentage of cells expressing the NSC specific markers (A) 
nestin and (B) SOX2 across all conditions. 
 
 
140 
 
 
3.3.7 The developed protocols have no effect on the differentiation profile of NSCs 
Part of the therapeutic potential of NSCs relies on their ability to generate their daughter cells for 
replacing cells that are lost or damaged in disease/injury. Therefore, an investigation of NSC 
progeny after labelling was performed. Daughter cells produced from labelled NSC populations 
had normal morphology and all cell types displayed some evidence of retaining the MPs (Figure 
3.14A-C). This was most apparent in the astrocyte population where large particle accumulations 
were evident in a large majority of cells (Figure 3.14A). Neurons and oligodendrocytes were 
labelled to a lesser extent and often displayed small accumulations when intracellular MPs were 
observed (Figure 3.14B and C). Labelling NSCs under all conditions did not affect the proportions 
of cells that differentiate into astrocytes, neurons or oligodendrocytes (Figure 3.14D-E). 
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Figure 3.14. Post labelling differentiation of NSCs. Representative images of the three major cell 
types generated from NSCs (A) astrocytes, (B) neurons and (C) oligodendrocytes. The images 
display examples of particle retention by the individual cell types indicated by the white arrows. 
Note that particle accumulations appear to be larger and more frequent in astrocytes (A) than in 
neurons (B) and oligodendrocytes (C). Bar charts displaying quantification of the proportions of (D) 
astrocytes, (E) neurons and (F) oligodendrocytes generated from NSCs from each condition 
between which there were no significant differences. 
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3.3.8 NSCs could be trapped by magnetic force in an in vitro flow system 
To test the functional utility of the formulated MPs, labelled NSCs were passed through an in vitro 
flow system and subjected to a magnetic field gradient designed to form a simulation of 
intravascular delivery and in vivo magnetic cellular capture. A basal level of retention was 
observed of 18.1 ± 4.9% of cells retained within the system when NSCs were labelled with the 
Non-mag particle. The percentage of cells trapped in the system increased along with increasing 
the magnetite content of the particles used to label the NSCs, up to a maximum of 66.7 ± 3.3% 
when labelling was performed with MP-5X (Table 3.4). Microscopic examination of the tubing 
after the magnetic localisation experiments revealed large aggregates of rounded bodies with the 
morphological appearance of trypsinised cells (see Section 3.3.9 for an example of dissociated 
cells). These co-localised with particle fluorescence indicating the trapped labelled cells (Figure 
3.15). 
Particle formulation used to 
label NSCs 
% Cell retention in flow system 
Non mag 18.1 ± 4.9 
MP-1X 18.9 ± 9.0 
MP-3X 40.1 ± 9.2 
MP-5X 66.7 ± 3.3**
,++
 
Table 3.4. Magnetic localisation in an in vitro flow system. Table shows percentage of cells 
retained after NSCs had been labelled with the indicated MP formulation and passed through an in 
vitro flow system which was exposed to a magnetic field gradient. Significant differences are: 
**p<0.01 vs Non-mag and ++p<0.01 vs MP-1X labelling (one-way ANOVA with Bonferroni’s MCT, n 
= 3). 
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Figure 3.15. NSCs labelled with MP-5X could be magnetically localised in an in vitro flow system. 
Representative image taken from the tubing next to the magnet after NSCs that had been labelled 
with MP-5X were passed through the flow system. Rounded cellular bodies can be seen indicative 
of trypsinised cells (white arrows). Inset shows the fluorescence counterpart indicating the cells 
that have accumulated are labelled with the fluorescent MP. 
 
3.3.9 Assessment of the transplantation of NSCs onto organotypic SCI slice models 
To assess the utility of the organotypic slice cultures of SCI for investigation of protocol safety, 
NSCs labelled with MP-5X were transplanted into lesion sites. Figure 3.16A shows dissociated 
single NSCs, after trypsinisation, displaying retention of the MP label. Focal transplantation of 
labelled NSCs was achieved in the lesion of the slice (Figure 3.16B). 48 h post transplantation, cells 
co-labelled with DAPI (mostly absent within the slice body) and fluorescent particles were 
observed in areas of characteristic SCI pathology including axonal outgrowth (Figure 3.16C) and 
GFAP up-regulation (Figure 3.16D). One week post-transplantation, labelled cells appeared to be 
expressing the astrocytic marker GFAP (Figure 3.16D, inset) indicating NSC survival and 
differentiation in the slice. Labelled neurons were rarely observed and labelled oligodendrocytes 
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were never observed; similar to the pattern of labelling seen after differentiation on glass 
coverslips. 
 
 
Figure 3.16. Labelled NSC transplantation into organotypic spinal cord slices. (A) Representative 
image of dissociated NSCs retaining MP-5X after trypsinisation. The cells were also labelled with 
DAPI. (B) Focal transplantation of fluorescent MP labelled NSCs immediately after transplantation. 
Labelled NSCs (white arrows) were observed 48 h post-transplantation in areas of (C) axonal 
growth and (D) GFAP reactivity; hallmark features of SCI pathology. One week post-
transplantation labelled cells were expressing the astrocytic marker GFAP (D - inset) indicating 
some NSCs had survived and differentiated into astrocytes within the lesion. 
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3.3.10 MP-5X particles were retained in NSC daughter cells for up to three weeks 
To examine the potential for long-term targeting strategies using these particles, MP-5X labelled 
NSCs were differentiated and cultured for three weeks. Cells still retained the particles up until 
this time-point (Figure 3.17) although the extent of labelling throughout the culture appeared to 
be less (estimated to be less than half the levels of labelling) than after one week in culture 
(Figure 3.17 inset and Figure 3.11) indicating some particle loss over the course of this 
experiment. 
 
Figure 3.17. Daughter cells generated from labelled NSCs retain MPs for up to three weeks. 
Representative image showing astrocytes generated from NSCs labelled with MP-5X still retain the 
label (white arrows) although the pattern of labelling is less extensive than in cultures 
differentiated for one week post labelling (inset and Section 3.3.7). 
 
3.4 Discussion 
This is, as far as I am aware, the first study of systematically modulating particle magnetite 
content and assessing the impact on stem cell labelling alone and in conjunction with applied 
magnetic fields. It was found that, by simply increasing magnetite content of MPs, high labelling 
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can be safely achieved in a hard to label cell type without the use of chemical or biological 
strategies, which as discussed in the Introduction (Section 3.1.1) may not be suitable for clinical 
translation. As an alternative, the physical delivery strategy described in this chapter has 
considerable advantages for clinical use, including, a good safety profile and relatively simple and 
adoptable methodology. This has significant clinical implications for achieving high labelling 
efficiencies of novel designs of neuro-compatible MPs for a range of applications along with 
magnetic cell localisation. The protocols were also shown to impart functional benefit, at least in 
an in vitro flow system, where it was observed that MP labelled cells could be captured by 
magnetic force. Further, labelled cells survived and differentiated in a slice model of SCI. Taken 
together, these two findings demonstrate the potential clinical utility of using high magnetite 
content, PLA-based MPs as agents to facilitate magnetic NSC targeting to sites of injury and 
disease in the CNS. 
 
3.4.1 Mechanisms of increased labelling utilising the described protocols  
It is of interest that field application only significantly enhanced uptake of the MP-1X formulation, 
which has the lowest magnetite content, in a pattern reminiscent of that in MP mediated 
transfection of NSCs (Chapter 2); with the F = 4 Hz condition proving to be the most efficient in 
terms of percentage of cells labelled. It is well recognised that transfection grade particles have 
low iron content and good colloidal stability so they require a magnetic field to enhance their 
sedimentation on to the surface of the cells,92 presumably a similar mechanism applies to the MP-
1X formulation. The mechanism of oscillating magnetic field action in increasing cellular uptake is 
not yet known, however, was speculated to act through either increasing the dispersion of MPs in 
the media, therefore enhancing particle-cell contact, or stimulating the cellular membrane to 
promote endocytosis of the particles, or, be a combination of the two mechanisms. Whether, the 
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increase in MP-1X uptake after application of the oscillating fields follows the same mechanism as 
Neuromag (the particle used in Chapter 2) or whether there are even inter-particle differences in 
the interaction with magnetic fields cannot yet be elucidated. As in Chapter 2, it may be possible 
to study the mechanisms of action of the oscillating field by using the high resolution membrane 
imaging technique termed OTOTO-FESEM. To achieve this, FESESM could be used to visualise 
changes in the cellular membrane which may be indicative of increased endocytotic activity 
stimulated by application of magnetic fields. 
In contrast to the MP-1X particle formulations, MP-3X and MP-5X showed no significant 
enhancement of the percentage of cells labelled or the extent of uptake of MPs after application 
of magnetic fields. However, the latter measure was conducted using a semi-quantitative analysis 
which may be limited in highlighting subtle differences in particle uptake between different field 
conditions. Our lab is currently investigating the use of confocal microscopy to measure the 
intracellular volume occupied by the particles as a more quantitative assessment of particle 
uptake. This approach may be used for future studies to examine the differences in uptake when 
using fluorescent particles. In this study, the fact that no differences were observed between field 
conditions may be explained in terms of the colloidal stability of the particles which, in sub-micron 
sized particles, depends on viscosity of the medium and particle density. It is likely that increasing 
particle iron content increases particle density sufficiently to facilitate sedimentation onto the 
surface of the cells and stimulate uptake mechanisms. Indeed, in recently published observations 
in our laboratory it was noted that when NSCs are incubated with MP-5X particles, membrane 
activity appeared to be up-regulated in comparison to labelling with the Non-mag particle 
formulations (paper attached as Appendix 3).185 Specific membrane features that were enhanced 
are possibly related to particle uptake mechanisms and included membrane ruffling, filopodia 
(short 2-3 µm protrusions on the cell membrane), pits and nanopodia (cellular protrusions 
attached to the substrate). For the heavier particles this could mean that field application is 
148 
 
 
unnecessary to further enhance sedimentation and cell labelling (at least over 24 h) possibly 
demonstrating there is a ‘magnetite limit’ where field application is no longer required to 
enhance labelling. However, it should be noted that there may be cell type differences in 
response to applying magnetic fields. For example, in the presence of a magnet, BAECs 
internalised ca. 90% of high iron content particles from the media in comparison to just 30% in 
the absence of a field (over a 24 h incubation period).162 Although 24 h magnetic field application 
could represent an additional step to enhance particle labelling in NSCs, in this study particle 
aggregation of the MP-5X particles was noted over extended exposure to the magnet. As 
discussed in the Introduction (Section 3.1.1), particle aggregation can lead to non-internalised 
iron precipitates leading to false identification by MRI or adverse immune responses after 
transplantation. Therefore, this strategy may not be applicable in the context of translating this 
particle formulation into clinical use. 
 
3.4.2 Clinical utility of the developed protocols for NSC transplantation therapy 
Most studies to date involving the use of labelling NSCs with MPs have relied on the use of uptake 
enhancing strategies, including: lengthy incubation protocols; exposure to high particle 
concentrations; and transfection agents which as explained in the Introduction (Section 3.1.1) 
may not be clinically translatable. In addition, a large number of studies have reported their 
findings using NSC cell lines which may not represent particle uptake dynamics of primary NSCs (a 
more physiologically relevant cell population) and can display remarkable resistance to toxicity. 
The latter point means that safety data relating to developed protocols for cell tracking or 
magnetic cell localisation for labelled cell lines may not translate to primary NSCs. In this regard, 
the protocols developed here utilised primary NSCs, are rapid (24 h incubation) and can be 
performed in the absence of chemical or biological uptake enhancing strategies. High labelling 
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was reported (a maximum of ca. 96% cell labelled) with no obvious effects on key regenerative 
properties of the NSCs including proliferation, stem cell marker expression and differentiation. 
Further, labelled NSCs were captured in an in vitro flow system and survived and differentiated in 
a slice model of SCI demonstrating the potential for the protocols to be used for clinical magnetic 
cell targeting approaches. In combination with the technical simplicity of the protocols, 
translation of the approach into the clinic seems feasible. 
In terms of clinical application, using the MP-5X particle in combination with a 4 Hz oscillating field 
resulted in the highest levels of labelling which corresponded to an average iron content per cell 
of 5.7 pg. Although this was proved here to be sufficient for cellular capture in an in vitro flow 
system, it is substantially lower than the levels of labelling (ca. 260 pg Fe/cell) achieved in NSCs 
magnetically localised in ischemic rat brains. It should be noted however that this latter study 
utilised an immortalised cell line combined with a transfection agent to enhance labelling.64 Cell 
lines can display high uptake compared to primary cells. For example, PC-12 cells, often used as a 
neuronal cell line, displayed markedly greater labelling (ca. 77%) than primary neurons (ca. 13%) 
when comparing the same particle.115 It remains to be determined if the extent of uptake 
achieved in this study will allow for magnetic targeting approaches in vivo. Of further clinical use, 
the average iron per cell reported in this study is comparable to the amounts reported from other 
studies which have tracked NSCs using MRI.173,176 However, as iron content in cells is reduced over 
time due to proliferative dilution this amount may only be enough to track cells through one cell 
division; therefore intracellular iron may need to be increased. As this is the realistic maximum 
amount of iron that can be incorporated in the particle using this formulation method, particle 
design strategies to increase intracellular iron might involve utilising larger particles of the same 
formulation or utilising a different method of synthesis. For example, chemically binding PLA onto 
amine functionalised magnetite particles (prepared by silanisation) using EDC/NHS binding agents 
could reduce the amount of PLA which contributes to the final particle – increasing magnetite 
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content.186 All novel particle designs would also have to be rigorously tested for safety and 
function. 
Importantly for use in the clinic, all formulations tested were found to be safe with respect to key 
regenerative properties of the NSCs including cell proliferation, cell viability, stem cell marker 
expression, differentiation profiles and survival in an organotypic slice model. Indeed, it was 
desirable from the outset to formulate the particles with safe and potentially translatable 
components. In this regard, PLA is well known to be biocompatible and has been previously FDA 
approved for contact with biological fluids.187,188 In addition, PLA is relatively stable, with 
extracellular degradation shown to last over weeks to months189 and 15% degradation shown 
intracellularly over 3 days.190 Confirming this, no evidence for particle degradation over a 24 h 
time period was observed in this study, as judged by TEM analyses. This could be a factor in the 
demonstrated safety of the particle, as our laboratory has previously shown that breakdown of 
MPs is a major correlate with toxicity,124 possibly due to overwhelming the cell with intracellular 
iron. Therefore, particle stability is key for both retaining the MP for successful cellular 
imaging/targeting over the therapeutic time-course and for the safety profile. Magnetite based 
particles have been shown to be safe in animal studies191,192 and some FDA approved magnetite 
particles are used as clinical grade contrast agents for MRI.193 PVA and oleic acid used to stabilise 
the MPs are also considered safe, with PVA approved for embolization and neurological 
applications194 and oleic acid rapidly absorbed and metabolic products utilised and excreted 
(according to www.fda.com). Therefore, in comparison to some novel particles that have been 
tested for labelling NSCs,174,178 all the components of the particle are potentially safe highlighting 
the translational potential of the described protocols. 
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3.4.3 Particle formulation method could allow for modifications to enhance regenerative 
utility 
Further advantages to regenerative neurology may be derived from the formulation method used 
to generate the particle in this study. Similar formulations to those presented here allow for 
biomolecule encapsulation within the polymer matrix – this can happen without modification of 
the biomolecule being necessary therefore avoiding altering the biological function of the drug – 
for release into target cells.195 Further, degradation rates of the particles can be tuned by mixing 
PLA with a co-polymer poly(lactic-co-glycolic acid), PLGA, for slow release of incorporated drugs; 
this approach has been shown for release of the anti-proliferative drug, paclitaxel.181 This could 
provide a novel approach for delivering drugs to the CNS, which is normally hampered by lack of 
drug penetration across the BBB. As discussed in the General Introduction (Section 1.5) 
combinatorial therapy is likely to be essential for promoting successful repair in the CNS and 
combining drug delivery with MP labelling of NSCs could be a promising strategy to achieve this.  
 
3.4.4 In vitro tests could be suggestive of the in vivo potential of the labelling protocols 
The translational potential of the developed labelling protocols was tested in two in vitro models. 
The first is a simple in vitro flow system. Here, MP labelled cells were effectively captured using 
magnetic force highlighting the functional capability of these particles to mediate magnetic cell 
localisation. The pattern of enhanced retention matched that of the particle labelling 
experiments, namely, MP-5X > MP-3X >MP-1X > Non-mag, suggesting this approach may provide 
reliable information on the ability to magnetically capture MP labelled cells. Improving the 
complexity of the flow system described in this chapter, for example, to provide continuous flow 
or performing the experiments with CSF, could allow a better representation of the in vivo 
response of MP labelled cells to magnetic localisation.  
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The second model involved transplantation of labelled NSCs onto organotypic slices mimicking 
SCI. In this study the slices demonstrated hallmark features of SCI pathology including axonal 
regeneration and evidence of astroglial scarring which is in agreement with the previous 
characterisation of these slices by our laboratory.120 Post-transplantation, labelled NSCs 
predominately differentiated into astrocytes, a finding which has been shown for in vivo 
transplantation of NSCs into sites of SCI.46 Crucially, for successful transplantation therapies, after 
one week, labelled cells were observed and predominately astrocytes. This suggests labelled NSCs 
can survive and differentiate in host tissue, indicating that the protocols developed for labelling 
NSCs are safe. Findings from the slice model could be important for future nanotechnology 
translational research as, compared with in vivo transplantation, the slice model described here 
offers several advantages, including: straightforward examination of cell fate and regenerative 
outcomes; technical simplicity; consistent generation of SCI lesions; and reduced animal suffering. 
In terms of clinical utility, the model mimics injured tissue and has previously been used to 
demonstrate the regenerative potential of using implantable nanofibres to promote axonal 
outgrowth from the lesion edges.120 In combination with the data presented in this chapter, this 
suggests that the model could provide a platform to not only assess the survival and 
differentiation of transplanted labelled NSCs but also assess their functional capacity, for 
example, in terms of promoting axonal outgrowth. Indeed, slice models have previously shown 
utility for assessing magnetic stem cell targeting80 and MRI capabilities121 when utilising MP 
labelled NSCs. 
Taking the findings from the two in vitro models, these results indicate that the protocols 
developed in this chapter could be useful for in vivo magnetic stem cell targeting applications, 
potentially for transplant into sites of SCI. For in vivo application, systemic delivery of cells reduces 
the risk of secondary damage; however, clearance of transplant cells by the macrophages in the 
lung, liver and kidney when delivered by this route is a well-known problem.56 To counteract this, 
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labelled NSCs could be introduced in close proximity to sites of SCI (identified by MRI) via the 
spinal segmental arteries and external magnets used to hold and concentrate the transplanted 
cells in the desired location. This could potentially lead to greater beneficial effects compared to 
the transplantation of non-labelled cells. However, in vivo experiments would have to be 
conducted to assess the feasibility of this approach. 
An important observation from both the transplantation experiments, and differentiation of the 
labelled NSCs on glass, is that astrocytes appear to dominate particle inheritance post-
differentiation. This observation has significant implications for the manipulation of neurons and 
oligodendrocyte progeny of labelled NSCs after transplantation. This could be of importance in 
diseases such as Alzheimer’s where the affected cell types are neurons, or multiple sclerosis 
whose main pathological feature is demyelination (secondary to oligodendrocyte loss). The 
reasons for this phenomenon are unclear. It could be that as the NSCs differentiate, cells destined 
to become neurons or oligodendrocytes eject the particle through exocytosis. Differentiating 
labelled NSCs whilst under time-lapse observation may be a strategy to confirm this. Daughter cell 
morphologies are straightforward to distinguish so cells that eject the particles could be 
identified. However, it will be of vital importance to overcome the labelling deficiency in neurons 
and oligodendrocytes for future clinical use of novel MPs. Although limited, some work has been 
performed on generating cell specific peptides for targeting cells of the CNS. One study has 
screened domains of GP1, a viral protein which semi-selectively infects glial cells of the CNS and 
identified a peptide they termed ‘TD2.2’.196 Fusion proteins were generated with EGFP attached 
to TD2.2 and applied to cultures of OPCs, astrocytes, NSCs and fibroblasts. Percentages of cells 
fluorescing in each culture; OPCs (41%), astrocytes (29%), NSCs (3%) and fibroblasts (3%), suggest 
some selectivity towards maturing and mature glial cells. It is especially interesting that OPCs 
were labelled to a much greater extent than NSCs potentially allowing a strategy to target this cell 
type in mixed co-cultures of cells, including differentiating NSCs. 
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3.4.5 Conclusions and future work 
The data presented in this chapter demonstrate a rapid, safe and technically simple methodology 
to achieve efficient MP labelling in NSCs, a cell population of high clinical relevance. Further, the 
labelling procedures did not affect NSC differentiation and survival after transplantation into an 
organotypic model of SCI and resulted in labelled NSCs which were able to undergo magnetic 
capture, suggesting the developed protocols may be clinically translatable for neural cell 
therapies. The findings have relevance for the design of novel neurocompatible particles both for 
the functions outlined in this chapter and for multimodal functions such as gene delivery coupled 
with magnetic labelling. Delivering genetically engineered cell populations with the ability to 
magnetically guide them to sites of injury and visualise the transplant population could provide a 
step-change in the realisation of combinatorial therapies to promote repair in the CNS.  
Future work will have to focus on increasing the iron content of cells which could be achieved by 
combining these protocols with other uptake enhancing strategies such as incorporation of CPPs 
into the particle design. Further, utilisation of the particles for delivery of drugs or genetic 
material could be an exciting avenue to pursue to explore the potential of these particles for 
delivering combinatorial therapies. In terms of the in vitro models of SCI and magnetic cell 
targeting, more physiologically relevant systems may be developed by combining magnetic cell 
targeting with the slice culture systems. Perfusion culture is well established and media could be 
pumped at physiologically relevant flow rates over the slice with magnets placed beneath the 
lesion sites. MP labelled cells could then be introduced and visualised by time-lapse microscopy to 
establish the number of MP labelled cells captured by the technique. This would have high 
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importance in terms of the 3R’s principles of reducing animal usage as good experimental data 
could be obtained before ultimately progressing to animal studies.b 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
b
 Much of the data concerning labelling of NSCs with PLA based particles (Sections 3.3.2 – 3.3.8) has been 
published by Nanomedicine:NBM. The published paper is attached as Appendix 2 and has been licensed for 
use in this Thesis by Elsevier. 
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Chapter 4: Magnetofection of 
intraconstruct neural cells 
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4.1 Introduction 
As described in the General Introduction (Section 1.5), transplantation of genetically modified 
NSCs can offer several benefits for repair in the CNS. However, it is hampered by poor functional 
integration of the transplant population. The main reason for this, also discussed in the General 
Introduction (Section 1.6 – barrier 4), is the inability to control stem cell differentiation into the 
required functional cell types needed for repair following transplantation. Further, the majority of 
NSC transplant studies use cellular injection as a delivery method which has several 
disadvantages, such as cell death, poor cellular distribution throughout the lesion site, 
uncontrolled stem cell differentiation and a lack of 3-D reconstruction through the depth of the 
injury (Section 1.6 – barrier 2).  
An exciting platform to address these multiple challenges could be to fuse cell transplantation 
with hydrogel technology, which has several clinical benefits for cell delivery (expanded in depth 
in the General Introduction, Section 1.12). For example, incorporating transplant cells within a 
polymer scaffold can promote cell survival and distribution throughout a 3-D matrix,106–108,197 
facilitating repair throughout the depth of a lesion site. In addition, hydrogel dimensions can be 
easily tuned to match those of the lesion. This is of particular importance in the CNS where lesion 
size can be quite varied. For example, in SCI, lesion size can affect one or more sections whose 
size can range from 6-13 mm in diameter with length of about 6 mm.198 Therefore, it is essential 
that the implant can adopt a variety of shapes.  
Further, hydrogel design strategies offer the potential to control stem cell differentiation and 
direct regeneration, to facilitate functional integration of the transplanted cells.111,112,120,199 
Combining scaffold materials into the hydrogel formulation can improve implant design by 
providing a guide for regenerating tissue and differentiating transplant populations. This strategy 
was demonstrated by Nomura et al. who seeded NSCs onto chitosan tubing for implantation into 
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sites of complete transecting SCI.200 After transplantation, tissue bridges formed around the 
chitosan tubing within the lesion gap, containing a mixture of donor and host cells, with little 
evidence of repair in a no-channel group. NSCs displayed high survival and differentiated into 
astrocytes and oligodendrocytes within the lesion site. Although this study shows the potential of 
transplanting NSCs in combination with a scaffold capable of directing regeneration, no 
behavioural improvement was observed after transplantation suggesting further modifications 
are necessary to induce functional repair.  
Similarly, most studies combining NSCs with hydrogels report enhanced survival of the cells post-
transplantation, but not necessarily functional integration of the transplant population or 
behavioural improvements. For example, Bible et al. transplanted PLGA microparticles acting as a 
scaffold for the NSC cell line, MHP36, into ischemic areas within rat brains.201 Cells survived 
implantation (although no quantification for extent of survival is shown) and differentiated into 
astrocytes and neurons showing the capacity for cell replacement. However, blood vessel 
penetration into the implant was not seen and no evidence was provided for axonal infiltration; 
two key regenerative targets for long term graft survival and functional integration respectively. 
Therefore it may be necessary to increase the complexity of the scaffold design to provide 
combinatorial modes of therapeutic intervention. One strategy to enhance the regenerative 
potential of NSC seeded scaffolds is to use genetically modified cells to release neurotrophic 
factors. As discussed in Chapter 2 (Section 2.1), genetically modifying NSCs can improve their 
ability to promote repair and this could represent the next steps in implant design for achieving 
combinatorial therapy. However, as far as I am aware, a thorough examination of the feasibility of 
combining genetically engineered NSCs with hydrogels has not yet been described in the 
literature.  
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4.1.1 Clinical considerations for combining genetically manipulated NSCs with hydrogels 
In terms of associating genetically modified cells within an implantable matrix there are two main 
strategies: to engineer the cells prior to incorporation or perform ‘intraconstruct genetic 
engineering’ at a desired time-point after the cells have been combined with the scaffolding. In 
this regard, engineering the population after incorporation into the hydrogel has several clinical 
advantages (summarised in Figure 4.1). These include: (1) No repeat culturing steps in cell plating, 
transfection and trypsinisation before incorporation into the matrix. This reduces risks of infection 
and cell loss associated with these procedures – important for safe and efficient production of 
therapeutic implants. (2) Rapid implantation after genetic manipulation. This is especially 
important in terms of non-viral plasmid delivery which results in transient expression of the 
desired protein; therefore, quicker implantation after manipulation allows for maximum 
therapeutic benefit derived from the expressed protein. (3) The ability to transplant mature 
populations of genetically modified cells. Differentiation of NSCs into their daughter cells may 
require several days, over which time there can be a dramatic reduction in expression of the 
therapeutic protein – leading to a loss of action after cell transplantation. Allowing the cells to 
mature on the scaffold before transfection offers a strategy to overcome this. This has 
implications for successful transplantation of mature oligodendrocytes or neurons which, due to 
fragile and more extensively branched processes, are more likely to die following either 
trypsinisation or transplant procedures.202 Despite the clinical advantages of this approach, an 
intraconstruct engineering strategy for neural cells previously propagated within hydrogel 
materials has not yet been attempted. 
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Figure 4.1. Schematic detailing the advantages of genetically engineering cells within scaffolds 
designed for implantation. 
 
One interesting study has examined gene delivery to cells (in this case, the fibroblast cell line, NIH 
3T3) previously propagated throughout 3-D collagen scaffolds.203 In their initial experiments, they 
found that widely used non-viral transfection systems (based on lipoplexes and polymer particles) 
displayed negligible (<1%) transfection of cells within the 3-D scaffolds, representing a major 
barrier to this approach. However, based on these findings, the authors synthesised small MPs 
(ca. 45 nm in hydrodynamic diameter after complexing with DNA) which they predicted would be 
able to penetrate pores within the collagen. They subsequently applied their MP-DNA complexes 
to the 3-D cultures in the presence of a magnetic field to pull the complexes into the gel. Under 
optimal conditions (3 h magnetic field application) the authors reported transfection efficiency of 
76%, assessed by flow cytometry. This strategy is particularly compelling for genetically 
engineering cells within hydrogels for clinical application, as the use of MPs for gene delivery 
offers several advantages to regenerative medicine including safety and non-invasive cell tracking 
through MRI (addressing barriers 1 & 2 described in the General Introduction, Section 1.6). A 
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fusion of hydrogel technology, to improve cell survival and integration after transplantation, with 
MP mediated gene delivery could therefore simultaneously address multiple barriers to the 
translation of genetically engineered NSC transplantation therapy. 
However, the results from this study cannot be extrapolated to NSCs due to cell intrinsic 
differences in the handling of MPs (described in the General Introduction, Section 1.11) and the 
potentially complex effects of MPs on NSCs. These include effects on NSC viability, proliferation, 
stemness and differentiation, which may all ultimately affect the clinical utility of novel genetic 
engineering procedures. In addition, an important step for the clinical application of 
magnetofection protocols could be the use of oscillating fields during transfection (demonstrated 
to improve MP mediated transfection efficiencies in Chapter 2) which have never been tested for 
hydrogel based magnetofection. Further, as the biology of cells cultured in hydrogels can be 
profoundly different compared to when they are grown on glass,199,204 their interaction with MPs, 
and response to oscillating field magnetofection, cannot be extrapolated from previous 
magnetofection studies in NSCs grown on glass. 
 
4.1.2 Objectives 
Given the potential clinical benefits of fusing magnetofection technology with hydrogel culture of 
NSCs and the lack of studies of this nature in the literature, this chapter aims to examine the 
feasibility of such an approach. This will be initially achieved by culturing NSCs on top of pre-
formed collagen hydrogels, a material currently used for several medical devices.205 Culturing 
NSCs in this manner will be referred to as 2-D culture. Magnetofection procedures will then be 
tested for their efficiency to genetically manipulate the hydrogel cultured NSCs. The safety of 
developed protocols will also be investigated followed by a preliminary examination of the 
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efficiency of MP mediated gene delivery to NSCs cultured through the depth of collagen gels, 
which will be referred to as 3-D culture. 
As this is the first time these protocols have been developed in the laboratory, techniques to 
observe the cell-hydrogel interaction also need to be developed. A high resolution imaging 
technique termed OTOTO-FESEM has been developed in this laboratory (described in Chapter 2, 
Section 2.4.4) which can allow detailed analysis of cellular membranes and polymeric materials. 
Using this technique it may be possible to examine features such as NSC invasion and association 
with the hydrogel and, in the case of magnetofection, particle-membrane interactions. 
Information such as this is important for assessing the biocompatibility of the hydrogel matrix and 
to potentially examine mechanisms of internalisation of MPs. Therefore, the specific objectives of 
this chapter are: 
(i) To develop protocols to culture NSCs with collagen and develop microscopy 
techniques to examine their interaction with the collagen substrate. 
(ii) To investigate the feasibility of genetically modifying intraconstruct NSCs (cultured in 
2-D or 3-D) using magnetofection procedures. 
(iii) To examine the safety of the magnetofection protocols and of culturing NSCs in 
collagen. 
 
4.2 Materials and methods 
All materials and methods are the same as for Chapter 2 including NSC derivation, media 
composition, fixation and immunostaining unless otherwise stated. 
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4.2.1 Reagents 
Extra reagents not described in the previous chapters were collagen which was from Corning 
(Tewkesbury, MA, USA) and powdered Gibco MEMα which was purchased from Life Technologies. 
The latter was made into a 10X MEMα solution by dissolving 10.17 g MEMα and 2.2 g NaHCO3 in 
100 mL distilled water. The solution was pH adjusted to 7.4 and filter sterilised using a 0.2 µm 
filter. The other reagents used are as in previous chapters unless otherwise mentioned. 
 
4.2.2 Collagen hydrogel formation 
Collagen is stored in monomer form at 4ᵒC dissolved in acetic acid. To form a gel, this solution has 
to be neutralised and warmed to at least room temperature. Under these conditions collagen 
polymerises and forms a hydrogel. In this chapter, collagen hydrogels were formulated for both 2-
D and 3-D cell culture. For 2-D culture, hydrogels were pre-formed and NSCs seeded on to the top 
of the gel (Figure 4.2A). For 3-D culture, NSCs were incorporated into the collagen solution prior 
to setting (Figure 4.2B). In this manner NSCs could be captured in-between the collagen fibrils. For 
both culture systems, gels were set in 24 well plates on top of glass coverslips. This was found to 
be a useful insert to aid lifting the gel out of the well (especially important for the low density 
collagen gels, which could easily tear during manipulation). Using a needle point, the collagen gel 
could be separated from the walls of the well and then the point could also be used to lever the 
coverslip, and therefore the gel up for collection by curved tweezers. 
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Figure 4.2. Schematic showing 2-D and 3-D culture of NSCs using collagen. Schematics depicting 
NSCs grown on the top of a pre-set collagen gel, referred to as 2-D culture (A) and through the 
depth of the collagen gel, referred to as 3-D culture (B). For magnetofection, complexes (red 
circles) are added into the media above the gel. 
 
For gel formulation several reagents were combined including 10X MEMα (for biocompatibility), 
collagen (to form the gel), acetic acid (to adjust the concentration of the collagen) and NaOH (to 
neutralise the acetic acid). The formulae to calculate the required volumes of each reagent are 
given in Table 4.1. All reagents were kept on ice during the formulation procedures. For both 2-D 
and 3-D culture, collagen was dissolved in acetic acid to the required concentration before 
addition of 10X MEMα. This was then neutralised with NaOH and, for 2-D culture, 350 µL added 
immediately into each well of a 24 well plate before transfer to the incubator for 30 min (37ᵒC) to 
set the gel. For 3-D culture, the neutralised solution was added to the cell suspension and 
thoroughly mixed before 250 µL added to wells of a 24 well plate and transferred to the incubator 
(30 min, 37ᵒC). Following gelation, for 2-D culture 0.4 mLs of NSC suspension was added to each 
well; for 3-D culture 0.5 mLs of ML-M was added to each well. 
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Reagent (concentration) 
Formula to calculate required volume 
2-D 3-D 
10X MEMα 
 
VM = VF x 0.1 VM = VF x 0.1 
Collagen (CS) 
 
VC = (CR x VF)/CS VC = (CR x VF)/CS 
Cells (10 x 106 cells/mL) 
 
N/A VN = VF x 0.1 
Acetic acid (0.02M) 
 
VA = VF - VC - VM VA = VF - VC - VM - VN 
NaOH (1M) VS = (VA + VC) x 0.023 VS = (VA + VC) x 0.023 
 
Table 4.1. Formulae for deriving volumes of reagents to formulate collagen gels. VF – final 
volume; VM – volume of MEMα; VC – volume of collagen; VN – volume of cell suspension; VA – 
volume of acetic acid; VS = volume of NaOH; CR – required concentration of collagen; CS – collagen 
stock concentration.  
 
4.2.3 2-D NSC culture on collagen hydrogels 
In preliminary experiments, the optimal density of collagen was established for NSC culture. To 
investigate the effect of collagen density on NSC proliferation, stemness and differentiation, 
dissociated NSCs were seeded on to the top of pre-formed collagen gels of different density (0.6 – 
3 mg/mL), in 24 well plates. NSCs were seeded at 3 x 104 cells/cm2 in ML-M and either cultured for 
3-5 days (until confluent) or changed to differentiation medium after 24 h and subsequently 
cultured for 7 days. Cells were then fixed in either 4% PFA (20 min, RT) for immunocytochemistry 
or 2% glutaraldehyde (2 h, RT) for FESEM.  
For subsequent experiments investigating magnetofection of NSCs grown on the surface of pre-
formed collagen gels, NSCs were cultured on 0.6 mg/mL density gels. Here, NSCs were allowed to 
attach to the collagen for 24 h before transfection was performed. This was carried out as a 
monolayer transfection as in Chapter 2 (Section 2.2.7) with application of the appropriate 
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magnetic field for 30 min at the start of transfection. In this instance controls involved just the 
application of DMEM:F12 to the wells. To assess the effect on the efficiency of magnetofection of 
leaving the complexes on for 48 h (i.e. a long particle incubation), transfection was performed 
using the same conditions without removal of complexes after 1 h. In all experiments, NSCs were 
fixed 48 h post-transfection to coincide with optimal GFP expression as previously reported.30 
Safety assessments were also performed at this time-point. For an assessment of the 
differentiation potential of magnetofected NSCs grown on collagen, ML-M was changed to 
differentiation medium 24 h post-transfection. GFP crystallisation was observed to occur over the 
course of the normal seven day differentiation protocol which confounded analysis of the 
numbers of GFP expressing cells and which cell types were expressing GFP. Therefore, cells were 
cultured for five days after the medium switch to try to reduce this problem (with feeding every 2-
3 days) and then fixed (4% PFA, 20 min, RT). 
 
4.2.4  3-D NSC culture in collagen hydrogels 
Pilot experiments were also performed to assess whether magnetofection protocols could be 
utilised to transfect NSCs incorporated through the depth of the collagen matrix. The lowest 
density collagen, with the largest pore size, that could form a gel was found to be 0.3 mg/mL. As it 
has been reported that MP penetration into collagen matrices is dependent on particle size,203 it 
was reasoned that using a low collagen density may allow for particle penetration through the 
pores of the gel and greater transfection compared to high density collagen. Indeed, in 
preliminary experiments when magnetofection was conducted on NSCs grown through 0.6 mg/mL 
density collagen gels, transfection efficiencies appeared to be markedly reduced compared to 
when NSCs were magnetofected after culture in 0.3 mg/mL gels. Therefore, gels of 0.3 mg/mL 
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collagen were subsequently used. The same transfection procedure was applied here as Section 
4.2.4 and complexes were left on for 48 h until fixation in 4% PFA (20 min, RT). 
 
4.2.5 OTOTO processing of collagen gels for FESEM 
Glutaraldehyde fixed samples were washed three times in SCB (defined in Chapter 3, Section 
3.2.8) before post-fixation in a 1% osmium solution (RT, 1 h). Samples were then sequentially 
stained with the high affinity osmium binding agent thiocarbohydrazide (T) for 20 min then 
osmium (O) for 2 h (repeated twice) with six SCB washes between each step to obtain the OTOTO 
layering. Stained samples were dehydrated through a graded series of ethanols before critical 
point drying with liquid CO2 as the transition fluid – CO2 is used to replace the alcohol and is 
subsequently evaporated. Samples were then mounted on SEM stubs with application of silver 
paint around the coverslip edges to enhance conductivity. 
 
4.2.6 Immunocytochemistry 
Nestin and SOX2 staining was performed on PFA fixed samples and achieved as described 
previously (Chapter 2, Section 2.2.17). Modifications were made to the standard 
immunocytochemistry protocols described in this thesis for staining differentiated cells as, in early 
experiments, staining intensity was low and could not be distinguished from background staining. 
This was especially apparent when comparing fluorescent images to phase images (where cell 
morphologies can be distinguished) and an absence of staining for a particular cell type, e.g. 
neurons, was observed. Therefore, after fixation, samples were incubated in blocking solution for 
1 h then primary antibody for 48 h before washing three times in PBS. Subsequently, samples 
were incubated in secondary antibody for 4 h and washed three times in PBS with an elongated 
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final washing step (at least 2 h) before mounting using Vectashield mounting medium with DAPI. 
The concentration of primary antibodies was also doubled so that concentrations used were GFAP 
(1:250), Tuj-1 (1:500) and MBP (1:100). 
 
4.2.7 Imaging 
Fluorescence and phase microscopy: Imaging and processing were performed as described in 
Chapter 2 (Section 2.2.18). 
FESEM: Processed samples were examined using a Hitachi S4500 FESEM operated at 5kv 
accelerating voltage.  
Confocal microscopy: Samples were examined using an Olympus FluoView FV1200. Images were 
captured and processed using FV10-ASW 4.1, Imaris 7.6.4 software. 
 
4.2.8 Assessment of transfection efficiency 
A microscopic method was chosen to analyse transfection efficiency of the NSCs grown on 
collagen. This allows for parallel assessments of transfection efficiency and cell health (including 
cell numbers, adherence and morphology) to be conducted. This is especially important in the 
context of examining the behaviour of transfected cells in a hydrogel environment (including 
integration and migration within the matrix) which could mimic a potential transplant scenario. 
However, NSCs propagated on collagen form spheres over time which prevents quantification of 
transfection efficiency, in terms of an absolute number of cells, as individual cells cannot be 
distinguished. Therefore, for a preliminary quantification of the efficiency of magnetofection 
protocols to transfect NSCs grown on collagen substrates, the proportions of transfected spheres 
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was assessed in three double merged images taken at X100 magnification. To further quantify the 
extent of transfection, numbers of GFP positive cells per field were counted and the proportions 
of transfected spheres which had two or more transfected cells within the sphere were also 
assessed using the same images. To quantify proportions of transfected astrocytes following 
magnetofection and differentiation on collagen, the same images used to assess neural marker 
expression were used to count the number of GFAP+ cells, expressing GFP. This was expressed as 
a proportion of total GFAP+ cells. This analysis was restricted to astrocytes as these cell types 
predominately retained expression of GFP after differentiation. 
NSCs propagated and transfected in 3-D were examined by fluorescence and confocal microscopy. 
These images were used to estimate transfection efficiencies of the various magnetofection 
protocols when applied to 3-D cultures. An examination of NSC morphology and nestin expression 
was also performed. Quantification of the numbers of cells expressing GFP or positive for nestin 
was not possible in these studies due to the close proximity in 3-D of the cells. This confounded 
analysis meaning accurate numbers could not be generated. 
 
4.2.9 Assessment of the safety of magnetofection of NSCs grown on collagen 
Safety was assessed by examining the effect of magnetofection procedures on key regenerative 
properties of the NSCs. First, numbers of spheres per field were counted and sphere diameter was 
measured across three images taken at X100 magnification; two parameters which are 
representative of the proliferative capacity of NSCs. Stemness was assessed by evaluating NSC 
marker expression in triple merged images (DAPI, GFP and appropriate neural marker; either 
nestin or SOX2 for NSCs). Viability was investigated by performing LIVE/DEAD staining as 
described in Chapter 2 (Section 2.2.12) and images were taken at X200 magnification. 
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Differentiation of NSCs, under all conditions, was assessed by examining triple merged images 
(X400) of cells stained with the appropriate neural marker. Proportions of daughter cells 
generated were counted and an assessment made of the cell types expressing GFP in at least 
three images (>100 cells counted). 
 
4.2.10 Statistical analysis 
All comparable data was analysed using Prism software (version 6.03, Graphpad). Data are 
presented as mean ± SEM and statistical differences were measured by one-way ANOVA with 
Bonferroni’s MCT. Repeat experiments (‘n’) are using cells derived from a different mouse litter. 
 
4.3 Results 
4.3.1 NSCs proliferate on collagen and display sphering behaviour which increases with 
collagen density 
NSCs were successfully propagated on pre-formed collagen gels of varying density (0.6 – 3.0 
mg/mL). Normal intact and circular nuclei were observed in the cells with the majority of cells 
positive for the NSC marker nestin, suggesting the cells are healthy and retain a stem cell 
phenotype (Figure 4.3A-B). Across all collagen densities, NSCs demonstrated a propensity to form 
spheres of aggregated cells, with this phenomenon most apparent when NSCs were cultured on 
the highest density collagen matrix, 3.0 mg/mL (Figure 4.3B). On lower density collagen more 
single cells were apparent and appeared to be spreading out from the neurosphere (Figure 4.3A). 
A high resolution imaging technique termed OTOTO was used to visualise NSCs grown on collagen 
and their interactions with the collagen substrate. Using this methodology, spheres of cells were 
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frequently observed (Figure 4.3C), confirming the finding from fluorescence microscopy that the 
NSCs tend to proliferate as spheres attached to the collagen. Dividing NSCs could also be observed 
suggesting the NSCs retain the ability to proliferate (Figure 4.3D). Further, bi-polar morphology of 
stem cells was apparent, with evidence of cellular protrusions extending into the fibre matrix of 
the collagen (Figure 4.3D, inset). Utilising this technique, membrane features can be observed, 
such as, filopodia (short 2-3 µm cellular projections), in high resolution (Figure 4.3D). 
 
Figure 4.3. NSC propagation on collagen. Representative fluorescent images of NSCs propagated 
for 4 days on (A) 0.6 mg/mL and (B) 3.0 mg/mL density collagen. Note that more cellular migration 
from the sphere seems to be apparent when NSCs are cultured on the lower density collagen. (C) 
FESEM image of NSCs after OTOTO processing forming a sphere on 0.6 mg/mL collagen. FESEM 
images of (D) dividing NSCs and (inset) a bipolar NSC following propagation on 0.6 mg/mL 
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collagen and subsequent OTOTO processing. Arrows point to filopodia which can be observed on 
the membrane of the NSC. 
 
4.3.2 NSCs differentiate on collagen into all the daughter cell types and can be visualised by 
fluorescence microscopy and FESEM 
The developed staining protocols for fluorescence microscopy facilitated imaging of each of the 
daughter cell types generated from differentiated NSCs. Some problems in imaging arose from 
cells growing in different planes of focus, presumably due to undulation of the collagen and cells 
migrating through layers of the matrix (Figure 4.4A-C). Despite that, it was observed using 
fluorescence microscopy, that NSCs grown on collagen could be successfully differentiated into all 
the daughter cell types; astrocytes, neurons and oligodendrocytes (Figure 4.4). These appeared to 
be generated in similar proportions to those differentiated on glass (quantification performed in 
Section 4.3.5) with broadly similar and characteristic morphologies (Figure 4.4 and see Chapter 2; 
Figure 2.11 and Chapter 3; Figure 3.14 for examples of differentiated cells cultured on a glass 
substrate). High magnification imaging using OTOTO-FESEM was also achievable after cells had 
been differentiated (Figures 4.4D-F) with some evidence of cell integration into the collagen 
matrix, especially evident in the case of a neuron that appears to be growing below the top layer 
of collagen (Figure 4.4E). Again, membrane features were straightforward to identify and a clear 
difference can be noted between the astrocytes, which appear to have an extensive covering of 
filopodia, and the neurons and oligodendrocytes which appear to be relatively quiescent (Figure 
4.4D-F). 
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Figure 4.4. Differentiation of NSCs on collagen substrate. Representative fluorescent images of 
(A) astrocytes, (B) neurons and (C) oligodendrocytes generated from NSCs propagated, and 
allowed to differentiate, on 0.6 mg/mL collagen. Daughter cells appear to have characteristic 
morphologies suggesting differentiation of NSCs on collagen is safe. Representative FESEM images 
following NSC differentiation on collagen and fixation using the OTOTO methodology of (D) 
astrocytes, (E) neurons and (F) oligodendrocytes. Arrow heads in (D) indicate two astrocytes in the 
image from a recent division and in (E) indicate neurons. Note membrane features such as 
filopodia can be readily identified (arrows in D) and cell protrusions appear to be growing 
underneath collagen fibrils (especially apparent in E). 
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4.3.3 Magnetic field application can enhance MP mediated gene delivery to NSCs grown on 
collagen gels 
To investigate the feasibility of MP mediated gene delivery to cells in collagen gels, NSCs were 
propagated on a collagen density of 0.6 mg/mL. At this stiffness it was observed that more single 
cells were present than on 3.0 mg/mL; possibly allowing MP access to a greater number of cells 
and therefore resulting in higher transfection efficiencies in a similar manner to monolayer vs 
neurosphere transfection, described in Chapter 2. After transfection, GFP expression was 
observed in nestin positive cells within spheres that had formed on the collagen and single cells 
separate from the spheres (Figure 4.5). Microscopic analysis of the NSCs revealed that a greater 
level of transfection was obtained after adding complexes in the presence of magnetic fields 
(Figure 4.5). Quantification of transfection efficiencies revealed that application of a static and an 
oscillating magnetic field significantly enhanced the number of transfected spheres compared to 
no-field transfection (Figure 4.6A). Application of an oscillating field also significantly enhanced 
the number GFP expressing cells per field compared to no-field, whereas no significant effect was 
observed with static field application compared to no-field (Figure 4.6B). A tendency towards 
increased proportions of spheres displaying two or more transfected cells was noted when using 
the oscillating field in comparison to no-field and static field conditions (Figure 4.6C). 
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Figure 4.5. Field application enhances MP mediated gene delivery in NSCs grown on collagen 
gels. Representative images of NSCs grown on 0.6 mg/mL collagen and transfected under (A) no 
field or (B) F = 4 Hz oscillating magnetic field. White arrow indicates GFP expressing cell co-
expressing nestin. Note that more cells appear to be expressing GFP in the F = 4 Hz condition than 
in the no field condition which has been quantified in Figure 4.6. 
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Figure 4.6. Quantification of transfection efficiency of magnetofection in NSCs propagated on 
collagen. Bar charts depicting (A) proportions of transfected spheres (B) number of transfected 
cells per field (C) proportions of transfected spheres which contain two or more transfected cells 
across the different transfection conditions. Significant differences are **p<0.01 and *p<0.05 vs 
no-field (one-way ANOVA and Bonferroni’s MCT, n = 4). 
 
4.3.4 The developed protocols have no effect on NSC proliferation, stemness and viability 
Following magnetofection of NSCs grown on collagen, healthy spheres containing phase bright 
cells were observed in all conditions, including controls where no MPs were added. Quantification 
of spheres revealed no differences in sphere number or size across all conditions (Figure 4.7A-B). 
Figure 4.7C shows recently divided NSCs, both positive for nestin, indicating magnetofection does 
not affect cell division events. Further, all spheres observed microscopically were nestin or SOX2 
positive and all transfected cells were also nestin or SOX2 positive (Figure 4.7C-D), demonstrating 
magnetofection protocols have no effect on stem cell marker expression. As a further assessment 
of the safety of magnetofection a LIVE/DEAD assay was performed. High NSC viability was 
observed after oscillating field magnetofection (estimated to be above 90%) which was similar to 
control cells where no particles were added (Figure 4.8). Dead cells were observed in the spheres 
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although the majority of dead cells appeared as single cells, outside of spheres. The high viability 
across all conditions observed here also suggests that culturing NSCs on collagen is safe.  
 
Figure 4.7. Safety assessments of the magnetofection procedures. Bar charts depicting (A) 
numbers of neurospheres per field and (B) sphere diameter after transfection of NSCs on collagen 
across all conditions. (C) Cellular division of transfected NSCs on collagen (F = 4 Hz) producing two 
nestin positive cells which are both expressing GFP, indicated by white arrow. (C – inset) Double 
merged image showing same area as (C). (D) Representative image of a SOX2 positive sphere after 
transfection under the 4 Hz oscillating field condition with GFP expressing cells that are also 
positive for SOX2. (D – inset) Triple merged image of same area as (D) with the addition of DAPI 
staining to show the nuclei. 
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Figure 4.8. LIVE/DEAD assay of transfected cells on collagen. LIVE/DEAD staining of NSCs grown 
on collagen either (A) under control conditions or (B) transfected under the 4 Hz oscillating field. 
Live cells appear green and dead cells appear red. Note the majority of dead cells appear to be 
single cells outside of spheres shown by the white arrows. Similar proportions of LIVE and DEAD 
cells appear to be present in each condition. However, quantification was not performed in this 
experiment as single cells could not be distinguished. 
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4.3.5 Magnetofected NSCs differentiated normally on collagen 
The ability of NSCs to generate their daughter cells on collagen was not affected by 
magnetofection protocols, with astrocytes, neurons and oligodendrocytes all produced (Figure 
4.9A-C). Daughter cells were also produced in similar proportions across all conditions indicating 
magnetofection has no effect on the differentiation profile of NSCs (Figure 4.9D-F). It should be 
noted that daughter cells are generated in similar proportions to those observed on glass in the 
previous chapters (Chapter 2, Section 2.3.6 and Chapter 3, Section 3.3.7). The majority of 
transfected cells were astrocytes with small numbers (< 3%) of transfected neurons observed. The 
proportions of GFP expressing astrocytes (no-field – 3.5 ± 1.6%; static field – 5.7 ± 2.1%; F = 4 Hz – 
9.1 ± 1.5%) followed a similar pattern to the numbers of transfected cells counted per field in 
NSCs, although no significant differences were found. 
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Figure 4.9. Differentiation of magnetofected NSCs on collagen. Representative fluorescent 
images of (A) astrocytes, (B) neurons and (C) oligodendrocytes generated from NSCs transfected 
under the F = 4 Hz condition and allowed to differentiate on collagen. (D) Separate channels for 
each fluorophore from (A). The majority of transfected daughter cells were astrocytes and the 
overlap of GFP expression with GFAP staining can be observed in (A and D). GFP expressing cells 
with the morphological appearance of astrocytes can also be observed next to cells staining 
positive for (B) Tuj-1 and (C) MBP. Bar charts displaying quantification of the proportions of (D) 
astrocytes, (E) neurons and (F) oligodendrocytes generated under all tested conditions. 
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Proportions of daughter cells generated appear to be similar across all conditions suggesting that 
the protocols are not having an effect on the differentiation profile of NSCs. 
 
  
4.3.6 Field application has no effect with longer particle incubations 
When complexes were incubated with the constructs for 48 h before terminating the experiment, 
proportions of transfected spheres were approximately 56% regardless of field condition (Figure 
4.10A). This is slightly higher than the optimal condition from the 1 h incubation experiments (ca. 
50% at F = 4 Hz). An increase was noted in numbers of GFP expressing cells per field when 
incubating the complexes for 48 h (ca. 26 per field; all groups) as compared to 1 h (17.2 ± 3.6 per 
field; F = 4 Hz); however, this had no effect on the proportions of spheres with two or more 
transfected cells which were similar across all conditions and matched that achieved in the F = 4 
Hz group (ca. 67%) from the 1 h incubation experiments (Table 4.2). Preliminary safety assays 
indicated that incubating the complexes for 48 h had no effect on sphere number (Figure 4.10B) 
and size (Figure 4.10C) suggesting there is no significant effect on proliferation of NSCs, although 
a thorough safety assessment will have to be performed to confirm the safety of these 
procedures. 
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Figure 4.10. The effect on transfection efficiency after incubating the complexes for 48 h. Bar 
charts displaying (A) proportions of transfected spheres grown on collagen after incubating 
complexes for 48 h under different field conditions, (B) sphere number per field 48 h post-
transfection across all conditions and (C) sphere diameter 48 h post-transfection across all 
conditions. 
 
 Transfection condition 
 48 h incubation 1 h incubation 
 No field F = 0 Hz F = 4 Hz F = 4 Hz 
Number of GFP+ cells per field 25.1 ± 4.9 24.4 ± 3.5 29.9 ± 9.1 17.2 ± 3.6 
Proportions of spheres displaying two 
or more transfected cells, % 
 
66.8 ± 7.0 61.8 ±10.0 68.9 ± 8.1 67.9 ± 3.2 
Table 4.2. Quantification of magnetofection efficiency in NSCs grown on collagen and 
transfected under different conditions. 
 
4.3.7 Oscillating fields enhance transfection efficiency in NSCs incorporated in 3-D collagen 
constructs 
In pilot experiments, NSCs were also successfully propagated in 3-D by incorporation into collagen 
gels before polymerisation. Nestin positive cells, with some displaying characteristic bipolar 
morphologies, could be seen throughout the gel (Figure 4.11 and Video 4.1). Following 
183 
 
 
transfection, GFP expressing cells were also within the collagen matrix, and appeared throughout 
the gel, although were mainly found near the surface of the gel (Figure 4.11). Field application (F 
= 4 Hz) appeared to markedly enhance transfection levels as greater numbers of GFP expressing 
cells could be seen per unit area (Figure 4.12). However, transfection efficiency was low after 
oscillating field magnetofection with ca. 2-3% of cells expressing GFP from the total population. 
 
Figure 4.11. Confocal imaging of NSCs magnetofected after incorporation into a collagen 
scaffold. Selected slices from confocal z-stack analysis at various heights through the gel with 
measurements taken from the base of the sphere. Scale is the same for each image. 
Corresponding z-stack movie is attached on CD as ‘Z-stack of transfected sphere’. 
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Figure 4.12. Magnetofection of NSCs incorporated into a collagen scaffold. Representative 
fluorescent images of NSCs grown in 3-D transfected with MPs under (A) no-field or (B) a 4 Hz 
oscillating field. White arrows in (B) point to faint, GFP positive cells that are also out of focus 
suggesting transfection is occurring at different depths within the gel. 
 
4.4 Discussion 
As far as I am aware, this is the first time that primary NSCs cultured within a potentially 
implantable hydrogel matrix have been genetically engineered in situ. Further, gene delivery was 
achieved using MPs and could be significantly enhanced by application of magnetic fields. Utilising 
the MP platform for this purpose could also provide a strategy to enable non-invasive graft 
monitoring after transplantation to examine cell localisation, survival and integration. Given the 
clinical advantages of hydrogel application (in improving transplant survival and integration), the 
data presented in this chapter could have particular impact for regenerative neurology in the 
development of protocols to produce complex implants capable of achieving multiple therapeutic 
goals. The clinical utility of this approach is also demonstrated with the lack of an effect on NSC 
185 
 
 
viability, stemness, division or differentiation – key regenerative properties of the transplant 
population.  
 
4.4.1 Clinical utility of the developed protocols 
In terms of utilising hydrogel technology for CNS therapy, gels can be pre-formed prior to 
transplantation or injected and allowed to set in situ. The advantages of an injectable hydrogel 
include minimally invasive application and the ability to fill a variety of lesion shapes and sizes – 
often present in the CNS after disease or injury. Transplantable hydrogels on the other hand can 
be several orders of magnitude more complex with incorporation of multiple cell types arranged 
in specific 3-D architectures to better mimic the surrounding tissue and promote functional repair. 
Further, a defined structural implant can be produced to facilitate directed tissue regeneration by 
spatially controlling guidance cues within the matrix. This is especially important for the guidance 
of axonal growth as stiffer substrates can be incorporated which are required by the axonal 
growth cone to ‘pull’ on.106 Features such as this are difficult to achieve in injectable systems.  
In the study presented here, NSCs were successfully cultured on pre-formed collagen hydrogels 
with dividing NSCs observed by FESEM and differentiation into their daughter cells (astrocytes, 
neurons and oligodendrocytes). In addition, NSCs were successfully cultured by encapsulation into 
a collagen scaffold with numerous bipolar, nestin positive cells (indicative of normal NSC 
morphology) observed by confocal microscopy, suggesting culture of NSCs with collagen is safe. 
Although collagen is rarely found in the CNS, it has been used for many neural applications, 
including implantation with NSCs into sites of injury and disease.106 It has several advantages for 
regeneration in the CNS including the ability to reduce glial scarring, possibly by providing a 
scaffold for astrocytes to migrate into, and facilitating axonal growth and blood vessel infiltration 
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through the matrix.105 Further, collagen hydrogels have been shown to closely match the stiffness 
of neural tissue which is thought to be important for implant acceptance. For the collagen density 
used in this study, the stiffness has been reported to be about 1 kPa206 which is in the range of 
reported brain tissue stiffness (ca. 0.5 – 3 kPa).207,208 In terms of cell transplantation, it has been 
shown that when cells are mixed with collagen scaffolding prior to implantation, histological and 
functional readouts can be improved compared to transplanting cells alone. This has not been 
explicitly proven for NSC transplantation with collagen; however, Lu et al. transplanted MSCs with 
or without collagen into areas of traumatic brain injury in rats.209 The authors found that lesion 
volume was reduced (16 vs 11% of original lesion volume) and numbers of MSCs (ca. 14 vs 4 per 
mm2) was increased in the collagen-cell group compared to cells alone. These differences also 
correlated to improved behavioural outcomes in the collagen-cell group compared to cells alone 
when tested using a modified neurological severity score, indicating the clinical benefits of using 
collagen scaffolds. 
In this study, NSCs cultured on the collagen appeared to form spheres after two or more days in 
culture. In terms of transplantation, spheres are thought to be more protective of NSCs.129 
Combining the protective nature of sphere transplantation with cellular support from the collagen 
hydrogel could be a beneficial strategy to improve cell survival after transplantation – a key 
barrier to translation of NSC transplantation highlighted in the General Introduction (Section 1.6). 
Data from the literature and this chapter suggest that collagen may be used as a CNS compatible 
hydrogel for implantation of an NSC-collagen scaffold. Therefore, collagen seems a reasonable 
material to associate with NSCs to investigate intraconstruct genetic engineering. 
The data presented in this chapter indicate that magnetofection can be used to genetically 
engineer NSCs cultured using clinically translatable hydrogel matrices. Previous reports have 
genetically engineered NSCs cultured with MatrigelTM and an Atelocollagen scaffold;123 however, 
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MatrigelTM is currently not clinically translatable due to xenogenic components. Lack of flexibility 
and poor matching of CNS tissue stiffness associated with the Atelocollagen scaffold may also 
prevent application in the CNS. In addition, in this particular study, no information was provided 
on NSC invasion into the substrate (whether the cultures were dispersed throughout the matrix), 
transfection efficiency or safety of the procedures limiting the clinical relevance of this study. 
Further, this study involved combining the transfection complexes with the scaffold material 
before seeding the NSCs. In terms of clinical application, the protocols described in this chapter 
are suited to transfecting cells which have been previously cultured on the scaffold. This has 
particular relevance when cells are desired to adopt a specific 3-D architecture to enable their 
regenerative function (e.g. formation of neurospheres for cell protection post-transplantation). 
Applying the transfection complexes shortly before implantation, in a manner similar to that 
described in this chapter, can therefore maximise the time-course of therapeutic protein delivery. 
Further clinical advantages of the methodologies described in this chapter derive from the use of 
MPs to deliver genetic material. Clinical advantages of MP mediated gene delivery compared to 
viral transduction and other non-viral manipulation techniques have already been discussed in 
depth (multiple sections in the General Introduction and Chapter 2). However, a few key features 
are highlighted in the following section. Importantly, the protocols were shown to be safe and 
transfection could be achieved after a relatively rapid incubation time (1 h with application of 
magnetic fields). The procedures are also straightforward, allowing operation by non-skilled 
personnel, of importance to wide-spread clinical adoption. An additional point to note here is that 
it may be necessary for transfection complexes to be ‘driven’ into the hydrogel; especially for cells 
cultured throughout the matrix. Confirming this, Zhang et al. observed negligible transfection 
efficiencies in NIH 3T3 cells cultured within collagen hydrogels when using non-viral transfection 
techniques such as lipofection which rely on diffusion to contact cells.203 Therefore, 
magnetofection protocols may be vital for genetic manipulation of cells within hydrogel matrices. 
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The preliminary data presented in this chapter, regarding magnetofection of NSCs cultured in 3-D 
collagen matrices, suggest this may be the case with a dramatic increase in GFP expressing cells 
when utilising magnetic fields compared to no-field transfection.  
For cells cultured on top of the hydrogel matrix, application of magnetic fields increased 
transfection efficiencies although no difference was observed between static or oscillating fields. 
Application of the static component of the magnet field is likely to increase transfection 
efficiencies through a similar mechanism to that described previously, namely, drawing the 
particles onto the cell surface and increasing cell-particle contact.92 The reason for the absence of 
an effect when using the oscillating field is not currently known. However, a recent study 
suggested that the cell substrate might affect the efficiency of oscillating magnetic fields to 
transfect cells using MPs.210 Here, cardiomyocytes were plated on collagen coated or uncoated 
surfaces which the authors referred to as adherent or semi-adherent cell states respectively. After 
oscillating field magnetofection, adherent cells displayed higher transfection than semi-adherent 
cells suggesting a possible change in membrane responsiveness to an oscillating field. If the 
oscillating field acts through a mechanical stimulation of the membrane and cellular machinery to 
increase transfection, these processes might not be as effective in less ‘tense’ cells. Culturing NSCs 
on substrates of different stiffness does alter the elastic moduli of the cells – on softer gels, cells 
have lower elastic moduli199 – therefore the membrane may be less easy to deform to ultimately 
stimulate a response. Assessing membrane activity may be a strategy to observe whether this is 
the case. The fact that OTOTO-FESEM protocols can facilitate detailed examination of cellular 
membranes and interactions with the collagen substrate may mean this technique can provide a 
reasonable methodology to achieve this. 
However, an increasing trend was observed from static to oscillating field magnetofection for 
number of GFP positive cells per field and number of spheres displaying two or more transfected 
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cells, suggesting there may be a limitation to the methods of analysis. Further, following 48 h 
incubation of complexes greater numbers of transfected cells per field were observed than the F = 
4 Hz condition from the 1 h incubation group. However, this did not correlate with an increase in 
the percentage of spheres that were transfected. Enzymatically dissociating the construct and 
counting individual cells could be one future strategy to examine whether oscillating fields 
transfect more cells than static fields.  
Although a direct comparison cannot be made, MP mediated transfection efficiency appeared to 
be less in NSCs cultured on hydrogels than that achieved in NSCs cultured on glass. This is 
especially true in the case of magnetofection in NSCs cultured throughout the collagen hydrogel 
where transfection efficiencies were estimated to be between 2 and 3%. It is likely therefore that 
transfection will need to be improved for both scenarios in order to be clinically useful. A number 
of different strategies could be employed in order to potentially achieve this. The previous study 
by Zhang et al. used small nanoparticles to achieve transfection (ca. 45 nm in hydrodynamic 
diameter) of cells cultured in 3-D collagen gels.203 In their preliminary experiments, the authors 
also tested a commercial MP, PolyMag, which has a larger hydrodynamic diameter of ca. 250 nm 
and found this achieved less than 5% transfection efficiency. Although the chemistries of these 
two particles are different, which can significantly affect cellular uptake mechanisms, reducing 
particle size could be a reasonable strategy to increase gel penetration of the particles and 
subsequent transfection. Another more complex technique to improving particle uptake in cells 
within collagen gels could be to complex particles to CPPs, demonstrated by Child et al.211 Here, 
MPs were complexed to the CPP, penetratin, and applied to a fibroblast cell line cultured 
throughout a collagen gel. With application of a magnetic field, only penetratin coated particles 
(and not “plain” particles) were observed to be taken up by cells at 500 µm depth within the gel. 
In this study no quantification was performed of cellular uptake in the whole cell population, but 
attaching CPPs to particles has been shown to enhance particle uptake previously,177,178 
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suggesting this is a promising strategy for enhancing particle uptake in cells cultured within a 3-D 
scaffold. Multifection, as described in Chapter 2 (Section 2.4.1), or longer field application could 
be used although would increase procedure time which may be disadvantageous from a clinical 
perspective if transfection needs to be performed immediately prior to implantation. 
In areas with fewer resources this might not be possible as access to magnetic equipment may be 
limited, requiring alternative strategies to enhance transfection. In this respect, it is of interest 
that incubation of constructs with complexes for 48 h resulted in high transfection (56% of 
neurospheres) without the need for magnetic field application. This is in agreement with a similar 
result obtained by Child et al. with their plain MPs (counterparts to the penetratin particles 
described above).211 Here, an 18 h incubation period resulted in improved particle association 
with the gel compared to 1 h incubation. However, although magnetic field application improved 
uptake over 1 h no effect was observed over the 18 h incubation period. As cells are at various 
heights in the medium, due to culture with collagen, the complexes may be able to sediment over 
a shorter period of time and contact more cells than when the cells are cultured in monolayer 
format. In this manner, magnetic field application is not required to enhance the sedimentation of 
the complexes to achieve optimal transfection. Lengthening incubation periods could therefore 
provide a simple means to enhance the intraconstruct engineering of neural cells by MPs, 
facilitating wide-spread use. 
Different materials may ultimately be used in clinical application. The procedures described are 
straightforward; however, it is difficult to predict how they would translate across various 
materials as there are numerous discrepancies in the literature reporting different responses of 
NSCs to a range of materials. It is likely that varying the chemical and physical properties of the 
hydrogel matrix will affect NSC biology and subsequent interactions with MPs, therefore results 
from this study may not extrapolate to other biomaterials. In addition, changes in porosity of the 
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hydrogel will likely effect particle penetration into the gel. Demonstrating this principle, in 
preliminary studies investigating transfection of NSCs propagated in higher density collagen than 
reported in this chapter, I found transfection levels to dramatically drop-off. This could possibly be 
a result of reduced pore size and leading to poor particle penetration. A detailed assessment still 
needs to be performed to assess the extent of particle penetration into gels and to develop 
techniques to improve this. 
A final point to note is that after differentiation of the collagen associated magnetofected NSCs, a 
multicellular construct containing genetically modified cells is obtained. As far as I am aware this 
is the first time that multiple, genetically engineered, neural cell types have been cultured in a 
single hydrogel system. The data provides promise for producing complex, multicellular implants 
using neurocompatible protocols – as both collagen and magnetofection have been shown to be 
safe for use with neural cells. This has implications for implantation of mature cells not usually 
amenable to transplantation, such as neurons or oligodendrocytes. Of particular interest could be 
promoting repair in accessible sites such as in SCI where implanted neurons can aid in 
reconnecting lost electrical circuitry, therapeutic biomolecules can promote axonal growth and 
oligodendrocytes can provide protection for the regenerating axons.  
 
4.4.2 Conclusions and future work 
The data presented in this chapter show that it is feasible to safely genetically engineer 
intraconstruct NSCs cultured with collagen, important due to the combined advantages of 
hydrogel and MP technology for NSC transplantation. For this preliminary study, relatively simple 
technologies have been used – the collagen gel was unmodified and Neuromag is primarily 
designed for gene delivery. However, the findings prove that intraconstruct cell engineering is 
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possible and could be useful with further improvements in transfection efficiency and 
sophisticated hydrogel design.  
For example, hydrogels not only provide support for the transplant population but can be further 
functionalised to influence the transplanted cells and the host tissue. Incorporating growth 
factors into their formulation can improve NSC survival and differentiation into required cell 
types. Controlled differentiation of NSCs into neurons was observed after transplantation with a 
GDNF functionalised poly-caprolactone scaffold. In this scenario, neurite extension into the 
scaffold was also increased compared to an unfunctionalised scaffold.212 Promotion of 
oligodendrogenesis from NSCs transplanted with a hyaluronan/methyl cellulose hydrogel has also 
been performed by immobilising PDGF-α onto the scaffold. Upon transplantation of the cell-
polymer matrix, sparing of perilesional host oligodendrocytes and neurons was also observed 
with a reduction in injury site cavitation when compared to transplantation of NSCs alone.213 
These two studies suggest that NSC differentiation can be controlled by hydrogel formulation, 
facilitating repair for different injury paradigms. Coupled with genetic manipulation of the cells to 
also secrete disease specific therapeutic biomolecules this approach is attractive for providing 
advanced repair in the CNS. 
In terms of the particles used, more clinically relevant particles could also be studied. Particles 
with higher iron content and different chemistries may be more amenable to hydrogel 
penetration and cellular uptake. Technologies such as plasmid mini-circles could also aid in 
reducing complex size. Here, non-essential DNA, such as bacterial promoters and antibiotic 
resistance genes are removed resulting in much smaller plasmids.214 Therefore, combining small 
MPs with small plasmids might improve complex penetrance. These strategies could improve 
transfection levels overall but also provide a system for monitoring the graft post-implantation 
through MRI detection of MPs. It would be interesting to investigate this potential in future 
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studies. However, this preliminary study provides a platform from which sophisticated 
implantable hydrogels may be developed. 
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Chapter 5: Final conclusions and 
future directions 
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5.1 Summary of key thesis findings 
Chapter 2. Safe and efficient gene delivery to NSCs grown as monolayers and neurospheres 
using magnetofection protocols 
Oscillating magnetic fields were found to produce optimal MP transfection efficiency in NSCs 
cultured as neurospheres and monolayers. Monolayers displayed higher transfection efficiency 
than neurospheres (ca. 33 vs 10%) with a frequency of 4 Hz proving optimal, for both culture 
systems, in these studies. Standard safety assessments (of cell viability, proliferation, stemness 
and differentiation) proved that oscillating magnetofection protocols were non-toxic in both 
culture systems. GFP expressing daughter cells generated from transfected NSCs were mostly 
astrocytes with very few transfected neurons detected (<1% in daughter cells generated from 
monolayer NSCs) and no transfected oligodendrocytes observed. A preliminary proteomics 
analysis of monolayers showed proteins expressed and their levels of expression in 
magnetofected NSCs could be interrogated. GFP was positively identified within magnetofected 
samples suggesting the ability to perform analysis of safety and transfection success using one-
step protocols. Further safety was demonstrated in monolayers by survival and differentiation of 
magnetofected NSCs after transplantation into cerebellum slice cultures. This test also shows the 
potential of using slice cultures as low cost and high throughput means of testing novel 
nanomaterial technologies designed to enhance NSC transplantation therapy. 
 
Chapter 3: Developing high iron content particles for the efficient labelling of NSC transplant 
populations  
In terms of NSC labelling with MPs, increases in iron content of non-functionalised PLA based MPs 
were found to lead to increases in NSC labelling. Using the lowest iron content particles field 
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application enhanced labelling in a pattern similar to that achieved with the Neuromag 
transfection grade particles (which also have low iron content). However, a high iron content 
particle was found to efficiently label NSCs (ca. 93% labelling) without need for magnetic field 
application. All labelling procedures were shown to be safe in terms of cell viability, proliferation, 
stemness and differentiation. Post-differentiation, astrocytes often displayed large accumulations 
of particles compared to single particles observed in neurons and oligodendrocytes – a similar 
finding to MP transfected NSCs where most daughter cell expressing GFP were astrocytes. MP 
labelled NSCs could be trapped in an in vitro flow system by application of a magnetic field. The 
efficiency of cell retention achieved after magnetic trapping of NSCs labelled with the different 
particle formulations was: Non-mag < MP-1X < MP-3X < MP-5X – reminiscent of the pattern of 
labelling of the NSCs with the different particle formulations. MP labelled NSCs survived after 
transplantation into slice models of SCI and appeared to retain the magnetic label. Labelled NSCs 
also differentiated, mostly into astrocytes consistent with NSC differentiation in vivo. In addition, 
the SCI slice model displayed characteristic hallmarks of SCI pathology including axonal 
regeneration and reactive astrocytosis. Along with the data collected using the cerebellum slices, 
the data utilising the SCI slice model suggest that these systems may be used to test 
nanotechnology as a means of improving NSC transplantation. The added benefit of the SCI slice 
model is that it mimics an injury site so potentially has more clinical relevance. 
 
Chapter 4: Magnetofection of intraconstruct neural cells 
NSCs were also successfully propagated and differentiated using collagen hydrogels as a 
substrate. Both fluorescence microscopy and FESEM could be used to visualise the NSCs and their 
daughter cells. The feasibility of magnetofection was demonstrated in NSCs cultured using 
collagen with transfection efficiency enhanced by application of magnetic fields, although no 
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additional benefit was seen by applying an oscillating field compared to a static field during 
transfection. Protocols developed here were also shown to be safe in terms of cell viability, 
proliferation, stemness and differentiation. Daughter cells generated from transfected NSCs 
grown on collagen and subsequently differentiated continued to express GFP, with the majority of 
transfected cells appearing to be astrocytes. Therefore, a multicellular collagen hydrogel was 
created also containing genetically engineered cells. A pilot study also demonstrated that MP 
mediated transfection of NSCs cultured throughout the collagen hydrogel was feasible and that 
application of an oscillating field appeared to show the highest transfection efficiency. Using 
confocal microscopy, GFP expressing nestin positive cells could be observed throughout the 
hydrogel indicating the safety of the developed protocols i.e. neither culture throughout collagen 
nor MP mediated transfection appeared to alter NSC specific marker nestin expression. 
 
5.2 Implications of findings and future research directions 
Taken together, the data in this thesis suggests that magnetofection may be used as a clinical 
grade transfection protocol for neural transplant populations. In order to apply this strategy in the 
CNS, introducing multiple therapeutic genes would be desirable to achieve several repair goals 
simultaneously. Single gene delivery has been demonstrated in this thesis; however, dual delivery 
(separate plasmids encoding GFP and RFP) has been demonstrated to OPCs143 and to NSCs in our 
laboratory (paper in preparation). Therefore, enhancing the complexity of therapeutic gene 
delivery seems feasible. A further step in this regard could be to introduce temporal control over 
therapeutic genes after delivery. This would be especially important in neural repair where 
controlled biomolecule release could allow targeted regenerative events to occur sequentially, for 
example, break down of the glial scar followed by promotion of axonal outgrowth. To achieve 
this, plasmids could be engineered with inducible systems such as the tetracycline-on system. 
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Using this system, expression of GDNF from transduced MSCs has been shown to remain ‘off’ until 
activated by doxycycline,215 a drug which has the potential to be used in vivo.216  
Some genetic diseases highlighted in this thesis would also benefit from sustained gene 
expression to correct defective phenotypes resulting from misexpression of the target gene. 
Although plasmid delivery generally results in transient gene expression, there are multiple 
strategies for increasing the duration of expression.217 One particular strategy is to utilise the 
sleeping beauty transposon system which is capable of transferring the desired gene from the 
plasmid into a targeted site within the genome.218 This can enable sustained expression and, 
concomitantly, reduce risks associated with insertional mutagenesis. In this manner, a technique 
combining the sleeping beauty transposon system and electroporation to stably introduce a gene 
encoding a CD19 antigen (which recognises a specific leukaemia cell lineage), into T-cells before 
transplantation, has been approved for clinical trials (identifier: NCT00968760).219 Therefore, this 
could represent an area of investigation in order to safely achieve long term gene expression in 
NSCs following magnetofection.  
Further to gene delivery, data in this thesis also suggest that high iron content PLA based MPs 
could be used as neurocompatible particles for magnetic stem cell targeting. Along with data from 
other studies, demonstrating the capability of MPs to label transplant cells for tracking via 
MRI,67,70 these findings indicate that novel multifunctional MPs could be used as a tool to achieve 
multiple biomedical outcomes. This will require testing of a range of particle formulations (which 
can differ in size, shape and surface chemistries) for transfection efficiency, NSC targeting 
capability and MRI contrast enhancement alongside toxicity analyses. With the wealth of 
materials available, assessing numerous particles for their translational potential will require 
detailed and high throughput tests. Developing the functional and safety assays and in vitro slice 
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models described in this chapter could provide methodologies to achieve this; without resorting 
to animal testing.  
A major step in enhancing the high throughput capability of the in vitro tests is to adapt the 
protocols to automation. Automation of cell culture and online monitoring can already be 
achieved.132,133,220 For measurement of fluorescent endpoints (which can provide information on 
viability, proliferation, stem cell marker expression, differentiation and transfection efficiency if 
using a reporter gene) automated cell culture could be coupled with high content imaging – a 
technique which is emerging as a popular tool for drug discovery.221 Here, characteristics such as 
fluorescence intensity (for assessments of transfection efficiency or LIVE/DEAD staining) and 
shape (for assessments of fragmented nuclei and cellular morphology) can be interrogated by 
computerised imaging software to generate data on cell behaviour after treatment with various 
nanoparticle formulations. Using these protocols large numbers of wells can be treated, and 
endpoints measured, to provide powerful statistical analysis of differences between the particles 
in each category (in cell behaviour and transfection readouts). Currently, this is mostly achieved 
using cell lines with easily definable endpoints, such as, nuclear fragmentation as an indicator of 
cellular toxicity. Adapting these protocols for primary neural cells and more complex readouts 
(such as differentiation analysis) could create rapid tests for assessing the usefulness of 
nanotechnologies in regenerative neurology. 
In addition to fluorescent readouts, automation of a molecular analysis performed using mass 
spectrometry (as described in Chapter 2) also seems feasible. Additional steps to cell culture and 
particle addition would include trypsinisation, cell lysis, protein extraction and separation which 
could all be optimised for online performance. Mass spectrometry is a fully automated procedure 
which outputs peptide fragmentation patterns to an external computer. With parallel research 
identifying important biomarkers for safety and transfection outcomes, these patterns could be 
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matched by the computer to a database containing these biomarkers, therefore providing a rapid 
non-biased analysis of transfection and safety of the tested nanoparticles.  
Automating and monitoring slice culture may prove more challenging as moving slices requires 
delicate handling and the fact they are cultured on membranes restricts real time imaging. One 
possibility for their future application in nanomaterial testing, is that the culturing and 
manipulation of slices will be done manually and only promising nanotechnologies, identified in 
previous rounds of testing, assessed. However, after fixation, slices could be transferred to vessels 
where staining and subsequent imaging could be automated. Smart, high content imaging 
software could then be used to gather data on safety and functional readouts of fluorescence 
images, such as, fragmented nuclei or axonal outgrowth. If a list of simple and powerful outputs 
can be generated this will greatly expand the utility of slice culture as a strategy to assess 
advances in nanotechnology for neurological repair, especially in comparison to animal models. 
Further development of the in vitro tests described in this thesis should focus on enhancing their 
predictive utility to accurately represent cellular and host tissue responses to nanomaterials; 
which could be achieved by utilising human cells and tissue. Human NSCs have been propagated 
as monolayers128 and neurospheres126 so would be amenable to the manipulations and standard 
safety and functional (assessing transfection efficiency) assays described in this chapter. However, 
oscillating field magnetofection protocols have never been tested in primary human neural cells. 
Therefore, it is not known whether there will be a difference in human cellular responses to MPs 
deployed with these oscillating fields compared to the mouse cells used in this study, 
representing a significant knowledge gap for the translation of this technology. In addition to 
testing the developed protocols on human cells, in order to achieve clinically relevant safety and 
functionality information, novel nanotechnologies may be tested on slices derived from human 
tissue. Such slice models would have to be developed in collaboration with hospital departments 
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but could provide valuable information on human tissue responses to nanomaterials – before 
their use in humans and with better predictive quality than that achieved using in vivo animal 
models. With detailed research into how molecular responses to nanomaterial manipulation and 
subsequent behaviours in tissue slices represent in vivo responses, sophisticated models such as 
this could lead to successful and safe clinical trials, reducing associated cost and risk. 
In terms of utilising hydrogels as cell delivery systems, enhancing the complexity of the hydrogel 
system was discussed in detail in Chapter 4 (Section 4.4.1). Testing of various materials is vital as 
different materials can have distinct advantages for neuroregeneration. For example, self-
assembling peptides have only recently been described for neurological applications. These 
materials offer a greater control over hydrogel stiffness than natural materials such as collagen, 
important to be able to accurately match the implant to the destination tissue stiffness. In 
addition, tight control over hydrogel stiffness may also impart some control over encapsulated 
NSC differentiation crucial for functional integration of transplanted cells. As cellular responses 
can vary when cultured on substrates which only have small changes in mechanical properties 
(tens of Pascals)105 materials such as self-assembling peptides will be crucial in determining, with 
high precision, the optimal hydrogel stiffness for implantation area and desired transplant cell 
phenotypes.  
Using MPs can enhance the regenerative potential of the cells embedded in hydrogels as 
discussed in Chapter 4. Further investigations into how particles interact with cells within the 
matrix could be useful to inform future particle design in order to enhance particle uptake. The 
FESEM-OTOTO technique could be used as a high-resolution imaging modality to probe particle 
cell interaction. Using this technique, iron oxide particles can be examined using energy dispersive 
microanalysis, to detect their associated iron, and membrane features involved in particle uptake 
such as filopodia and membrane ruffles can also be identified in parallel. 185 Data generated from 
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such studies could highlight differences in particle handling by the cell membrane in response to 
different particle formulations. Time-lapse microscopy may also be a valuable tool in this regard 
to assess the kinetics of particle uptake, important for developing optimal labelling protocols, and 
their subsequent cellular handling. The latter point is especially of relevance to the long term 
retention of MPs which impacts on the ability to track labelled cells by MRI.  
Finally, the protocols described in this chapter appear to have clinical potential given the safety of 
the nanomaterials tested. Several MP formulations have been previously approved for clinical use 
by the FDA for MRI,76 and also as iron supplements for anaemia,222 and MRI facilities are widely 
available. Genetically engineered cells have also been approved for clinical trials within the 
CNS,223 with non-viral delivery regarded as safer than viral manipulation of transplant populations. 
Implantation of hydrogels is still rare in the CNS; however, several polymer formulations have 
been used for other clinical applications, such as in cartilage and intervertebral disc repair,103 and 
given their extensive advantages to cell transplantation therapy, it is likely that efforts will be 
focussed on translation into CNS applications. Therefore, the findings in this thesis represent 
important steps in developing translatable protocols for genetic manipulation, efficient cell 
delivery and potentially non-invasive tracking and functional integration of NSCs after 
transplantation. It is hoped that, with further improvements to particle uptake and hydrogel 
design (for which strategies have been outlined in the various chapters), these protocols could 
facilitate development of the next generation of therapies in regenerative neurology by 
combining nanotechnology with cell transplantation. 
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Appendix 1. Nanomedicine:NBM publication. 
“Magnetic nanoparticle mediated transfection of neural stem cell suspension cultures is enhanced 
by applied oscillating magnetic fields”. 
Adams, CF. Pickard, MR. Divya, DM. Nanomedicine:NBM, 2013 
This publication contains data found in Chapter 2 which has been licensed for use in this Thesis by 
Elsevier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Short Communication
Magnetic nanoparticle mediated transfection of neural stem cell
suspension cultures is enhanced by applied oscillating magnetic fields
Chris F. Adams, MSc, Mark R. Pickard, PhD, Divya M. Chari, DPhil⁎
Cellular and Neural Engineering Group, Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, United Kingdom
Received 5 March 2013; accepted 31 May 2013
Abstract
Safe genetic modification of neural stem cell (NSC) transplant populations is a key goal for regenerative neurology. We describe a
technically simple and safe method to increase transfection in NSCs propagated in the neurosphere (suspension culture) model, using
magnetic nanoparticles deployed with applied oscillating magnetic fields (‘magnetofection technology’). We show that transfection
efficiency was enhanced over two-fold by oscillating magnetic fields (frequency = 4 Hz). The protocols had no effect on cell viability, cell
number, stem cell marker expression and differentiation profiles of ‘magnetofected’ cultures, highlighting the safety of the technique. As far
as we are aware, this is the first successful application of magnetofection technology to suspension cultures of neural cells. The procedures
described offer a means to augment the therapeutic potential of NSCs propagated as neurospheres – a culture model of high clinical
translational relevance – by safe genetic manipulation, with further potential for incorporation into ‘magneto-multifection’ (repeat
transfection) protocols.
From the Clinical Editor: This team of investigators describe a simple and safe method to increase transfection in neural stem cells using
magnetic nanoparticles deployed with oscillating magnetic fields, demonstrating a greater than two-fold transfection efficiency increase by
applying low frequency magnetic oscillation.
© 2013 Elsevier Inc. All rights reserved.
Key words: Neural stem cell; Neurosphere; Magnetic nanoparticle; Transfection; Nonviral
The central nervous system (CNS, i.e. brain and spinal cord)
displays limited regeneration post-injury, generally leading to
poor clinical prognoses. Current treatments can prevent further
degeneration, but successful repair and return of functionality are
key goals for regenerative neurology. Transplantation of repair
mediating cell populations is a promising strategy to enhance
repair (via replacement of damaged cells or protective bystander
effects e.g. releasing therapeutic biomolecules).1 Neural stem cells
(NSCs), including genetically engineered populations, are a key
transplant population in this regard given their high integrative
capacity and differentiation into the three major cell populations of
the CNS (neurons, astrocytes and oligodendrocytes).2 Several
studies using NSCs have progressed to the stage of clinical
trials,1 highlighting their major translational potential for
regenerative medicine.
In this clinical context, transplantation of NSCs grown as
‘neurospheres’ (a suspension culture model used globally to
propagate NSCs, including those of human origin) rather than
dissociated cells offers several key advantages. Firstly, high NSC
survival has been observed following transplantation of neuro-
spheres in various models of CNS pathologies, including spinal
cord injury,3 possibly due to the maintenance of cell-cell
contacts and associated pro-survival cell signalling.4 Secondly,
neurosphere cultures yield high cell numbers within a relatively
small surface area, facilitating the provision of large cell numbers
for transplantation (e.g. 8–12 foetuses are required per patient for
grafting in Parkinson’s disease5), which is currently a major
barrier to clinical translation.
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Currently, genetic engineering of NSCs (to augment their
therapeutic potential) overwhelmingly relies on viral methods
that are associated with numerous disadvantages including safety
risks and costly scale-up production procedures.6 In this context,
magnetic nanoparticles (MNPs) offer significant advantages as
nonviral gene delivery agents, with transfection significantly
enhanced using ‘magnetofection’ methods (application of static/
oscillating magnetic fields to assist MNP mediated biomolecule
delivery).7 We recently demonstrated that neurospheres can be
successfully transfected using MNPs, although application of a
static magnetic field had no effect on transfection levels.8
However, we recently proved that application of oscillating
magnetic fields, generated by high gradient NdFeB magnets,
dramatically enhance transfection in monolayer (2D) cultures of
major neural transplant populations such as oligodendrocyte
precursor cells (OPCs).9
To date, the effects of oscillating magnetic fields have not
been tested in the context of neurosphere transfection and indeed,
as far as we are aware, in any suspension culture system. Given
the translational advantages of the neurosphere culture system,
the goals of this study were to determine the effects of oscillating
magnetic fields on MNP mediated transfection, and to evaluate
the safety of the procedures used.
Methods
Expanded methods are in Supplementary Information.
Briefly, mouse subventricular zone-derived NSCs were main-
tained as neurospheres.8 For magnetofection experiments, at 24
hours after passage, transfection with pmaxGFP:MNP com-
plexes (or pmaxGFP only for controls) was performed
previously8 under four magnetic field conditions: no field, static
field and oscillating fields (1 and 4 Hz).
All quantitative analyses have been performed using a
combination of phase and fluorescence microscopy observa-
tions, to allow for readouts of transfection efficiency as well
as morphological assessments (for procedural safety) to be
carried out in parallel. At 48 hours post-transfection (time point
which coincides with peak green fluorescent protein [GFP]
expression, as previously reported8), neurospheres were
dissociated for determination of transfection efficiency (%
GFP expressing cells), total cell number and cell viability (by
trypan blue exclusion). Cells were then replated as monolayers
in appropriate media for quantitation of pyknotic nuclei
(nuclear shrinkage or chromatin fragmentation indicative of
cell death) and determination of NSC phenotype and
differentiation potential. Immunocytochemistry was performed
Figure 1. Effects of Magnetic Fields on Neurosphere Transfection. Double merged images of neurospheres 48 hours after MNP mediated transfection performed
using (A) no field (B) a 4 Hz oscillating magnetic field compared with (C) neurospheres treated with plasmid alone, in the no field condition. (D) Bar chart
displaying mean transfection efficiencies under all conditions, *P b 0.05 versus no field, n = 6 cultures (one way ANOVA and Bonferroni’s MCT).
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to detect NSC specific markers nestin and Sox-2 (quantified at
72 hours post-transfection), and for glial fibrillary acidic
protein (GFAP – astrocytes), neuron specific class III beta-
tubulin (Tuj-1 – neurons) and myelin basic protein (MBP –
oligodendrocytes) for differentiation profile analysis (quanti-
fied at 9 days post transfection).
All data were analysed by one-way ANOVA and Bonferro-
ni’s multiple comparison test (MCT) using Graphpad Prism
software (version 4.03). Data are expressed as mean ± SEM.
Results
Effects of magnetic fields on neurosphere transfection
Under all experimental conditions, neurospheres appeared
intact and of similar size, with GFP expressing cells present
throughout transfected spheres (Figure 1, A–C). At 48 hours,
basal transfection (no field) was found in 4.2 ± 0.4% of cells.
Application of all fields showed a tendency to increase
Figure 2. Viability and ‘stemness’ of transfected NSCs. Bar charts displaying (A)mean cell viabilities of NSCs, n = 5, (B)mean cell number per well, n = 5 and (C)
percentage pyknotic nuclei, n = 3, across all conditions. Merged images of magnetofected (F = 4 Hz), GFP+ NSCs, staining for NSC markers nestin (D) and Sox-2
(inset). Bar charts displaying percentage of nestin (E) andSox-2 (F) positive cells, n = 4 cultures.None: no field, F(N): frequency of oscillation, C: control, T: transfected.
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transfection levels; the increase was maximal and statistically
significant for the 4 Hz condition [approximately two-fold
increase (9.9 ± 1.7%)] (Figure 1, A, B & D). Monitoring of
spheres at 12 hour time points post-transfection revealed a similar
pattern in GFP expression (F = 4 Hz N no field and F = 0 Hz) to
that seen at 48 hours. Transfected cells were not observed under
any condition in the plasmid only, control cultures.
Viability, ‘stemness’ and differentiation profiles of
transfected NSCs
NSC viability, cell number and percentage of pyknotic nuclei
were similar across all conditions (Figure 2, A, B& C). Further, co-
localisation of NSC markers and GFP was observed (Figure 2, D)
and the protocols had no effect on the expression of nestin and Sox-2
Figure 3. Differentiation profiles of transfected NSCs. Triple merged images of magnetofected (F = 4 Hz) NSCs post-differentiation showing cells positive for
GFAP (A) Tuj-1 (B) and MBP (C). GFP expressing GFAP+ cells are seen in (A, arrows) and GFP+ cells with the morphological appearance of astrocytes in (B
and C, arrows). (D-F) Bar charts showing proportions of GFAP, Tuj-1 and MBP positive cells, n = 4 cultures. None: no field, F(N): frequency of oscillation, C:
control, T: transfected.
Figure 4. Proposed mechanism of transfection of neurospheres. Schematic diagram illustrating a hypothetical model to explain the mechanism of oscillating field
enhancement of transfection in neurospheres.
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(Figure 2, E & F). The differentiated progeny of transfected NSCs
were exclusively astrocytes (Figure 3, A–C); transfected neurons/
oligodendrocytes were never observed in these experiments. NSC
differentiation profiles were also unaffected post transfection -
similar proportions of astrocytes, neurons and oligodendrocytes
were generated under all conditions (Figure 3, D–F).
Discussion
We report here a simple method to enhance MNP mediated
gene transfer in a widely used NSC culture model. Technical
ease, accompanied by high safety, as evidenced by negligible
effects on ‘stemness’ and differentiation profiles, highlight the
clinical potential of this technique. We previously showed that
‘multifection’ (repeat transfection) can safely enhance MNP
based gene transfer in neurospheres.8 Future work will focus on
repeat transfection in conjunction with oscillating magnetic
fields, and we predict that the safety of the protocols reported
here will easily extrapolate to such a ‘magneto-multifection’
approach to further augment transfection levels. With further
development, combined neurosphere culture and magnetofection
could also be amenable to automation - essential for reproducible
and scalable production of genetically engineered cell transplant
populations,10 including human NSCs for clinical use.
The underlying mechanism for enhanced transfection by
oscillating magnetic fields in neurospheres in the current
experiments is unclear. It is well established that static magnetic
fields assist transfection by increasing particle-cell contact, and that
MNP uptake occurs via various forms of cellular endocytosis.7
Further, magnetofected NSCs (in monolayer cultures) which have
been exposed to high frequency (4 Hz) fields reveal a greater
degree ofmembrane ruffling comparedwith untreated cultures (our
unpublished observations), suggesting endocytotic stimulation.
Taking these observations together, we propose a model to explain
our findings wherein sedimentation of MNP labelled spheres
(through the vertical component of the magnetic field) would
increase particle-cell contact, the first barrier to transfection when
using MNPs.7 Subsequent stimulation of NSC membrane
endocytotic activity (by the horizontal magnetic field component)
may provide a reasonable explanation for the observed oscillation
dependent increase in transfection (Figure 4).
In conclusion, we believe this study highlights the efficacy of
the MNP vector platform for technically simple gene transfer to
neurospheres for translational applications in transplantation
neurobiology.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2013.05.014.
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Original Article
Increasing magnetite contents of polymeric magnetic particles
dramatically improves labeling of neural stem cell transplant populations
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Abstract
Safe and efficient delivery of therapeutic cells to sites of injury/disease in the central nervous system is a key goal for the translation of
clinical cell transplantation therapies. Recently, ‘magnetic cell localization strategies' have emerged as a promising and safe approach for
targeted delivery of magnetic particle (MP) labeled stem cells to pathology sites. For neuroregenerative applications, this approach is limited
by the lack of available neurocompatible MPs, and low cell labeling achieved in neural stem/precursor populations. We demonstrate that high
magnetite content, self-sedimenting polymeric MPs [unfunctionalized poly(lactic acid) coated, without a transfecting component] achieve
efficient labeling (≥90%) of primary neural stem cells (NSCs)—a ‘hard-to-label’ transplant population of major clinical relevance. Our
protocols showed high safety with respect to key stem cell regenerative parameters. Critically, labeled cells were effectively localized in an
in vitro flow system by magnetic force highlighting the translational potential of the methods used.
From the Clinical Editor: Utilizing self-sedimenting polymeric magnetic particles, the authors demonstrate an efficient method for
magnetically labeling primary neural stem cells for magnetic localization in the central nervous system.
© 2015 Elsevier Inc. All rights reserved.
Key words: Polymeric magnetic particles; Neural stem cells; Labeling; Transplant cells; Magnetic cell targeting
Advances in stem cell technology have had a major impact in
the field of regenerative neurology. Several transplant cell
populations show improved neurological outcomes in pre-
clinical models of injury and disease, including spinal cord
injury (SCI), stroke, Parkinson's disease, Huntington's disease
and birth defects.1 A major obstacle in the translation of cell
transplantation is the safe and efficient delivery of cells to sites of
disease/injury. The two main methods for cell delivery (systemic
and direct local injection) have associated problems in this
regard. Injecting cells systemically can lead to their eventual
clearance in the spleen, liver or lung resulting in low cell
accumulation at the desired site.2,3 Multiple direct injections can
result in secondary pathology due to blood brain barrier damage,
bleeding or embolization.4 To overcome these issues, several
reports have shown that transplant cells labeled with magnetic
particles (MPs) can be efficiently “trapped” at foci of injury by
application of a magnetic field gradient, as part of so called
‘magnetic cell localization’ strategies.5–9 Application of fields
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over sites of pathology can trap systemically injected cells as they
pass through the vasculature.6,8 This would offer considerable
benefits if used in conjunction with the ‘homing’ capability of
some stem cell types to sites of injury (after intravenous
administration).10 Field application has also been suggested to
localize cells near injury sites after intrathecal injection7 and can
thereby remove the need for multiple injections over time.
Enhanced cell accumulation using this method has been shown
in the heart,9 on the surface of intraarterial steel stents8 and also for
some neurological applications.5–7
Despite being a promising method to safely enhance cell
accumulation at injury sites, a major limiting factor for
neurological applications is the relatively low MP labeling
efficiency achieved in stem cell transplant populations; few
neurocompatible particles have been developed for neurological
use. Diverse chemical/biological strategies have been adopted to
promote intracellular MP accumulation. These include chemical
transfection coating agents (such as chitosan or polylysine)6,11,12
or cell uptake enhancing molecules (such as the RGD/TAT
peptides).13 While effective from a research perspective, such
strategies are not optimal in the clinical context as the related
methods can be time consuming, involve significant technical
challenges in generating nanoparticle constructs, and are limited
by non-specificity of cellular targets. Moreover, these can be
associated with cellular toxicity14,15 and the effects of targeting
molecules on neural cell physiology are poorly understood.
As an alternative physical delivery approach, MPs have been
deployed with external magnetic fields to enhance cellular
uptake.16,17 From a translational perspective, these magnetic
assistive methods rely on intrinsic endocytotic uptake mecha-
nisms of cells and have high associated safety.16 As magnetic
force is proportional to the particle magnetic moment, magnetite
entrapment within MPs is a major parameter that can influence
cell–particle interactions and cellular uptake. Despite this, the
relationship between magnetite concentration, applied magnetic
fields and cellular labeling in ‘hard-to-label’ stem cell transplant
populations has never been investigated. It should be noted that
studies investigating the relationship between magnetic force and
cell loading in neural cells, using applied magnetic fields, have
primarily used transfection (gene delivery) grade MP reagents,
many of which have low iron content, and where particle uptake is
strongly influenced by properties specific to the transfecting
component.18 As such, these cannot provide insights into the
relationship betweenMPmagnetite content and ‘magnetolabeling’
of stem cells.
To address these issues, the goal of this study is to investigate
the effects of systematically modulating MP magnetite concen-
tration on labeling of multipotent, primary neural stem cell
(NSC) transplant populations, in conjunction with applied
magnetic fields (static and oscillating). The translational
potential of the labeling methods has been evaluated by assessing
the magnetic cell localization potential of the labeled NSCs in a
flow system, using applied magnetic force. NSCs were selected
as the target stem cell population given their high clinical
relevance for the repair of neurological injury and their capacity
to migrate towards sites of pathology, a phenomenon termed
‘pathotropism’. Available MP labeling studies indicate that
NSCs have intrinsically low MP labeling efficiencies in the
absence of delivery enhancing strategies,19–21 making these an
ideal test population for the current study.
Methods
Magnetic particle formulation and characterization
Fluorescent poly(lactic acid) (PLA) coated non-magnetic
(termed Non-mag) and MP samples with varied magnetite content
(MP-1X, MP-3X and MP-5X, indicating their relative magnetite
content) were prepared using published methods.17,22 Expanded
methods including reagent information/particle formulation are in
Supplementary Information. Particles were fully characterized
using dynamic light scattering (DLS), transmission electron
microscopy (TEM), magnetometry, zeta potential measurement,
Fourier-transform infrared (FTIR) spectroscopy, elemental analy-
sis, and powder x-ray diffraction (XRD). Full experimental details
are also in the Supplementary Information. Figure 1 illustrates a
schematic procedure for preparing the PLA MPs.
Preparation of NSC cultures and MP labeling procedures
NSCs derived from the subventricular zone of CD1mouse pups
(postnatal days 1-3)23 were maintained as neurospheres in
complete medium (defined in Supplementary Information).
Neurospheres (passages 1-3) were dissociated to a single cell
suspension and maintained as monolayers by plating 1.2 × 105
cells in 600 μL of monolayer medium (defined in Supplementary
Information) onto glass coverslips (or aclar for TEM) coated with
poly-ornithine and laminin in 24 well plates. Cells were allowed to
adhere for 24 hours before changing to fresh monolayer medium
with or without particles.
To prepare particle suspensions, lyophilized aliquots (contain-
ing the same number of particles for each particle type) were re-
suspended in water and added to monolayer medium so that final
suspensions contained a 1:1000 ratio of particle solution to
medium (approximately 15 μg/mL of dry weight for MP-1X,
19 μg/mL for MP-3X and 26.5 μg/mL for MP-5X). Cells were
incubated for 24 hours under no field, static (oscillation frequency:
F = 0 Hz, 200 μm amplitude) or oscillating (F = 4 Hz, 200 μm
amplitude) magnetic fields for the first 30 minutes. Field
application was restricted to 30 minutes as heating effects were
observed in pilot experiments using oscillating fields for longer
time periods, and static fields applied for 24 hours resulted in
significant particle aggregation. After incubation, cells were
washed 3-5 times with phosphate buffered saline (PBS) to remove
particles not internalized. Cells were fixed using 4% paraformal-
dehyde (15 minutes, room temperature) for immunocytochemistry
or 2.5% glutaraldehyde for TEM analysis or switched to
differentiation medium (complete medium minus growth factors,
supplementedwith 1%FCS). Cells in differentiationmediumwere
cultured for a further 7 days with medium changes every 2-3 days.
TEM samples were processed as previously described.24
Assessment of proliferation, stemness and differentiation of
labeled NSCs
To assess safety of the procedures, cells fixed at 24 hours post
particle addition were stained for the NSC specific markers
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nestin (NSC-specific cytoskeletal protein) and Sox-2 (a tran-
scription factor). Double merged fluorescence images using
specific markers and DAPI (nuclear marker) were used to count
the proportions of cells expressing each marker under different
conditions. Counts from control cultures were used to estimate
culture purity. To further examine safety of the procedures, the
images were also used to estimate numbers of nuclei per field and
percentage of pyknotic nuclei (an indicator of cell death
evidenced by nuclear shrinkage, fragmentation or DNA
condensation). Three fields were assessed, with at least 100
nuclei assessed for each condition. These methods of safety
analysis allow for qualitative microscopic evaluation of cell
health (through observations of cell morphology), and quanti-
tative measurements to be performed on the same sample. As an
additional measure of toxicity, an MTS (mitochondrial toxicity)
assay was performed according to the manufacturer's instruc-
tions (Supplementary Information).
To assess the proportions of each daughter cell type generated
from labeled NSCs, differentiated cells were fixed at 1 week
following 24 hours of labeling of parent NSCs (therefore 8 days
post-labeling) and cells expressing neural cell markers GFAP
(astrocytes), Tuj-1 (neurons) or MBP (oligodendrocytes) were
counted (100-200 nuclei per condition) using a minimum of
three double merged fluorescent images.
Assessment of particle uptake in NSCs
Particle internalization was quantified microscopically in
nestin (NSC specific, cytoskeletal protein) positive NSCs. We
previously validated the microscopic method of analysis used
here for assessing particle uptake in a range of neural cells.24,25
This approach was chosen as simultaneous assessment of particle
uptake and features of cell health, such as adherence and
morphology, can be conducted. Particle localization within the
cells can be discriminated from adherence to the cell membrane
and the extent of particle uptake can also be assessed—
particularly important in primary NSCs which display heteroge-
neous particle uptake. Measurements of ‘intracellular’ iron
content (using colorimetric absorbance assays of lysed cells) in
neural cells can include substantial proportions of extracellular
(membrane-bound) iron oxide particles, suggesting that this
method alone cannot be used as a robust indicator of labeling.26
Quadruple merged microscopic images (including phase images)
were assessed in order to confirm whether particles were
intracellular. Three fields totaling ca. 250 nuclei were counted
for each labeling condition. Proportions of labeled cells were
determined and cells scored for extent of labeling (unlabeled,
low, medium or high labeling). The extent of labeling was
determined by subjective assessment of the area within each cell
occupied by particles: b10%, 10-50%, N50% of the average
nuclear area being scored as ‘low’, ‘medium’ and ‘high’ labeling
respectively, as previously described.24,25 In addition to the
microscopic analysis, MP quantification within cells was
determined spectrophotometrically after lysing cells with radio-
immunoprecipitation assay buffer and dissolving the particles in
1 N HCl (λ = 335 nm) as described elsewhere.17,22
Assessment of magnetic localization capability of MPs
To examine magnetic localization of the labeled NSCs, cells
were labeled for 48 hours with application of the F = 4 Hz
magnetic field for the first 30 minutes. Labeled cells were washed
three times with PBS to remove free particles, then trypsinized
(using TrypLE) and cells triturated. Cells were collected by
centrifugation followed by two more washes with PBS before
finally re-suspending in PBS at a concentration of 105 cells/mL.
Labeled cells were subjected to a single pass through a 1.6 mm
diameter tubular flow system. Preliminary experiments indicated
Figure 1. Schematic illustration for the step-wise synthesis of the PLA-coated MPs.
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that flow rates ≤1 mL/minute resulted in high cell loss,
presumably due to cellular adherence and aggregation within the
flow system, whilst flow rates≥4 mL/minute resulted in minimal
magnetic capture. Therefore, an optimal experimental flow rate of
2 mL/minute was chosen with an approximate flow velocity of
1.7 cm/second broadly similar to blood flow rates in arterioles
and venules.27 To generate the magnetic field for cell capture,
the tubing was placed on top of a magnetic plate (field strength:
316 ± 8 mT) and surrounded by two bar magnets (field strength:
410 ± 10 mT). Magnetic field strengths were measured by
an F.W. Bell 5080 Gaussmeter (Pacific Scientific-OECO,
Milwaukie, OR). Cell density was estimated before and after
passage through the flow system using a hemocytometer and
the percentage value for cell retention within the system was
calculated as cell count after magnet applicationcell count before magnet application 100.
Statistical analysis
Data were split into comparable groups (i.e. with only one
variable change per group, for example: Non-mag,MP-1X,MP-3X
and MP-5X uptake compared under the no field condition only,
represented a single dataset) for analysis by one-way ANOVA and
Bonferroni's multiple comparison test (MCT) using GraphPad 4
software (version 4.03). Data are expressed as mean ± SEM with
‘n’ referring to the number of different cultures, each derived from a
different mouse litter, except for the magnetic localization
experiments where ‘n’ refers to number of experiments.
Results
Particle formulation and characterization
We formulated MPs of distinct magnetite content with the
nomenclature Non-mag, MP-1X, MP-3X and MP-5X, to provide
MPs with a range of magnetic responses—the nomenclature is
based on theweight percent ratios of incorporatedmagnetitewithin
the polymer matrix (given in Supplementary Table 1). The MPs
exhibited dose-dependent superparamagnetic behavior showing
no significant hysteresis (Figure 2, A). The average normalized
values of MP magnetizations calculated at 5.0 kOe (saturation
magnetization) were found to be 2.1, 15.3 and 24.6 [emu/g
composite] for MP-1X, MP-3X and MP-5X respectively. The
average MP hydrodynamic diameters ranged from 262 to 278 nm
for different magnetite concentrations (by DLS) with a relatively
high polydispersity index (PDI) of 0.15-0.23 (Supplementary
Table 1). In particle size distribution analysis, the PDI is a measure
of the width of the particle size distribution being calculated as the
square of the standard deviation divided by mean nanoparticle
Figure 2. Size and magnetization of MP formulations. (A) Magnetization curves of MP formulations. All MP formulations have negligible remnant
magnetization, an indicative of superparamagnetism (B) Particle size distribution by DLS. Transmission electron micrographs of (C) Non-mag, (D) MP-1X,
(E) MP-3X and (F) MP-5X particle formulations.
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diameter. Indices less than 0.1 typically describe the system as
“monodisperse”. The PDIs of 0.15-0.23 show that our particles are
“polydisperse”, but overlapping MP size distribution curves
indicate that the MP size distribution and PDI are independent of
magnetite concentration in MPs and are predetermined by the MP
formulation method per se. MP sizes obtained by TEM were in
agreement with DLS data (Figure 2, B-F) and magnetite crystal
density in these images was consistent with the extent of magnetite
loading (Figure 2, C-F). Zeta potential, a measure of surface
charge, can influence particle stability, interactions with cell
membranes, cellular uptake and intracellular trafficking.28–31
Zeta potentials of the studied formulations were slightly negative
(−9.46 to−14.4 mV) and systematically increased fromMP-1X to
MP-5X (Supplementary Table 1). Usually PLA has uncapped end
carboxyl groups that result in a relatively high (above −30 mV)
negative surface charge of particles dispersed in a neutral buffer.32
However, when PLA particles are formulated with poly(vinyl
alcohol) (PVA) as an emulsifier, the zeta potential becomes less
negative (−6 to −10 mV at pH7)33 because the PVA coating
shields the charged surface groups of PLA. The slight systematic
elevation in zeta potential for higher magnetite loads could be
attributed to increase in free oleic acid molecules engrafted
between PVA chains at the MP surface as previously proposed.34
However, the stabilization of MPs in the present study was mainly
due to steric hindrances between PVA chains on the surface of
neighboring MPs rather than by charge due to low values of zeta
potential of ourMPs.32,33 The nearly identicalMP size for all three
magnetite concentrations, and proportionally increased magnetic
Figure 3. Particle uptake confirmation and toxicity in NSCs. (A) Representative triple merged z-stack image of NSCs labeled with MP-5X showing internalized
particle accumulation around the nucleus (B) TEM micrograph of internalized MP-5X particles with comparative image of internalized MP-1X (inset) both
indicated by black arrows. Bar charts displaying quantification of (C) nuclei per field, representing cell proliferation, (D) pyknotic nuclei, indicative of cell
death, and percentage of cells expressing the NSC specific markers (E) nestin and (F) Sox-2. No significant toxicity or differences in NSC marker expression
were found in any of the labeling conditions, n = 4.
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responsiveness for particles of higher magnetite loadings, suggests
that the differences in magnetic responsiveness are due to different
magnetite content within the polymeric core, which is supported
by our TEM data (Figure 2, C-F).
Results from FTIR spectroscopy indicated that the
particles were similar in organic composition with expected
peaks observed for PLA, oleic acid and PVA (Supplementary
Figure 1, A). Full peak assignment can be found in the
Supplementary Information. XRD patterns of the samples
were dominated by the PLA coating regardless of MP content,
suggesting that the magnetite core particles are buried under
a layer of PLA. Nonetheless, the XRD pattern for the oleic
acid-coated magnetite particles (Supplementary Figure 1, B.i)
confirmed the magnetite nature of the core.
Characterization of primary stem cell cultures used for
MP labeling
Monolayer cultures routinely established for these experiments
were of high purity with 98.3 ± 0.7% (n = 5) and 96.4 ± 1.4%
(n = 5) cells expressing nestin and Sox-2 respectively. NSCs
displayed typical bipolar morphology and normal, rounded nuclei
as judged by phase contrast microscopy and DAPI staining.
Confirmation of MP uptake and safety analyses
Z-stack fluorescence microscopy (to rule out cell surface
particle adherence) showed that NSCs labeled with MPs displayed
cytoplasmic and perinuclear particle accumulations (Figure 3, A);
TEM analysis further confirmed this pattern of internalization
Figure 4. Assessment of the differentiation potential of NSCs after labeling with the different particle formulations. Representative triple merged z-stack images
of (A) GFAP positive astrocytes (B) Tuj-1 positive neurons and (C) MBP positive oligodendrocytes generated from NSCs labeled with the MP-5X
formulations under the F = 4 Hz magnetic field. White arrows point to labeled cells. Note large accumulations of particles within astrocytic progeny compared
with relatively small accumulations in neurons and oligodendrocytes. Bar charts displaying quantification of the proportions of (D) astrocytes (E) neurons and
(F) oligodendrocytes generated from cells labeled with the different particle formulations and under various field conditions. No significant differences in
expression of the neural markers were found in any of the labeling conditions, n = 3.
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(Figure 3, B). MP-5X strikingly demonstrated electron dense rings
(Figure 3, B), reflecting their high magnetite content, and were
usually found in clusters. A similar, although correspondingly
less dense, ring like structure was seen for internalized MP-1X,
which were usually observed as single particles within the cells
(Figure 3, B, inset). Particles displayed similar magnetite content
to that seen in the whole particle TEM images (Figure 2, C-F),
however, sectioning through the particle results in the ring like
structures of electron dense material observed here. No intra-
nuclear particles were observed, under any conditions.
Post labeling, several parameters were investigated to
examine if the labeling protocols had any associated toxicity.
NSC counts were found to be similar across all conditions, with
cells retaining their bipolar morphology and substrate adherence.
Counts of nuclei/field (an estimation of NSC proliferative
capacity), counts of pyknotic nuclei (indicative of cell death),
and estimates of cell viability using the MTS assay were also
similar across all conditions (Figure 3, C and D and
Supplementary Table 2 respectively). Further, no significant
differences were observed in the proportions of cells expressing
NSC-specific markers nestin and Sox-2 (Figure 3, E and F).
All three major cell types of the central nervous system (CNS)
could be generated from labeled NSCs with similar proportions
generated across all conditions (Figure 4, A-F), suggesting that our
protocols did not adversely affect the differentiation capabilities of
labeled NSCs. Particles were found to be ‘inherited’ primarily into
astrocytes, with smaller accumulations noted in neuronal and
oligodendrocyte progeny of the labeled NSCs.
Effects of magnetite modulation and applied magnetic fields on
MP uptake in NSCs
Labeled cells under all conditions displayed internalized
particles throughout the cell body but rarely in the processes
(Figure 5, A-C). For non-magnetic particles, basal levels of
labeling (under the no field condition) were approximately 35%,
with low levels of particle accumulation (Figure 5,D); as expected,
no labeling enhancement was induced by applied fields. The
proportions of cells labeled with MP-1X, was systematically
improved from basal levels (39.6 ± 2.7%, Figure 5, A and D)
upon application of both static (53.4 ± 2.4%) and oscillating
(63.7 ± 3.5%, Figure 5, B and D) magnetic fields. For all field
conditions, the percentage of cells labeled was greater when using
MP-3X and MP-5X, compared with MP-1X, with the highest
proportions of cells being labeled when using MP-5X, up to a
maximum of 95.8 ± 1.0% when using the oscillating magnetic
Figure 5. Assessment of test particle formulation uptake in NSCs under different magnetic fields. Representative triple merged images of NSCs labeled with MP-1X
under (A) no field and (B) F = 4 Hz magnetic fields and (C)MP-5X under F = 4 Hz magnetic field. (D)Bar chart displaying quantification of percentage of
NSCs labeled with the various particle formulations under different magnetic fields. Statistical differences are: *P b 0.05 and ***P b 0.001 versus no field
condition at the same particle iron concentration; +++P b 0.001 versus MP-1X under the same field condition; ƟƟP b 0.01 and ƟƟƟP b 0.001 versus MP-3X
under the same field condition. (E) Bar chart displaying semi-quantitative analysis of extent of particle uptake using the various particle formulations under
the different magnetic field conditions. Comparable low, medium and high groups were analyzed for statistical differences and are: *P b 0.05, **P b 0.01 and
***P b 0.001 versus MP-1X under the same field condition; +P b 0.05, ++P b 0.01 and +++P b 0.001 versus MP-3X under the same field condition (one way
ANOVA with Bonferroni's MCT, n = 5).
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field (Figure 5, D). Under these optimal labeling conditions
(MP-5X, F = 4 Hz oscillating magnetic field) approximately
5.7 pg Fe/cell was measured using spectrophotometry.
In marked contrast to MP-1X, field application had no
significant effect on the proportions of cells labeled with either
MP-3X or MP-5X, although oscillating fields did show some
tendency to increase labeling. In parallel with increased
proportions of labeled cells, higher magnetite concentration
also led to larger particle accumulations within cells, with a
progressive shift towards a greater proportion of cells displaying
‘high’ and ‘medium’ levels of labeling compared with lower
magnetite content particles (Figure 5, E). Although the rate of
MP-5X sedimentation was found to be 200 times greater upon
application of a magnetic field (data not shown), it should be
noted here that for a given particle formulation, the percentage of
labeled cells was independent of the applied field (Figure 5, E).
Assessment of NSC localization capability of MPs in an in vitro
flow system
The ability of MPs to localize labeled NSCs was assessed in a
flow system with applied magnetic fields/gradients, as shown
(Figure 6, A). After trypsinization and dissociation, a single cell
suspension was obtained with clear intracellular accumulations
visible within cells (Figure 6, B). Some cell attrition was seen in
all conditions after passage through the flow system, with a basal
cell retention by the system of 18.1 ± 4.9% when using NSCs
labeled with non-magnetic particles (Figure 6, C). A similar
retention level was seen in NSC retention for cells labeled with
MP-1X (the particle formulation with the lowest magnetite
content), however, cell retention increased as cells were labeled
with particles of increasing magnetite content to a maximum of
66.7 ± 3.3% when using the MP-5X particles (3.7-fold greater
Figure 6. Assessment of magnetic localization capability of the different particle formulations on NSCs within a flow system. (A) Schematic diagram of the flow
system consisting of tubing placed on a magnetic plate surrounded by two bar magnets all of which provide magnetic field gradients for cell capture. (B)MP-5X
labeled NSCs after trypsinization showing typical rounded morphologies and particle accumulations. (C) Table depicting the percentage of NSC retention after
labeling with the different particle formulations and passage through an in vitro flow system in the presence of magnetic fields. (D) Representative counterpart
phase and fluorescent (inset) images depicting aggregation of MP-5X labeled NSCs in the flow system at the site of magnet application. White arrows in this
image indicate rounded cells.
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than basal levels of cellular retention). Microscopic examination
of the flow tube in the area of magnet application revealed
striking cell localization using cells labeled with MP-5X
(Figure 6, D).
Discussion
This study demonstrates for the first time that increased MP
magnetite content can safely and systematically improve labeling
of clinically important but hard-to-transfect NSCs (in the absence
of any cellular delivery enhancing strategies) using technically
simple, inexpensive and one-step protocols. The potential
translational utility of the particles has been proven for magnetic
localization of labeled NSCs using a simple in vitro system.
Further research will be required to confirm that our findings can
be extrapolated to neurological lesions using live animal models
of neurological injury and disease and various routes of cell
administration, in conjunction with magnetic field application.
The enhancement of cell labeling with particles of increasing
magnetite content was reflected in the improved efficacy of
magnetic cell capture, likely due to greater magnetic forces
acting upon cells with higher magnetite content.
The pattern of increase in cell labeling using MP-1X with
applied fields is similar to that observed when using commercial
transfection grade MPs for gene delivery applications.35,36 It is of
note that such commercial magnetofection-compatible particles
typically tend to have a good colloidal stability and therefore low
sedimentary properties of the particles, necessitating application of
magnetic fields to promote particle–cell contact.37 In this context,
gravitational sedimentation of sub-micron sized particles depends
on several factors including particle diameter/density and fluid
viscosity/density.38 With other parameters being constant, the
gravitational sedimentary forces due to the increased particle
density (as a result of higher magnetite content) are likely sufficient
to induce particle sedimentation, cellular contact and hence
increased uptake by NSCs to achieve efficient cell labeling.
Therefore, our results suggest a MP ‘magnetite limit’, beyond
which magnetic field application strategies do not offer a
significant benefit for cell loading, at least in the case of NSCs.
However, it should be noted that intercellular differences appear to
exist; indeed in cells such as bovine aortic endothelial cells, MP
loading can be dramatically improved using magnetic fields in
conjunction with high magnetite particles.17
Using our experimental flow system, efficient magnetic
targeting of NSCs was achieved after one pass through the
magnetic system. Intraarterial and intravenous deliveries have both
been utilized for clinical cell delivery to the CNS.1,39 However, a
well-recognized problem with intravascularly delivered cells is
subsequent clearance by the tissue macrophage system.2,3 In terms
of an effective clinical delivery strategy, cells injected close to the
injury site (by delivery via local blood vessels supplying the area of
injury) could be trapped by magnetic field application thereby
providing a means to limit this problem. For example, labeled
NSCs could be introduced near known anatomical sites of
pathology (determined by MRI) via the spinal segmental arteries
(accessed through the aorta by catheterization of the femoral
artery under fluoroscopic guidance). These could subsequently be
localized to areas of pathology via external magnets applied over
sites of SCI, potentially leading to greater beneficial effect when
compared with non-targeted NSCs. Systemic delivery reduces the
risk of secondary damage from local invasive surgical procedures.
Further, smaller numbers of cells can be administered due to a
higher percentage of cell integration at the desired sites, while
reducing off-target effects such as non-targeted integration, as well
as costs associated with cell production.
The test particles used were formulated with biocompatible
and biodegradable components, which have the potential for
clinical application. PLA, comprising the core, is a well-known
non-toxic bio-absorbable polymer, approved by the US Food and
Drug Administration (FDA) in the early 1970s for direct contact
with biological fluids.40,41 Slow PLA degradation has been
reported both extracellularly (weeks to months)42 and intracel-
lularly (15% degradation over 3 days)43 and our TEM data also
suggest minimal particle degradation and iron leaching in NSCs
over 24 hours. This indicates that the degradation time-frame of
PLA, could be sufficient to enable stem cell targeting of
therapeutic cells laden with intact or minimally degraded
particles over the experimental or therapeutic time course.
PVA, aMP surface stabilizer is also approved by the US FDA for
general and neurological embolization use.44 Oleic acid used to
stabilize magnetite nanoparticles is considered as a safe material;
it is rapidly absorbed after oral administration, metabolized, and
the metabolic products are utilized and excreted (www.fda.gov).
Magnetite nanoparticles have been shown to be safe in animal
studies45,46 and approved by the US FDA for use in humans as
an MRI contrast agent.47
In addition, the process used here to formulate the polymeric
magnetite-loaded particles could offer further advantages for
regenerative applications. First, the polymer matrix of such
particles can be impregnated with additional bioactive molecules
that can be released intracellularly to influence biological
processes48—these can be incorporated within the polymeric
matrix without chemical reactions, an important factor for
preserving bioactivity. Additionally, blending the polymeric
matrix with a fluorescently labeled polymer (such as BODIPY®
564/570 used in this study) produces fluorescent MPs that offer
potential for multimodal tracking by fluorescence microscopy and
MRI. Indeed, the cellular iron loading under optimal labeling
conditions of 5.7 pg Fe/cell is in line with other reported values in
NSCs and can facilitate cell tracking by MRI.21,49 Second,
controlled release of bioactive molecules as well as particle
degradation characteristics can be readily modulated by the choice
of matrix constituents.50 For example, we previously showed that
magnetic polymeric particles prepared with poly(lactic-co-glycolic
acid) at various copolymer ratios enabled tuning of particle
degradation rates, thereby modulating the release profiles of the
incorporated anti-proliferative drug paclitaxel.22 Finally, these
polymeric particles can be further surface functionalized (to bear
charge or specific biological ligands) to enable binding of nucleic
acids for gene transfer in potential multimodal applications,
highlighting their versatility.34
Under all test conditions, the high viability we observed in
NSCs post-labeling is likely due to the labeling method
exploiting natural cellular internalization mechanisms, combined
with the slow degradation profile of the PLA matrices of the
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particles. Previous ultrastructural studies from our laboratory
indicate that rapid particle degradation and extensive iron
leaching within neural cells are the major pathological correlates
of MP-induced cellular toxicity,24 highlighting the translational
benefits of the biocompatible coatings used here. Additionally,
the labeling protocols had no effect on the differentiation of
NSCs into their daughter phenotypes, vital for successful cell
replacement after transplantation, further highlighting their
translational utility for clinical applications.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2014.07.001.
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Appendix 3. Particle and Particle Systems Characterization publication. 
“Early membrane responses to magnetic particles are predictors of particle uptake in neural stem 
cells” 
Fernandes, A. Adams, CF. Jenkins, SI. Furness, DN. Chari, DM. Particle and Particle Systems 
Characterization, 2015. 
This article is referred to in Chapter 3 and describes the OTOTO-FESEM technique. The full article 
has been reproduced here with permission from John Wiley and Sons. 
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 Magnetic particles (MPs) offer several advantages for neural cell therapy, but 
limited particle uptake by neural cells is a barrier to translation. It is recently 
proved that tailoring particle physicochemical properties (by enhancing their 
iron content) dramatically improves uptake in neural stem cells (NSCs)—a 
major transplant population. High-throughput screening of particles with 
varying physicochemical properties can therefore aid in identifying particles 
with optimal uptake features, but research is hampered by the lack of simple 
methodologies for studying neural cell membrane responses to nanoparticle 
platforms. A high-resolution–high throughput method has been used to study 
early membrane responses of primary rodent NSCs to particles of variant 
magnetite loading, to attempt to correlate these responses with known 
particle internalization profi les. Membrane imaging is enhanced through 
sequential staining with osmium (O) and thiocarbohydrazide (T), a method 
termed OTOTO, combined with fi eld-emission scanning electron microscopy 
(FESEM). A fi ve-point classifi cation system was used to systematically eval-
uate early MP-induced membrane responses to particles possessing distinct 
physicochemical properties. Signifi cantly different profi les of membrane acti-
vation were noted that correlate with particle uptake profi les. It is suggested 
that our method can serve as a valuable predictor of particle internalization in 
neural cells for diverse particle platforms. 
iron content of polymeric MPs can lead to 
effi cient and safe labeling of an important 
“hard to label” transplant population—
neural stem cells (NSCs) (see Figure S1, 
Supporting Information). In this study, 
non-magnetite particles (termed non-
Mag) showed labeling effi ciencies of ca. 
35% but on application of particles with 
enhanced magnetite loading (termed 5× 
particles), cell-labeling effi ciency dramati-
cally improved to ca. 96%. 5× particle-
labeled NSCs were shown to be amenable 
to magnetic cell localization strategies in a 
fl ow system, highlighting the translational 
benefi ts of such labeling approaches. [ 9 ] 
NSCs offer key benefi ts post-transplan-
tation in several neural pathologies such 
as spinal cord injury [ 10 ] and Parkinson’s 
models, [ 11 ] with clinical trials being com-
menced in some centers. [ 12 ] Therefore, our 
fi ndings suggest that investigations into 
the infl uence of chemical and physical 
modifi cations of particle properties on 
cellular uptake can be of signifi cant value 
in informing the development of tailored, 
neurocompatible platforms for neural cell 
therapies. In this context, the neural cell 
plasma membrane is a critical mediator of particle uptake, both 
in sensing extracellular particles and through a range of uptake 
events such as endocytosis and micropinocytosis. [ 13 ] As such, 
it can be predicted that early changes/activation profi les in the 
cellular membrane following interaction with nanoparticles will 
be informative predictors of subsequent particle uptake. 
 Despite this, our understanding of the relationship between 
the physicochemical properties of particles and their infl u-
ence on neural cell uptake is very limited. An important point 
to note is that research in this area is signifi cantly hampered 
by the lack of high throughput and simple methods for stud-
ying neural cell responses to nanoparticle platforms. Current 
methods are heavily reliant on conventional fl uorescence and 
confocal microscopy, permitting examination of large cell 
numbers but at low resolution, meaning membrane events 
cannot be reliably studied. Emergent methodologies involving 
the study of model biological membranes using atomic force 
microscopy (AFM), optical tweezers, and electrophysiological 
measurements are useful to some extent, though direct une-
quivocal visualization of particle–membrane binding is chal-
lenging due to the intrinsically low resolution of these methods 
and subjective data interpretation. [ 14 ] Transmission electron 
microscopy (TEM; conventional or cryo-TEM) is a commonly 
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 1.  Introduction 
 Magnetic particles (MPs) are versatile tools for diverse applica-
tions in neuro-nanotechnology. A major emergent application 
area is in neural cell therapies where MPs can mediate trans-
plant cell imaging in vivo, [ 1,2 ] magnetic cell targeting to foci of 
pathology [ 3 ] and can also function as vectors for genetic engi-
neering of neural cell populations. [ 4–6 ] For such applications, 
the limited uptake of MPs by neural transplant cells has widely 
been considered a signifi cant barrier to translation, neces-
sitating the use of chemical transfection agents or targeting 
peptides to enhance uptake—approaches that may be toxic and 
alter cellular physiology. [ 7,8 ] By contrast, we recently proved that 
simple tailoring of particle properties by enhancement of the 
Part. Part. Syst. Charact. 2015, 32, 661–667
FU
LL
 P
A
P
ER
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim662 wileyonlinelibrary.com
www.particle-journal.com www.MaterialsViews.com
used high-resolution approach for ultrastructural analyses of 
membrane features. Although this is an excellent approach 
for detailed membrane analyses, the method is associated with 
high technical complexity, lengthy protocols, laborious quanti-
fi cation procedures and is typically very low throughput. Given 
the drawbacks of current methods, there is a substantial need 
for a simple, cost effective, and rapid experimental/analytical 
approach to study membrane responses to nanoparticles for 
neuro-nanotechnology research. 
 Scanning electron microscopy (SEM), specifi cally fi eld-
emission (FESEM) could offer a realistic solution to the above 
challenges. The resolution of FESEM can be enhanced by 
sequential-repeat staining of cells using osmium (O) and a 
high-affi nity osmium binding agent, thiocarbohydrazide (T) 
(a method known as OTOTO) [ 15 ] enabling reliable analysis of 
ultrastructural membrane features at the nanoscale level. We 
recently proved that this high throughput, high-resolution 
method can be used to reliably examine detailed intercellular 
membrane differences between the major classes of brain cells 
(derived from NSCs), on stimulation with transfection-grade 
MPs. [ 16 ] However, it has never been established if this simple 
approach can be employed to identify distinctive membrane 
responses to MPs possessing differing physiochemical prop-
erties, in order to correlate particle properties with known cel-
lular uptake profi les. The goal of this study therefore was to 
use the OTOTO–FESEM approach to examine early membrane 
responses of primary rodent NSCs to MPs of varied iron con-
tent, (specifi cally the non-Mag and 5× particles used in con-
junction with a 4 Hz oscillating magnetic fi eld, conditions that 
resulted in the highest uptake levels of these particles, as pre-
viously reported). [ 9 ] We reasoned that employing particles with 
distinct physical properties, that in turn show dramatically dif-
ferent uptake levels in NSCs, would enable a robust dissection 
of differences in the induced membrane responses of the stem 
cells. We describe a fi ve-point classifi cation system of mem-
brane features (corroborated by TEM analysis), allowing for sys-
tematic quantifi cation of cell-surface activity in response to MP 
stimulation. 
 2.  Results and Discussion 
 2.1.  Identifi cation of MPs on Stem Cell Membrane Surfaces 
 Both particles used here have been fully characterized previ-
ously using powder X-ray diffraction (XRD), dynamic light 
scattering (DLS), TEM of both naked and intracellular particles 
in NSCs, SQUID magnetometry, Fourier-transform infrared 
(FTIR) spectroscopy, and elemental analysis. [ 9 ] FESEM images 
of magnetite-loaded particles ( Figure  1 A) and non-magnetite 
particles (inset) show similar diameters. Fluorescence micro-
scopy revealed “chains” of particles associated with the surface 
 Figure 1.  Particle identifi cation using FESEM and EDX. A) FESEM image of magnetite-loaded particles (white arrows) and non-magnetite-loaded 
particles (inset) showing similar particle diameters. B) Magnetite-loaded particles appear as cell surface chain-like aggregates in the fl uorescence 
image (white arrows), confi rmed by FESEM (C, white arrows) and TEM (C, inset). D–F) EDX analysis showing iron signal from particles on the NSC 
membrane surface; D) FESEM–particle cluster indicated by arrow; E) iron EDX analysis; and F) merged image. G) Osmium detected by EDX over the 
entire cell surface. H) Spectral mapping of magnetite-loaded particle location showing a distinct iron peak (6.4 keV), which was absent in non-magnetite 
particle spectra.
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of phalloidin-labeled NSCs (Figure  1 B). This fi nding was cor-
roborated by OTOTO–FESEM (Figure  1 C) and TEM (inset). 
The lengths of these particle chains were observed to be similar 
in the FESEM and fl uorescence images (3–4 µm). Elemental 
mapping using energy-dispersive X-ray microanalysis (EDX) 
showed a discrete iron signal corresponding to surface-asso-
ciated particle chains (Figure  1 D–F), distinct from the widely 
distributed osmium signal (Figure  1 G), which is present due to 
the OTOTO processing. Spectral analysis of particles confi rmed 
the presence of iron with a peak at 6.4 keV (Figure  1 H) that 
was absent in cells treated with non-magnetite particles (data 
not shown). In contrast to magnetite- loaded particles, it proved 
diffi cult to reliably generate equivalent images for non-mag-
netite particles, as we were unable to use X-ray microanalysis to 
robustly identify these particles on the cell surface. 
 Therefore, identifi cation and direct observation of metallic 
MP interactions with the NSC surface were feasible using 
OTOTO–FESEM and paralleled observations using standard 
fl uorescence microscopy. Combined use of our method with 
EDX suggests that the approach can be exploited in the future to 
study particle–membrane interactions for particles with a range 
of metal cores, without resorting to technically challenging sec-
tioning procedures, as with TEM. A further signifi cant advan-
tage of OTOTO processing for analysis of synthetic particles, 
including nanoparticles, is that the need for a gold coating of 
the sample (after critical point drying) is avoided. Gold coating 
can potentially obscure small diameter nanoparticles, and is 
not compatible with backscatter electron detection, which can 
be used to detect metal-containing particles, for example, iron 
oxide particles. [ 16 ] 
 2.2.  OTOTO–FESEM Allows for Examination of Parameters 
of Cell Safety and Overall Cell Membrane Activity 
 Cells in our samples appeared to be of high viability in both 
particle stimulated (magnetite-loaded and non-magnetite par-
ticles) and unstimulated cultures (no particles), as judged by 
normal membrane integrity and cellular adherence, and the 
characteristic bipolar morphology of NSCs ( Figure  2 A). Fur-
ther, mitotic NSCs were frequently observed (Figure  2 A, inset). 
This is in line with our previous observations where the poly-
meric particles used showed little evidence of toxicity based on 
normal adherence, absence of cellular detachment/rounding, 
normal morphology, and observation of dividing stem cells (a 
key property underpinning their regenerative potential). There-
fore, the OTOTO method allows for a high throughput and 
detailed analysis of cellular safety profi les, which parallel obser-
vations from standard and widely used fl uorescence micros-
copy methods. 
 Clear differences in membrane features were apparent 
between unstimulated and MP-stimulated cultures with greater 
overall cellular membrane activity obvious after MP stimula-
tion (Figure  2 B,C). Consistent with these observations, dextran 
uptake (indicative of macropinocytotic activity) was increased 
in MP-stimulated NSCs (Figure  2 D) compared to unstimulated 
control cultures (inset); non-magnetite particle-treated cultures 
demonstrated similar results to unstimulated cultures (data not 
shown). 
 The OTOTO methodology allowed for high-resolution anal-
ysis of several cells per sample. Sample processing using the 
method was technically simple and rapid (one day), with the 
ability to simultaneously process large sample numbers for 
imaging and analysis. Ultrastructural analyses such as TEM 
enable direct observation of particle uptake processes, and 
identifi cation of specifi c endocytotic events by visualization of 
endocytotic structures and vesicle formation. However, this is 
a time- and labor-intensive process, [ 18 ] and few uptake events 
may be observed in an individual sample, consisting as it does 
of an ultrathin section (typically 30–100 nm, rarely exceeding 
150 nm, as electrons less readily pass through biological mate-
rial of this thickness). [ 17 ] Additionally, artifacts may be intro-
duced into TEM samples due to damage during the sectioning 
process, which can be a particular problem for the study of 
cellular interactions with synthetic materials, as the interface 
between “soft” biological material and “hard” synthetic particles 
can be altered. [ 19 ] 
 OTOTO preparation also allowed for a greater proportion of 
each cell’s membrane to be studied compared with TEM sam-
ples. Following OTOTO, an entire coverslip could be placed 
into the scanning electron microscope, allowing therefore for 
an entire culture (and treatment condition) to be analyzed. By 
comparison, for TEM samples, the resin within which cells are 
embedded typically needed to be broken into smaller pieces to 
be amenable to ultrathin sectioning. Ultrathin sections con-
tained far fewer cells than an SEM specimen, even if sectioned 
100 µm
b
10 µm
B) Unstimulated NSC
C) Stimulated NSC
10 µm
A) D) Stimulated NSC
10 µm
10 µm
20 µm
Dextran
DAPI
10 µm
 Figure 2.  MP-induced responses in NSCs. A) Low-magnifi cation view showing large numbers of viable cells available for morphological analysis, 
including identifi cation of mitotic profi les (inset). Differences in membrane activity were apparent between B) unstimulated and C) MP-stimulated 
cells. Dextran (macropinocytosis marker) uptake was higher in D) stimulated cells compared to controls (inset).
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parallel to the original cell monolayer, a more diffi cult tech-
nique than sectioning perpendicular to the monolayer. Finally, 
TEM sections had to undergo a further staining process (uranyl 
acetate and lead citrate) individually. It should also be noted that 
only a small number of ultrathin sections could be studied by 
TEM at a time, and these were commonly all obtained from a 
single face of a single fragment of the original resin-embedded 
sample. These considerations make TEM analyses more expen-
sive and time consuming than OTOTO–FESEM, particularly 
when trying to generate a 3D reconstruction of the cell mem-
brane surface. [ 17 ] 
 2.3.  Comparison of Membrane Responses to Particles Using 
OTOTO–SEM Versus TEM: A Five-Point Classifi cation System 
 At higher magnifi cation, membranes of unstimulated NSCs 
appeared relatively smooth (i.e., fewer endocytotic features, 
less membrane infoldings) in OTOTO–FESEM ( Figure  3 A) and 
TEM (Figure  3 B). By contrast, the membranes of magnetite-
loaded particle stimulated NSCs appeared more activated, 
with several types of surface responses evident. Five mem-
brane features were quantifi ed: i) pits, which could be distin-
guished as depressions possessing a diameter of approximately 
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 Figure 3.  Membrane activity in NSCs. FESEM, TEM images and analyses of extent of A–E) membrane ruffl ing, F–H) numbers of fi lopodia, I–K) pits, 
L–N) nanopodia, and O–Q) circular ruffl es following MP addition. Statistical differences are * p < 0.05, ** p < 0.01, *** p < 0.001,  n = 3. Arrows indicate 
each respective feature; arrows in O and P also indicate particle clusters (see Figure  1 ).
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150–200 nm; ii) fi lopodia, identifi ed as fi ne, fi nger-like projec-
tions (ca. 200–250 nm in diameter) extending from the cell sur-
face; iii) nanopodia, identifi ed as fi nger-like projections similar 
to fi lopodia but extending on the cell substrate and possessing 
a relatively narrow diameter versus fi lopodia (75–100 nm); iv) 
membrane ruffl ing, defi ned as regular infoldings/undulations 
over the entire membrane surface; and v) circular ruffl es, iden-
tifi ed as highly distinctive rounded, cup-like projections with a 
translucent, parachute-like appearance. The quantitative anal-
ysis revealed a signifi cantly greater extent of membrane ruffl ing 
( p < 0.001; Figure  3 C-E), fi lopodia ( p < 0.01; Figure  3 F-H), pits 
( p < 0.001; Figure  3 I-K) and nanopodia ( p < 0.05; Figure  3 L-N) 
but not circular ruffl es ( p = 0.184 Figure  3 O-Q), after MP 
stimulation. 
 Membrane features showing similarity to those seen with 
SEM, were detected using TEM (Figure  3 D,G,J,M, and P). 
However, an unequivocal classifi cation approach in this regard 
was possible only for pits, where measured diameters were in a 
similar range (150–250 nm) as to those identifi ed by OTOTO–
FESEM. This observation suggests that FESEM captures iden-
tifi able membrane activation events more reliably than TEM. 
Based on these advantages, the OTOTO protocol described here 
can provide signifi cantly more quantifi able data than is achiev-
able with TEM analyses, given the same resources in terms of 
time and expense. 
 SEM has been used previously to study blebs, ruffl ing and 
fi lopodia in cultured cells, [ 20 ] but here we have demonstrated 
the feasibility of distinguishing additional features, specifi cally 
nanopodia, pits, and membrane ruffl es, with high resolution. 
These features have been shown in a range of studies to be 
related to particle traffi cking by cell membranes. For example, 
membrane pits have been shown to mediate MP uptake and 
both the morphology and diameter of the structures we iden-
tify as pits are consistent with that reported in the literature. [ 21 ] 
Filopodia/nanopodia are likely cellular sensors for extracel-
lular materials [ 22 ] and these are known to be highly dynamic 
structures. [ 23 ] Investigations into fi lopodia biology demonstrate 
considerable variation in the dynamics, length, and position of 
these cellular protrusions between various cell types and in dif-
fering microenvironments. However, the length and diameter 
of the structures that we classify as fi lopodia in our study are 
also consistent with the published literature. [ 23 ] The function 
of the fi fth class of circular dorsal ruffl es is somewhat obscure 
but such structures may be related to macropinocytosis. [ 24 ] Sup-
porting this concept, four of the features identifi ed showed a 
statistically signifi cant increase on stimulation of cells with 
magnetite-loaded particles (that we have previously proven 
to show high levels of uptake in NSCs) compared with parti-
cles with no magnetite (that show signifi cantly less uptake in 
the same cell type). This fi nding suggests that the enhanced 
levels of membrane surface activity exhibited by the NSCs in 
response to the magnetite-loaded particles, can act as a reliable 
and robust predictor of the extent of particle uptake in cells—
a fi nding further borne out by the enhanced levels of dextran 
uptake in cells stimulated with magnetite-loaded particles. 
 The OTOTO–FESEM method can be combined with tech-
niques such as backscatter detection of iron oxide particles and 
stereo image analysis, involving a red/green anaglyph, which 
produces 3D images and facilitates the measurement of the 
depth of membrane depressions/pits. [ 25 ] Such data can enable 
the identifi cation of the mechanisms responsible for cellular 
uptake of particles, and reveal which particular mechanisms a 
particular cell type employs for particle uptake. Therefore, there 
is the potential in the future to develop a high-throughput assay 
for counting “particle uptake events” by cells, by identifying and 
scoring instances of endocytosis. 
 3.  Conclusion 
 As far as we are aware, this is the fi rst report studying mem-
brane responses of primary NSCs following challenge with 
MPs. The fi eld of neuro-nanotechnology is heavily reliant on 
the use of a range of cell lines for nanoparticle activation and 
uptake studies. However, cells lines are associated with a range 
of drawbacks such as abnormal physiology, clonal behaviors, 
and high resistance to cell death. [ 4 ] As such, we consider it 
essential to develop imaging methods consistent with the use of 
primary cells for translational applications. To our knowledge, 
we are also the fi rst to develop a detailed classifi cation system 
by which such membrane responses can be robustly quantifi ed 
following particle challenge, in order to correlate early mem-
brane responses with particle uptake. We consider that the 
predictive utility of this approach is therefore of value for cel-
lular studies of particle uptake. The OTOTO procedure results 
in an electron-conductive cellular membrane, [ 26,27 ] allowing 
for observation of fi ne ultrastructural detail comparable to the 
resolution of TEM, and far exceeding that possible through 
standard fl uorescence microscopy methods. We consider there-
fore that OTOTO–FESEM offers a means to bridge the gap 
between fl uorescence imaging and TEM, particularly given the 
ready access of many researchers to SEM facilities, and greatly 
enhances the analytical power of microscopy for evaluating cell 
surface activity and safety profi les in response to nanoparticle 
activation. We conclude that this versatile methodology can be 
exploited for several applications in nanomedicine ( Figure  4 ), 
particularly as a tool to identify novel, neurocompatible mate-
rials for neural cell therapy. 
 4.  Experimental Section 
 The care and use of animals was in accordance with the Animals 
(Scientifi c Procedures) Act of 1986 (United Kingdom) with approval by 
the local ethics committee. 
 Materials/Equipment : Cell culture reagents were from Life Technologies 
(Paisley, Scotland, UK; including Alexa Fluor555-conjugated Dextran 
particles (10 kDa)) and Sigma (Poole, Dorset, UK; including FITC-
conjugated Phalloidin). Human recombinant epidermal growth factor 
(EGF) was from R&D Systems Europe Ltd. (Abingdon, UK). Human 
recombinant basic fi broblast growth factor (bFGF) was from Peprotech 
(Rocky Hill, NJ, USA). Thermo Scientifi c Nunc culture dishes (nontreated 
surface) and tissue culture-grade plastics were from Fisher Scientifi c 
UK (Loughborough, UK). Mouse anti-nestin was from BD Biosciences 
(Oxford, UK) and FITC-conjugated secondary antibodies were from 
Jackson Immunoresearch Laboratories Ltd (Westgrove, PA, USA). 
 BODIPY 564/570 (Life Technologies)-tagged, polylactide-based non-
magnetite and magnetite-loaded polymeric particles were a kind gift from 
Dr. Boris Polyak (Drexel University, Philadelphia). Vectashield mounting 
medium with 4′,6-diamidino-2-phenylindole (DAPI, nuclear marker) 
was from Vector Laboratories (Peterborough, UK). The magnefect-nano 
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24-magnet array system was purchased from nanoTherics Ltd. (Stoke-
on-Trent, UK) and comprises horizontal arrays of NdFeB magnets (grade 
N42), which correspond with 24-well cell culture plates. 
 Magnetic Particle Details : Detailed particle formulation and 
characterization of non-magnetite and magnetite-loaded particles are 
described in Adams et al. [ 9 ] Briefl y, DLS measurements indicated similar 
particle hydrodynamic diameters ranging between 262 and 278 nm with 
a polydispersity index of 0.15–0.23. Magnetite-loaded particles (referred 
to as “MP-5×” previously) are composed of a polymeric matrix and have 
a magnetization at 5 kOe of 24.6 ± 1.2 emu g −1 composite. [ 9 ] 
 Neurosphere and NSC Monolayer Culture : Primary NSC cultures 
were derived from the subventricular zone of CD1 mice (postnatal day 
0–3), then maintained and expanded under growth factor stimulation 
in neurosphere culture medium (DMEM:F12 (3:1 mix) containing B-27 
supplement (2%), penicillin (50 U mL −1 ), streptomycin (50 mg mL −1 ), 
heparin (4 ng mL −1 ), bFGF (20 ng mL −1 ), and EGF (20 ng mL −1 )) according 
to the well characterized “neurosphere” culture method. [ 6 ] Cultures were 
fed every 2–3 d and neurospheres were passaged weekly by dissociation 
with a mix of accutase-DNase I. For all experiments, NSCs (passages 
1–3) were dissociated and plated as 2D monolayers (i.e., a single layer of 
cells) on coverslips (sequentially coated with polyornithine and laminin) in 
24-well plates. Cells were maintained in monolayer maintenance medium 
composed of a 1:1 mix of DMEM:F12 containing N2 supplement (1%) with 
the above-mentioned antibiotic, heparin, and growth factor concentrations. 
 Particle Incubation with NSCs : The day after plating, equal numbers 
of non-magnetite or magnetite-loaded particles (600 µL well −1 , 
corresponding to about 7.8 and 22 µg total weight for each particle, 
respectively) were added to NSC monolayers. Culture plates were 
placed on the oscillating magnetic device (magnefect-nano; oscillation 
frequency ( F ) = 4 Hz, previously shown to enhance magnetite-loaded 
particle uptake in NSCs) [ 28 ] for 30 min, followed by washing (phosphate 
buffered saline, PBS) and fi xation. For fl uorescence microscopy, cells 
were fi xed in paraformaldehyde (PFA; 4%, 20 min; room temperature 
(RT)). For OTOTO and TEM preparation (see below), cells were fi xed 
in 2.5% (w/v) glutaraldehyde in sodium cacodylate (0.1  M )/calcium 
chloride buffer (SCB; 2 × 10 −3  M , pH 7.2; 2 h; RT). Control cultures were 
not exposed to particles or magnetic fi elds. 
 Phalloidin Labeling of NSCs : To visualize cellular boundaries 
and cytoskeletal elements, including possible associations with 
nanoparticles, PFA-fi xed cells were stained with FITC-conjugated 
phalloidin (20 µg mL −1 ; marker for actin fi laments) for 40 min at RT and 
washed in PBS three times before mounting with DAPI. 
 Dextran as an Indicator of Macropinocytosis : Fluorescently labeled 
dextran was used to confi rm the presence of macropinocytotic activity. 
Alexa Fluor 555-conjugated dextran (0.025 mg mL −1 ) was added to 
cells along with non-magnetite or magnetite-loaded particles before 
placing on the magnefect-nano for 30 min (4 Hz). Control cultures were 
incubated with dextran for 30 min, but without particles or exposure to 
a magnetic fi eld. Samples were fi xed in PFA (4%) and washed with PBS. 
 Fluorescence Microscopy : Fluorescence- and phase-contrast images 
were captured using an Axio Scope A1 fl uorescence microscope and 
an Axio Cam ICc1 digital camera (Carl Zeiss MicroImaging GmbH, 
Goettingen, Germany). Images were merged using AxioVision Software. 
 OTOTO Processing for FESEM : Glutaraldehyde fi xation of samples was 
followed by OTOTO conductivity staining (OsO 4 /thiocarbohydrazide/
OsO 4 /thiocarbohydrazide/OsO 4 ): OsO 4 (1%) was applied fi rst for 1 h 
followed by thorough washing in distilled water, then saturated fi ltered 
aqueous thiocarbohydrazide for 20 min, and then a further O (2 h), 
T (20 min), and O (2 h), with washing between each step. Finally, 
samples were dehydrated in a graded series of ethanols, critical point 
dried with CO 2 as the transitional fl uid, and mounted onto carbon pads 
on aluminum stubs. To improve electron conductivity, silver conducting 
paint (Agar Scientifi c) was used to coat the sample edges. 
 FESEM : Non-magnetite- and magnetite-loaded particles (air-dried 
on aluminum stubs) were visualized using a Hitachi S4500 FESEM 
(15 kV accelerating voltage). Membrane morphologies (see Results) were 
examined using a Hitachi S4500 FESEM (5 kV accelerating voltage) after 
OTOTO preparation. Analyses were carried out on 30 cells from three 
replicates ( n = 3) each generated from a different litter, by an observer 
blind to the conditions. Pits, fi lopodia, and nanopodia were expressed per 
unit area (area of measurement = 25 µm 2 ) and circular ruffl es per cell. 
For membrane ruffl ing, a semiquantitative score was assigned from 1–5. 
 TEM Preparation and Imaging : Glutaraldehyde-fi xed samples were 
postfi xed with osmium tetroxide (1%) in SCB for 1 h, washed, and 
OTOTO - FESEM 
Identify cell morphologies e.g. 
differentiated neurons, astrocytes, 
oligodendrocytes 
Assess cell safety profiles: e.g. 
apoptotic features, cell density, 
viability 
Nanoparticle and cell 
membrane interaction 
Examine and quantify 
ultrastructural membrane 
features e.g. extent of 
membrane ruffling, 
filopodia 
Nanoparticle identification 
on cell surface 
Particle internalisation e.g. 
using backscatter imaging 
Differentiate between 
similar structures e.g. 
nanopodia vs filopodia 
structures 
Novel Nanoparticle 
characterization 
• Compare membrane response of different cell types to different nanoparticles subclasses 
• Compare membrane response (same cell type) to particles with different physicochemical properties, 
eg ‘stealth’ coatings, peptide conjugated surfaces 
• Perform cross-cellular comparisons of particle uptake  efficiency, membrane responses and viability in 
differentiated, mixed or co-cultures 
• Investigate effect of endocytotic blockers on ultrastructural membrane features 
• Correlate membrane activity to predict particle uptake/transfection efficiency  
Nanoparticle-induced 
membrane response 
 Figure 4.  Schematic diagram showing the potential uses of OTOTO–FESEM for nanomedicine applications.
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then dehydrated in a graded series of ethanols, before infi ltration and 
embedding in Spurr resin. After polymerization of the resin at 60 °C for 
16 h, ultrathin sections were cut on a Reichert Ultracut E microtome. 
Sections were collected on 2000 µm hole, 3.05 mm copper grids 
coated with formvar, which provides a completely electron permeable 
surface for section mounting (without interruption from grid bars). The 
mounted sections were then stained with uranyl acetate (2%) in ethanol 
(70%) and Reynold’s lead citrate (2%) in distilled water. Sections were 
examined in a JEOL 100CX TEMSCAN (Tokyo, Japan) operated in TEM 
mode at 100 kV and images captured using a SIS systems Megaview III 
digital camera (Olympus, Tokyo, Japan). 
 EDX Microanalysis : To identify particles on the cell surface, X-ray 
microanalysis was carried out on OTOTO-treated samples using a JEOL 
100CX TEMSCAN operated in in-lens SEM mode at ×30 k magnifi cation 
(40 kV accelerating voltage; beam current 100 µA, spot size 30 nm), 
to detect iron within the particle. Dot mapping was performed using a 
full area raster while individual spectra were acquired using the SEM in 
spot mode. Processing of the X-ray counts was carried out using NSS 
Spectral Imaging software (Fisher Scientifi c, Loughborough, UK). 
 Statistics : All data were analyzed by one-way ANOVA with Bonferroni’s 
multiple comparison post-tests as appropriate, using Prism software 
(version 5.00, GraphPad, CA, USA,  www.graphpad.com ). All data are 
expressed as mean ± standard error of the mean. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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